











Manipulation of the inflammatory response in vivo 












A thesis submitted in partial fulfilment of the requirements for the degree of 




The University Of Sheffield 
Faculty of Medicine, Dentistry and Health 



























Page 3 of 246 
 
Acknowledgements 
Firstly, I would like to thank my supervisors, Professor Stephen Renshaw and 
Professor Simon Jones, for allowing me to work on a very interesting area of research, 
and for all their continued supervision, mentoring, and guidance over the last few years. 
I would particularly like to thank Dr. Katherine Henry, and Jenna and Charlie, as well as 
Joseph, Rosie, Alec, Sally, Rheanna, Dan C, Debs, Shannon, Sam and Esther, plus Anne, 
Cat, Noémie, Dave, Nik, Hannah, Kyle, Samir, Josie, Jo, Andrew, Becca, Ashlie, Dan J, Al, 
Bryony, Jonny and Ben, for their friendship outside of my PhD studies, as well as their 
support during my studies. I also thank the rest of D31 and the rest of the Jones group, 
as well as various technical members of staff, Denise, Louise and Sandra in the 
Department of Chemistry, the Aquarium staff, and the administrative team in the 
Medical School. I am grateful to The University Of Sheffield for funding my research. 
Finally, I would especially like to thank my family, especially Mum, Dad, Holly, Nana, and 














Page 4 of 246 
 
Declaration 
I declare that all the work contained herein is my own work, unless otherwise 
referenced.  
In Chapter 6, most figures, and some of the accompanying text, have been 
reproduced from my corresponding paper first published in Scientific Reports: 
Foulkes, M. J. et al. Expression and regulation of drug transporters in vertebrate 
neutrophils. Sci. Rep. 7, 4967 (2017).  
This is copyright-compliant, and in accordance with the Nature Publishing Group 












Page 5 of 246 
 
Contents 
Acknowledgements ..................................................................................................... 3 
Declaration ................................................................................................................... 4 
Contents ....................................................................................................................... 5 
Abbreviations and commonly-used terms ............................................................... 10 
List of figures .............................................................................................................. 15 
List of schemes ........................................................................................................... 17 
List of tables ............................................................................................................... 19 
1. Abstract .................................................................................................................. 20 
2. Introduction ........................................................................................................... 21 
2.1 Inflammation .................................................................................................... 21 
2.1.1 Neutrophils in the inflammatory response ............................................... 21 
2.1.2 Unresolved neutrophilic inflammation in human diseases ...................... 23 
2.1.3 Current and future treatments for unresolved inflammation .................. 24 
2.2 Zebrafish models of human disease ................................................................. 26 
2.2.1 Advantages of the zebrafish model ........................................................... 26 
2.2.2 Zebrafish models of the inflammatory response ...................................... 27 
2.2.3 Use of zebrafish models in compound screens ......................................... 28 
2.3 Tanshinones ...................................................................................................... 30 
2.3.1 Origin of tanshinones ................................................................................ 30 
2.3.2 Biological effects of tanshinones ............................................................... 31 
2.3.3 Chemical synthesis methods for TI and analogues ................................... 33 
2.3.4 Chemical synthesis methods for TIIA and analogues ................................ 41 
2.4 Hypothesis and research aims .......................................................................... 48 
3. Materials and Methods ......................................................................................... 50 
3.1 Reagents and equipment ................................................................................. 50 
3.2 Zebrafish husbandry ......................................................................................... 50 
3.3 Larval tailfin transection ................................................................................... 51 
3.4 Larval compound treatment ............................................................................ 52 
Page 6 of 246 
 
3.5 Neutrophil recruitment experiments ............................................................... 52 
3.6 Inflammation resolution experiments ............................................................. 53 
3.7 Statistical analysis ............................................................................................. 53 
4. Synthesis and evaluation of tanshinone I analogues and isotanshinone I 
analogues ........................................................................................................................ 55 
4.1 Introduction ...................................................................................................... 55 
4.2 Hypothesis and aims ........................................................................................ 56 
4.3 Initial synthesis of TI ......................................................................................... 56 
4.3.1 Initial steps ................................................................................................ 56 
4.3.2 Minisci-type radical decarboxylative alkylation reaction ......................... 58 
4.3.3 Intramolecular Heck reaction .................................................................... 61 
4.3.4 Demethylation reaction ............................................................................ 62 
4.3.5 Modified Feist-Bénary reaction ................................................................. 63 
4.4 Synthesis of TI analogues ................................................................................. 66 
4.4.1 Radical decarboxylative alkylation reaction .............................................. 66 
4.4.2 Use of Design of Experiments (DoE) studies in optimisation of the radical 
alkylation ................................................................................................................. 66 
4.4.3 Radical alkylation for analogue synthesis ................................................. 69 
4.4.4 Optimisation of the intramolecular Heck reaction ................................... 71 
4.4.5 Final demethylation and modified Feist-Bénary reaction steps ............... 75 
4.4.6 Synthesis of a TI-acetal .............................................................................. 77 
4.5 Biological evaluation of TI, iso-TI and analogues ............................................. 78 
4.5.1 Effect of TI on neutrophil recruitment ...................................................... 78 
4.5.2 Comparison of commercial and synthetic TI ............................................. 79 
4.5.3 Effects of TI analogues and isomers on neutrophil recruitment in vivo ... 80 
4.5.4 Initial in vivo inflammation resolution experiments ................................. 84 
4.5.5 Optimisation of inflammation resolution experiments and validation of 
new experimental timepoints using TI and TIIA ..................................................... 85 
4.5.6 Effects of TI analogues and isomers on resolution of neutrophilic 
inflammation in vivo ............................................................................................... 89 
Page 7 of 246 
 
4.5.7 Summary of effects of TI analogues and isomers on neutrophil behaviour 
during the inflammatory response in vivo .............................................................. 92 
4.5.8 Aqueous solubilities and in vivo toxicities of TI analogues and isomers .. 95 
4.6 Discussion ......................................................................................................... 96 
5. Synthesis and evaluation of other tanshinone analogues and related compounds
 ....................................................................................................................................... 103 
5.1 Introduction .................................................................................................... 103 
5.2 Hypothesis and aims....................................................................................... 107 
5.3 Towards the synthesis of TIIA and analogues ................................................ 108 
5.3.1 General strategy ...................................................................................... 108 
5.3.2 Dienophile synthesis................................................................................ 109 
5.3.3 Attempted synthesis of dienes ................................................................ 115 
5.3.4 Diels-Alder reactions using commercially available dienes .................... 117 
5.3.5 Summary .................................................................................................. 122 
5.4 Lapachone and lapachol compounds ............................................................. 123 
5.4.1 Chemical synthesis .................................................................................. 123 
5.4.2 Biological evaluation – recruitment experiments ................................... 125 
5.4.3 Biological evaluation – resolution experiments ...................................... 128 
5.4.4 Biological evaluation – summary ............................................................ 130 
5.5 Discussion ....................................................................................................... 132 
6. How tanshinones access neutrophils – expression of drug transporter molecules 
in human and zebrafish neutrophils ............................................................................ 138 
6.1 Introduction .................................................................................................... 138 
6.2 Hypothesis and aims....................................................................................... 139 
6.3 Methods ......................................................................................................... 140 
6.3.1 Identification of relevant genes and protein sequences ........................ 140 
6.3.2 Production of phylogenetic trees ............................................................ 141 
6.3.3 Expression and regulation of human transporter proteins .................... 141 
6.3.4 Expression and regulation of zebrafish transporter proteins. ................ 142 
6.4 Analysis of expression and regulation of drug transporters in human 
neutrophils ................................................................................................................ 143 
Page 8 of 246 
 
6.5 Expression analysis of drug transporters in zebrafish neutrophils ................ 151 
6.6 Comparison of drug transporter expression between human and zebrafish 
neutrophils ................................................................................................................ 158 
6.7 Discussion ....................................................................................................... 159 
7. Discussion............................................................................................................. 164 
8. Experimental ........................................................................................................ 169 
8.1 General ........................................................................................................... 169 
8.2 Synthesis of TI analogues and iso-TI analogues ............................................. 170 
8.3 Towards the synthesis of other tanshinone analogues ................................. 187 
8.4 Synthesis of structurally related compounds................................................. 193 
9. Bibliography ......................................................................................................... 196 
10. Appendix ............................................................................................................ 221 
10.1 Previous studies in the Renshaw group found that various tanshinones 
accelerated resolution of neutrophilic inflammation in zebrafish ........................... 221 
10.2 E3 medium.................................................................................................... 222 
10.3 Tricaine solution ........................................................................................... 222 
10.4 Phylogenetic trees with proportional branch lengths ................................. 223 
10.4.1 Subsets of SLC transporter proteins were expressed and regulated in 
primary human neutrophils .................................................................................. 223 
10.4.2 Subsets of ABC transporter proteins were expressed and regulated in 
primary human neutrophils .................................................................................. 225 
10.5 Comparison of human drug transporter expression between distinct RNAseq 
datasets ..................................................................................................................... 227 
10.5.1 Expression of SLC transporter proteins was largely consistent across two 
different datasets .................................................................................................. 227 
10.5.2 Expression of ABC transporter proteins was largely consistent across two 
different datasets .................................................................................................. 238 
10.6 Phylogenetic trees with proportional branch lengths ................................. 240 
10.6.1 Zebrafish larval neutrophils and non-neutrophil cells expressed distinct 
subsets of SLC transporter proteins ...................................................................... 240 
10.6.2 Zebrafish larval neutrophils and non-neutrophil cells expressed distinct 
subsets of ABC transporter proteins ..................................................................... 242 
Page 9 of 246 
 
10.7 Drug transporters expressed in both human and zebrafish neutrophils ..... 244 
10.7.1 A subset of SLC drug transporters was expressed in both human and 
zebrafish neutrophils ............................................................................................ 244 
10.7.2 A subset of ABC drug transporters was expressed in both human and 
zebrafish neutrophils ............................................................................................ 246 
 
 
Page 10 of 246 
 
 Abbreviations and commonly-used terms 
 ABC ATP-binding cassette 
 Ac Acetyl 
 AD Anno Domini 
 AMP Adenosine monophosphate 
 ANOVA Analysis of variance 
 app d Apparent doublet 
 app t Apparent triplet 
 aq Aqueous 
 Ar Aryl 
 ARDS Acute respiratory disease syndrome 
 ATR Attenuated total reflection 
 β-lap β-Lapachone 
 br d Broad doublet 
 br s Broad singlet 
 br t Broad triplet 
 Cas9 CRISPR associated protein 9 
 cat Catalytic quantity 
 CF Cystic fibrosis 
 cLogP Calculated LogP 
 comm Commercial 
 conc Concentrated 
 COPD Chronic obstructive pulmonary disease 
 CRISPR Clustered Regularly Interspaced Short Palindromic Repeats 
 CRISPRi CRISPR interference 
 d Doublet 
 DCE 1,2-Dichloroethane 
 DCM Dichloromethane 
 dd Doublet of doublets 
 ddd Double doublet of doublets 
Page 11 of 246 
 
 DDQ 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone  
  DMAP 4-Dimethylaminopyridine 
 DME 1,2-Dimethoxyethane 
 DMF N,N-Dimethylformamide 
 DMSO Dimethyl sulfoxide 
 DNA Deoxyribonucleic acid 
  DoE Design of Experiments 
 dpf Days post-fertilisation 
 dppf 1,1'-Bis(diphenylphosphino)ferrocene 
 dppp 1,3-Bis(diphenylphosphino)propane 
 dq Doublet of quartets 
 E3 Embryo medium 
 EI Electron impact 
 eq Equivalents 
 ESI Electrospray ionisation 
 Et Ethyl 
 FPKM Fragments per kilobase of exon per million fragments mapped 
 FT-IR Fourier-transform infrared spectroscopy 
 GEO Gene Expression Omnibus 
 GFP Green fluorescent protein 
 GM-CSF Granulocyte macrophage colony-stimulating factor 
 h Hours 
 HGNC HUGO Gene Nomenclature Committee 
 HMDS Hexamethyldisilazane 
 hpf Hours post-fertilisation 
 hpi Hours post-injury 
 HUGO Human Genome Organisation 
 IC50 Half maximal inhibitory concentration 
   
Page 12 of 246 
 
 IL Interleukin 
 iNOS Inducible nitric oxide synthase 
 IR Infrared 
 iTOL Interactive Tree of Life 
 J NMR coupling constant 
 Lap Lapachol 
 LC50 Half maximal lethal concentration 
 lit Literature 
 LPS Lipopolysaccharide 
 m Multiplet 
 max Maximum 
 Me Methyl 
  µw Microwave 
 mol Moles 
 mp Melting point 
 MPO Myeloperoxidase (human) 
 mpx Myeloid-specific peroxidase (zebrafish) 
  mRNA Messenger RNA 
 Ms Methanesulfonyl (mesyl) 
 m/z Mass divided by charge number 
 n Number of individual subjects 
 n- Normal 
 NAD Nicotinamide adenine dinucleotide 
 nBu Normal butyl 
 NCBI National Center for Biotechnology Information 
 NET Neutrophil extracellular trap 
 NMR Nuclear magnetic resonance 
 NQO1 NAD(P)H quinone oxidoreductase 1 
 Nor-β-lap Nor-β-lapachone 
Page 13 of 246 
 
 ns Not significant 
 ORDA Online Research Data 
 P Calculated probability value 
 PBIN Phospholipid bilayer diffusion is negligible 
 Ph Phenyl 
 pKa -log10(acid dissociation constant) 
 PPA Polyphosphoric acid 
 ppm Parts per million 
 py Pyridine 
 q Quartet 
 qd Quartet of doublets 
 quant Quantitative yield 
 r Pearson correlation coefficient 
 RNA Ribonucleic acid 
 RNAseq RNA-sequencing 
 ROS Reactive Oxygen Species 
 rt Room temperature 
 s Singlet 
 SD Standard deviation 
 SEM Standard error of the mean 
 SGK1 Serum- and glucocorticoid-regulated kinase 1 
 SLC Solute carrier 
 SP SP600125 
 synth Synthetic 
 t Triplet 
 TBAF Tetra-n-butylammonium fluoride 
 TBAI Tetra-n-butylammonium iodide 
 TBDMS tert-Butyldimethylsilyl 
 tBu Tertiary butyl 
 










 td Triplet of doublets 
 temp Temperature 
 Tf Trifluoromethanesulfonate (triflate) 
 TFEA 2,2,2-Trifluoroethyl trifluoroacetate 
 Tg Transgenic 
 THF Tetrahydrofuran 
 TI Tanshinone I 
 TIIA Tanshinone IIA 
 TIIB Tanshinone IIB 
 TIPS Triisopropylsilyl 
 TLC Thin layer chromatography 
 TNFα Tumour necrosis factor alpha 
 Ts Toluenesulfonyl (tosyl) 
 vol Volume 
 WHO World Health Organisation 
 ZFIN Zebrafish Information Network 
Page 15 of 246 
 
List of figures 
Figure 1. A simplified schematic outlining the role played by neutrophils during the 
inflammatory response. .................................................................................................. 21 
Figure 2. A transgenic larva, Tg(mpx:GFP)i114, age 3 days post fertilisation (3 dpf), as 
viewed under the normal brightfield (top) and GFP (bottom) channels of a fluorescence 
microscope. ..................................................................................................................... 28 
Figure 3. Exemplar tanshinones. ................................................................................ 30 
Figure 4. Published syntheses of various TI analogues (modified parts shown in red).
 ......................................................................................................................................... 41 
Figure 5. Published syntheses of various TIIA analogues (modified parts shown in red).
 ......................................................................................................................................... 48 
Figure 6. The larval tailfin was transected with a micro-scalpel blade at the position 
indicated by the red line, as viewed under the normal brightfield (top) and GFP (bottom) 
channels of a fluorescence microscope, thereby initiating an inflammatory response. 52 
Figure 7. All neutrophils in the blue box shown were included in counting. Larva 
shown as observed under the normal brightfield (top) and GFP (bottom) channels of a 
fluorescence microscope. ............................................................................................... 53 
Figure 8. Structures of the previously synthesised TI 1 and its 6-hydro derivative 31
 ......................................................................................................................................... 57 
Figure 9. Structures of iso-TI 1, iso-TIIA 78 and iso-TIIB 79. ...................................... 65 
Figure 10. Possible interaction of the heteroatom substituent with the inserted 
palladium. ........................................................................................................................ 74 
Figure 11. TI 1 treatment significantly reduced neutrophil recruitment to a site of 
injury. .............................................................................................................................. 79 
Figure 12. Commercial and chemically synthesised TI 1 both reduced neutrophil 
recruitment, and there was no difference between the two batches of TI 1. ............... 80 
Figure 13. TI 1 and iso-TI 13 resulted in decreased neutrophil recruitment to a site of 
injury, yet 6-hydro-TI 31 did not. .................................................................................... 81 
Figure 14. Neither 6-trifluoromethyl-TI 100, 6-fluoro-TI 102, 6-methoxy-TI 104, nor 4-
hydro-iso-TI 99 significantly affected neutrophil recruitment. ...................................... 82 
Figure 15. Trifluoromethyl- 101 and fluoro- 103 substituted isotanshinones resulted 
in decreased neutrophil recruitment, whilst neither 4-methoxy-iso-TI 105 nor the TI 
acetal 109 had any effect. ............................................................................................... 83 
Page 16 of 246 
 
Figure 16. Neither TIIA 2, TI 1, iso-TI 13, nor 6-hydro-TI 31 had any effect on 
inflammation resolution at 12 hpi. ................................................................................. 85 
Figure 17. The number of neutrophils at the site of injury reached a maximum at 
around 4 hpi, then resolved to pre-injury neutrophil numbers by 24 hpi. .................... 86 
Figure 18. TIIA 2 significantly accelerated inflammation resolution at 8 hpi. ........... 87 
Figure 19. Both TI 1 and TIIA 2 accelerated inflammation resolution. ...................... 88 
Figure 20. TI 1 resulted in decreased neutrophil recruitment, yet TIIA 2 did not. .... 89 
Figure 21. Iso-TI 13 significantly accelerated inflammation resolution, whilst TI 1 and 
6-hydro-TI 31 did not. ..................................................................................................... 90 
Figure 22. 6-Methoxy-TI 104 significantly accelerated inflammation resolution, yet 6-
trifluoromethyl-TI 100, 6-fluoro-TI 102, and 4-hydro-iso-TI 99 did not. ........................ 91 
Figure 23. The TI acetal 109 significantly accelerated resolution of neutrophilic 
inflammation, yet the isotanshinones 4-trifluoromethyl-iso-TI 101, 4-fluoro-iso-TI 103, 
and 4-methoxy-iso-TI 105 all did not. ............................................................................. 92 
Figure 24. Structures of related compounds β-lapachone 112 and nor-β-lapachone 
113, and their structural similarity, shown in red, with TI 1 and TIIA 2. ...................... 105 
Figure 25. Structures of related compounds lapachol 114 and norlapachol 115. .. 106 
Figure 26. Disconnection of the general TIIA structure to the phenol 58 and various 
dienes. ........................................................................................................................... 108 
Figure 27. The dimethyl diene 53 and the simplified diene 123 would give TIIA 2 and 
a tanshinone analogue 124, respectively. .................................................................... 115 
Figure 28. Norlapachol 115 significantly reduced neutrophil recruitment to a site of 
injury at 0.1 and 10 µM concentrations, but not at a 1 µM concentration. ................ 126 
Figure 29. β-Lapachone 112 significantly reduced neutrophil recruitment at a 
concentration of 1 µM, whilst at the same concentration, neither TI 1, lapachol 114, nor 
nor-β-lapachone 113 significantly affected neutrophil recruitment. ........................... 128 
Figure 30. Norlapachol 115 significantly accelerated resolution of neutrophilic 
inflammation at 10 and 25 µM concentrations, but not at 0.1 or 1 µM concentrations.
 ....................................................................................................................................... 129 
Figure 31. Neither lapachol 114, β-lapachone 112, nor nor-β-lapachone 113 
significantly enhanced resolution of neutrophilic inflammation at a concentration of 1 
µM. ................................................................................................................................ 130 
Figure 32. Possible routes to tanshinone analogues using an intramolecular Heck 
reaction (top) or C(sp3)-H activation chemistry (bottom). ........................................... 134 
Page 17 of 246 
 
Figure 33. Structure of the pancreatic cancer drug gemcitabine 141. .................... 139 
Figure 34. Subsets of SLC transporter proteins were expressed and regulated in 
resting primary human neutrophils. ............................................................................. 146 
Figure 35. Subsets of ABC transporter proteins were expressed and regulated in 
resting primary human neutrophils. ............................................................................. 148 
Figure 36. Expression levels of human SLC and ABC transporter proteins across two 
different datasets showed highly significant positive correlation. ............................... 150 
Figure 37. Structure of the SGK1 inhibitor GSK650394 142. ................................... 151 
Figure 38. Zebrafish larval neutrophils and non-neutrophil cells expressed distinct 
subsets of SLC transporter proteins. ............................................................................. 155 
Figure 39. Zebrafish larval neutrophils and non-neutrophil cells expressed distinct 
subsets of ABC transporter proteins. ............................................................................ 157 
 
List of schemes 
Scheme 1. Synthesis of TI 1 from podocarpic acid 6 .................................................. 34 
Scheme 2. Use of a Diels-Alder reaction to synthesise TI 1 in six steps .................... 35 
Scheme 3. A photochemical cyclisation strategy for synthesis of TI 1 ...................... 36 
Scheme 4. Use of a photochemical aromatic annulation strategy to give TI 1 in nine 
steps ................................................................................................................................ 37 
Scheme 5. Synthesis of TI 1 from 5-bromovanillin 27 ............................................... 38 
Scheme 6. Synthesis of TI 1 in three steps using Diels-Alder, epoxidation, and Feist-
Bénary reactions ............................................................................................................. 39 
Scheme 7. Large scale synthesis of TI 1 in three steps using a Diels-Alder strategy . 40 
Scheme 8. Synthesis of TIIA 2 from 7-methoxy-1-tetralone 37 ................................. 42 
Scheme 9. Synthesis of TIIA 2 in seventeen steps from 1,2,4-trimethoxybenzene 43
 ......................................................................................................................................... 43 
Scheme 10. TIIA 2 synthesis using a Diels-Alder reaction .......................................... 44 
Scheme 11. Use of ultrasound to improve the outcome of the Diels-Alder reaction in 
the synthesis of TIIA 2 ..................................................................................................... 45 
Scheme 12. Use of a photochemical aromatic annulation strategy to synthesise TIIA 
2 ....................................................................................................................................... 46 
Scheme 13. A SmI2-promoted radical cyclisation approach to TIIA 2 ........................ 47 
Page 18 of 246 
 
Scheme 14. Baeyer-Villiger oxidation of 5-bromovanillin 27. ................................... 58 
Scheme 15. Oxidation of the 1,4-hydroquinone 28 to the 1,4-benzoquinone 29. ... 58 
Scheme 16. Reaction of the 1,4-benzoquinone 29 with 3-(2-methylphenyl)propionic 
acid 75. ............................................................................................................................ 59 
Scheme 17. Radical alkylation using optimised conditions. ...................................... 60 
Scheme 18. Palladium-catalysed intramolecular Heck reaction. .............................. 61 
Scheme 19. Complete aromatisation using palladium on carbon. ............................ 62 
Scheme 20. Attempted O-demethylation using boron trichloride. ........................... 62 
Scheme 21. Attempted modified Feist-Bénary reaction. .......................................... 64 
Scheme 22. Synthesis of TI 1 and its isomer iso-TI 13. .............................................. 65 
Scheme 23. Radical alkylation of the benzoquinone 29 with 3-phenylpropionic acid 
80. .................................................................................................................................... 66 
Scheme 24. General radical alkylation reaction for optimisation studies using DoE.
 ......................................................................................................................................... 67 
Scheme 25. Radical alkylation reaction using various substituted carboxylic acids.. 71 
Scheme 26. General scheme for the intramolecular Heck reaction using the 
unsubstituted substrate 81. ............................................................................................ 72 
Scheme 27. Optimised intramolecular Heck reaction conditions. ............................ 73 
Scheme 28. Intramolecular Heck reaction using various substituted analogues. ..... 74 
Scheme 29. Aqueous hydroxide-mediated ether demethylation for various 
analogues. ....................................................................................................................... 75 
Scheme 30. Reaction of various alcohols 9, 30, 96-98 with chloroacetone to produce 
tanshinones 1, 31, 100, 102, 104 and isotanshinones 13, 99, 101, 103, 105................. 76 
Scheme 31. Attempted microwave reactions with sources of chloroacetaldehyde. 77 
Scheme 32. Synthesis of a dimethyl acetal 109 from TI 1. ........................................ 77 
Scheme 33. Use of a Diels-Alder reaction to synthesise various tanshinone analogues.
 ....................................................................................................................................... 104 
Scheme 34. Enamine formation from propanal 57 and piperidine 116. ................. 109 
Scheme 35. Attempted reaction of the enamine 117 with para-benzoquinone 32.
 ....................................................................................................................................... 110 
Scheme 36. Attempted benzofuranol 58 formation from propanal 57 and para-
benzoquinone 32 in the presence of L-proline. ............................................................ 111 
Page 19 of 246 
 
Scheme 37. Enamine 120 formation using morpholine 119 followed by reaction with 
para-benzoquinone 32 and chromatographic purification. ......................................... 112 
Scheme 38. Acid-mediated elimination to give 3-methyl-5-benzofuranol 58. ........ 113 
Scheme 39. Synthesis of 3-methyl-5-benzofuranol 58 in three steps from propanal 
57. .................................................................................................................................. 113 
Scheme 40. Selective oxidation of 3-methyl-5-benzofuranol 58 using Fremy’s salt to 
form the ortho-quinone 59. .......................................................................................... 114 
Scheme 41. The diene 123 could be synthesised from cyclohexanone 126 in two 
steps, comprising a Grignard reaction followed by dehydration. ................................ 116 
Scheme 42. Formation of the ortho-quinone dienophile 59 and subsequent Diels-
Alder reaction with cyclopentadiene 127. .................................................................... 118 
Scheme 43. Formation of the ortho-quinone dienophile 59 and attempted Diels-Alder 
reaction with cyclohexadiene 128. ............................................................................... 119 
Scheme 44. Use of an ultrasound-promoted Diels-Alder reaction to synthesise a 
mixture of tanshinone analogues 133 and 134. ........................................................... 120 
Scheme 45. Formation of the ortho-quinone dienophile 59 and subsequent Diels-
Alder reaction with Danishefsky’s diene 130. ............................................................... 121 
Scheme 46. Synthesis of β-lapachone 112 from lapachol 114. ............................... 123 
Scheme 47. Synthesis and proposed mechanism for the formation of norlapachol 115 
from lapachol 114 by a Hooker oxidation. .................................................................... 124 
Scheme 48. Synthesis of nor-β-lapachone 113 from norlapachol 115. ................... 125 
 
List of tables 
Table 1. Optimisation of conditions for the radical alkylation reaction. ................... 60 
Table 2. Reagents investigated for O-demethylation. ............................................... 63 
Table 3. The ten radical alkylation experiments carried out, as determined by the JMP 
DoE software. .................................................................................................................. 68 
Table 4. Summary of the effects of various tanshinones and isotanshinones on 
neutrophil recruitment and resolution of neutrophilic inflammation in vivo. ............... 95 
Table 5. Summary of the effects of norlapachol 115, lapachol 114, β-lapachone 112, 
and nor-β-lapachone 113 on neutrophil recruitment and resolution of inflammation in 
vivo. ............................................................................................................................... 132 
 
Page 20 of 246 
 
1. Abstract 
 During inflammation, retention of persistent neutrophils at the inflammatory site, 
either due to excessive neutrophil recruitment or failed spontaneous resolution of 
inflammation, can play a major role in many chronic inflammatory diseases, such as 
chronic obstructive pulmonary disease. Current treatments for dysregulated 
inflammation are generally ineffective, non-specific, and can exhibit undesired side 
effects, thus there remains a need to identify new effective clinical treatments. 
Tanshinones have shown promising anti-inflammatory effects by targeting neutrophils 
in vivo, yet are still an underexplored class of compounds in this regard. In this work, an 
optimised six step synthetic route was used to synthesise a series of substituted 
tanshinone analogues and isomeric isotanshinones. A radical decarboxylative alkylation 
and an intramolecular Heck reaction were key steps in this route, and optimisation of 
these processes was explored considerably, including the use of Design of Experiments 
software. Synthesis of additional tanshinones using a Diels-Alder reaction was 
investigated, whilst some further compounds with broad structural similarity to 
tanshinones were also produced. All synthesised compounds were evaluated in vivo 
using a zebrafish model of inflammation. Some of the compounds reduced initial 
neutrophil recruitment, whilst others accelerated resolution of neutrophilic 
inflammation, which allowed for the construction of broad structure-activity 
relationships and identification of compounds with promising in vivo anti-inflammatory 
effects. Notable differences in toxicity profiles between compound classes were also 
observed. In addition, to seek a greater understanding of how molecules such as 
tanshinones access their molecular target in vivo, analysis of the expression of drug 
transporter proteins in human and zebrafish neutrophils was carried out. Annotated 
phylogenetic trees were produced which are envisaged to provide a generally useful 








2.1.1 Neutrophils in the inflammatory response 
Inflammation is the body’s natural protective response initiated either when tissue is 
injured, or when infection is detected within the body, due to exposure to an external 
pathogen or toxin. Upon initiation, the inflammatory response is induced, an essential 
part of host defence which comprises a highly controlled sequence of events and 
consists of two components: the innate (non-adaptive) immune response, and the 
adaptive immune response.1 The innate response occurs immediately, and entails 
recognition of the pathogen, toxin or injury, followed by response from innate immune 
cells including neutrophils, macrophages, and eosinophils, and the involvement of 
various modulatory molecules including cytokines and lipid mediators, amongst other 
processes. The adaptive immune response, which only occurs in vertebrates, is 
considered the second line of defence, providing specificity towards any invading 
pathogen. Lymphocytes, comprising B cells, T cells, and natural killer cells, are primarily 
involved in this response.  
Neutrophils are one of the largest circulating populations of white blood cell found in 
humans as well as most other vertebrate and non-vertebrate organisms.2 They comprise 
around 50% of the human body’s white blood cells and are amongst the most important 
cell types involved in the inflammatory response, as one of the first responders to injury 
or pathogen invasion.3 Neutrophils thereby play a vital role in the mediation of all stages 
of the inflammatory response (Figure 1). This can be generally divided up into initial 
neutrophil recruitment, peak neutrophilic inflammation, and resolution of neutrophilic 
inflammation.4 
 
Figure 1. A simplified schematic outlining the role played by neutrophils during the 
inflammatory response. 
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Upon injury or pathogen invasion, neutrophils become activated and are 
subsequently recruited to the site of injury or infection in the affected organ(s), usually 
within 6 hours of initiation.5 This occurs in response to chemical pro-inflammatory 
stimuli, which include soluble cytokines such as interleukin-8 (IL-8), and reactive oxygen 
species (ROS).6,7  
At the site of injury or infection, recruited neutrophils act to defend and protect the 
body, eliminating any invading pathogens by phagocytosis, degranulation, release of 
neutrophil extracellular traps (NETs) and proteases, and production of ROS.6,8–11 It is 
essential that neutrophil function is strictly regulated: whilst these processes are 
required for effective host defence and response, they also need to be limited to avoid 
persistent inflammation.12  
Following this, timely removal of recruited neutrophils from the site of injury or 
infection, a key part of resolution of neutrophilic inflammation, is necessary.5,13,14 In 
healthy individuals, this is a tightly controlled process which ultimately leads to recovery, 
as the number of neutrophils at the inflammatory site returns to pre-inflammation 
levels, restoring homeostasis and mediating tissue repair.5,14,15 One way in which 
resolution is achieved is through neutrophil apoptosis, the programmed cell death of 
neutrophils, and subsequent engulfment of apoptotic cells by macrophages (another 
type of white blood cell), termed efferocytosis. The process of apoptosis has been 
recognised for over forty years,16 and is a well-documented process for the clearance of 
neutrophils in the resolution stage.11,17–22 Neutrophils may also be cleared by removal 
from the inflammatory site into inflammatory exudates.23 
An additional, more recently reported mechanism for the clearance of neutrophils is 
reverse migration of neutrophils from the inflammatory site to other parts of the body.24 
As early as 1997, movement of neutrophils away from an inflammatory site was 
reported for intravascular neutrophils in kidneys in a rat model, and was suggested to 
be a previously unreported mechanism which predominated over neutrophil 
apoptosis.25 An analogous retrograde mechanism was later identified for human 
neutrophils,26 including in microfluidic devices,27 as well as in mice.28 In zebrafish, this 
process was originally reported to be analogous to retrograde chemotaxis,29 and was 
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often termed as fugetaxis or chemorepulsion, meaning that the neutrophils were 
actively moving away from a chemokinetic agent: this suggested that neutrophil 
movement away from the wound was a persistent and directional phenomenon.30,31 
Later studies, also in zebrafish, also identified a bidirectional movement of neutrophils 
consistent with directional reverse migration.32–34 However, analysis of the patterns of 
neutrophil migration observed up to this point was relatively limited. Detailed 
characterisation of the neutrophil reverse migration dynamics later undertaken found 
that neutrophils were actually randomly dispersed from the wound in a redistribution 
process,35 and that their movement away from the wound was not directional or a form 
of fugetaxis as previously suggested. Recent work in zebrafish was found to be in 
agreement with this characterisation of reverse migration.36 A later study suggested that 
neutrophils which had reverse migrated showed no long-term phenotypic differences 
compared to neutrophils which had not been involved in the inflammatory response.37 
The relative contributions of apoptosis and reverse migration to neutrophil clearance 
processes are currently unclear, but have been much discussed in the literature, with 
both processes thought to occur, but to varying extents in differing studies.29,36,38,39 
 
2.1.2 Unresolved neutrophilic inflammation in human diseases 
Excess neutrophil recruitment or dysregulation of the mechanisms of inflammation 
resolution can result in persistent neutrophils remaining at the inflammatory site. This 
can have very damaging, often irreversible effects on the surrounding tissue, due to the 
release of toxic granule proteins, resulting in pathogenesis of chronic 
inflammation.11,40,41 Thus, failed resolution of neutrophilic inflammation is known to 
play a key role in various chronic inflammatory diseases. One of the main diseases which 
failed inflammation resolution can contribute to is chronic obstructive pulmonary 
disease (COPD),42,43 and the related acute respiratory disease syndrome (ARDS).44 COPD 
is the fourth highest cause of global mortality, claiming over three million lives annually, 
which corresponds to 5% of all global deaths, and this figure is projected to increase 
further in future years.45 
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Prominent neutrophilic inflammation has also been identified from analysis of the 
sputum of some asthmatic patients, in which neutrophils were the major inflammatory 
cell present.46 Further studies identified that higher neutrophil numbers were 
associated with severe asthma, suggesting that a lack of neutrophil clearance and 
unresolved inflammation made a major contribution to this chronic disease.47–49 A 
reduction in human neutrophil apoptosis in patients with chronic severe asthma was 
later identified.50 
In addition to COPD and asthma, failed efferocytosis and chronic neutrophilic 
inflammation have been associated with various other chronic inflammatory lung 
diseases. These include cystic fibrosis (CF), non-CF bronchiectasis, and other infiltrative 
pulmonary diseases.51,52 Furthermore, dysregulation of inflammation resolution is 
thought to contribute significantly to neurodegenerative disease, multiple sclerosis and 
rheumatoid arthritis,53–55 whilst harmful inflammation is also implicated in 
atherosclerosis,56 as well as obesity.54,57  
 
2.1.3 Current and future treatments for unresolved inflammation  
Chronic diseases characterised by unresolved neutrophilic inflammation largely 
respond poorly to current treatments, which include inhaled bronchodilators and 
glucocorticoids, a group of steroids which are used as anti-inflammatory agents for 
treating various diseases including asthma and rheumatoid arthritis.58–60 However, these 
compounds are non-specific, poorly effective, and can exhibit many undesired side 
effects.61,62 Long term usage of such treatments can lead to harmful effects such as 
increased susceptibility to infection.60 
Aside from these treatments, some of the most promising therapeutic approaches 
for promoting inflammation resolution involve replication of endogenous pro-resolution 
lipid mediators such as lipoxins, protectins, resolvins and maresins.63–68 Resolvins are a 
group of mediators produced in vivo during the inflammatory response, which 
themselves exhibit anti-inflammatory properties by promoting resolution of 
inflammation, exhibiting their maximal effect during the spontaneous resolution 
phase.64,65,69,70 Maresins (macrophage mediators in resolving inflammation) are a group 
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of powerful anti-inflammatory, pro-resolution mediators, which promote inflammation 
resolution by regulating the entry of neutrophils, and stimulating phagocytosis by 
macrophages.66,71,72 
Apart from lipid mediators, other classes of compounds have been found to 
accelerate inflammation resolution, a process which can be achieved by increased 
induction of neutrophil apoptosis.73,74 For example, cyclin-dependent kinase inhibitors 
such as R-roscovitine have been found to promote inflammation resolution by 
increasing apoptosis of neutrophils.22,75 Serum- and glucocorticoid-regulated kinase 1 
(SGK1) is also a kinase which can be targeted to enhance resolution of neutrophilic 
inflammation.76 
However, in general, there are currently very few treatments which are effective in 
promoting the resolution of neutrophilic inflammation without exhibiting unwanted 
side effects. This may in part be due to a lack of in vivo drug screening approaches, as 
well as limitations in understanding how drugs penetrate and access cells such as 
neutrophils. Whilst some treatments are showing promise, these are somewhat limited 
by a lack of understanding of their mechanism of action at a molecular level. Some of 
these also do not exhibit selectivity, for example in targeting the particular cell type of 
interest. There are currently no clinical treatments in use for treating unresolved 
inflammation which specifically target the neutrophil. Therefore, there remains a need 
to identify new safe and effective anti-inflammatory compounds which target 
neutrophils, either by modulating initial neutrophil recruitment to, and accumulation at, 
the site of inflammation, or by accelerating the clearance of neutrophils from the 
inflammatory site following peak inflammation (pro-resolution compounds), including 
by promoting reverse migration.13 Ideal compounds would exclusively accelerate 
resolution of neutrophilic inflammation, as this would promote tissue healing without 
compromising host defence. It is clearly not desirable to reduce neutrophil recruitment 
to such an extent that susceptibility to infection is compromised; however, 
pharmacological reduction of neutrophil recruitment could still be helpful in modulating 
inflammation in certain patients. In particular, such treatments could be beneficial for 
patients who are unable to clear neutrophils following initial recruitment, and/or those 
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who recruit a disproportionately large number of neutrophils and later experience 
difficulty in clearing all of these. Indeed, ongoing research in the pharmaceutical industry 
has involved the identification of several possible anti-inflammatory drugs which target 
the neutrophil recruitment stage of the inflammatory response.77–81 
 
2.2 Zebrafish models of human disease 
2.2.1 Advantages of the zebrafish model 
The zebrafish (Danio rerio) is an outstanding model system for studying biological 
processes, as a vertebrate with high gene homology to humans, particularly for the heart 
and blood.82 This provides important translational relevance, especially for modelling 
various human diseases.83,84 The genetic tractability of zebrafish means that genetic 
modifications, and therefore generation of transgenic lines, can be readily carried 
out.29,85,86 Mutations can be efficiently induced, whilst eggs can be fertilised in vitro and 
sperm can be frozen.87 Tailfin regeneration can occur not only in adults, but also in 
younger zebrafish,88 with a mechanism similar to that in adults, both at a cellular and 
molecular level. Zebrafish hearts can also regenerate,89 overcoming the scarring which 
typically occurs in humans. As a vertebrate in vivo model, use of the zebrafish allows for 
exploration of complex cellular processes in their native biological context, rather than 
in isolation as for in vitro approaches. Other advantages include the fast growth rate and 
cost-effectiveness of zebrafish.83,90  
In addition, use of in vivo models such as zebrafish provides an excellent phenotypic 
screening approach for evaluating numerous compounds in various disease models. In 
particular, any possible issues with drug efficacy and toxicity can be identified early in 
the drug discovery and development process, as well as off-target effects.90–94 This 
represents a great advantage compared to the more traditional drug discovery approach 
generally used by large pharmaceutical companies, in which in vivo studies are typically 
carried out much later on in the process. Indeed, this latter approach bears an incredibly 
high attrition rate, with drug toxicity and lack of efficacy representing two of the most 
common causes of a drug failing to reach the clinic.95–98  
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In the laboratory, the zebrafish provides further practical advantages. Due to the high 
fertility of adult zebrafish, a single mating can give rise to hundreds of larvae. Larvae and 
young zebrafish are transparent, meaning that individual cells can be easily tracked in 
vivo. Embryos can be visualised under a standard biological microscope, and their small 
size facilitates convenient handling in the laboratory, as they can be easily transferred 
into Petri dishes and 6-, 24- or 96- well plates, enabling efficient screening of large 
numbers of compounds. 
 
2.2.2 Zebrafish models of the inflammatory response 
Humans and zebrafish share highly conserved immune systems, meaning that 
zebrafish can be used as an effective model for the inflammatory response.84,99,100 The 
adaptive immune system of zebrafish does not fully develop and become completely 
functional until approximately four weeks after fertilisation, meaning that the innate 
immune response can be studied independently during the first few weeks of 
development.100–102 Similarities between the innate immune systems of the two 
organisms include the presence of conserved molecular components such as pro-
inflammatory cytokines,84,100 similar inflammatory response kinetics,5,86 and the 
presence of neutrophils, allowing for effective study of neutrophil behaviour.103  
Zebrafish neutrophils are functionally developed as early as 48 hours post-
fertilisation and have been found to resemble those of humans,104 containing 
segmented nuclei, cytoplasmic granules, and myeloid-specific peroxidase (Mpx), a 
protein which is a zebrafish equivalent of the human myeloperoxidase protein (MPO), 
and is specifically expressed in neutrophils.103–105 Like human neutrophils, zebrafish 
neutrophils are also able to phagocytose and kill pathogens,106 and produce NETs.107 
Myeloid precursors develop similarly in the zebrafish kidney and in the bone marrow of 
humans.105  
The genetic tractability of zebrafish means that various cell types of interest can be 
labelled and monitored, including innate immune cells such as neutrophils.100 This 
allows for in vivo manipulation and study of inflammation, including mechanisms 
governing different phases of the inflammatory response such as recruitment and 
Page 28 of 246 
 
resolution,33,86,108 as well as dissection of different clearance mechanisms for resolution 
of neutrophilic inflammation, namely apoptosis and reverse migration.  
The first transgenic zebrafish models for analysis of the inflammatory response which 
used fluorescently labelled neutrophils were established in 2006, in which the 
neutrophil-specific mpx promoter controls expression of green fluorescent protein (GFP) 
(Figure 2).86 Tissue injury was induced by injuring the tailfin with a sterile scalpel blade, 
initiating a reliable inflammatory response. Neutrophils were identified by their 
fluorescence and counted at various time points, whilst live microscopy could be used 
to track cells.39 Later work showed that neutrophils and macrophages could be imaged 
simultaneously using a closely related transgenic zebrafish model,109 and other 
macrophage-specific markers have also been identified,110,111 enabling macrophage 
behaviour to be studied both exclusively and in conjunction with neutrophils. 
Furthermore, the inflammatory response could be modulated using various 
pharmacological agents.38 Other methods apart from tailfin injury are known for 
inducing an inflammatory response in zebrafish, including the use of lipopolysaccharide 
(LPS),112 other chemicals such as copper sulfate,113 and manipulation of the swim 
bladder.114 
 
Figure 2. A transgenic larva, Tg(mpx:GFP)i114, age 3 days post fertilisation (3 dpf), as 
viewed under the normal brightfield (top) and GFP (bottom) channels of a fluorescence 
microscope. 
 
2.2.3 Use of zebrafish models in compound screens 
Since 2000, zebrafish have been used for undertaking large-scale compound screens, 
working towards identification of compounds that affect vertebrate development and 
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function.115 The small size and large numbers of larvae available enables utilisation of 
high throughput drug screens, which have been employed successfully in numerous 
cases.36,112,113,116–119  
Zebrafish have since been used for high throughput assays to identify potential anti-
inflammatory compounds. For example, a chemically-induced inflammation assay has 
been used as a method of quickly screening thousands of compounds, to identify new 
leads for potential therapeutic treatments for inflammation.113 More recently, a LPS-
induced inflammation assay was used to screen for anti-inflammatory compounds in 
vivo,112 whilst a zebrafish model was also used in the screening of a library of natural 
products to identify compounds which inhibited neutrophil recruitment.119 In an 
independent study, a larger compound screen using an in vivo zebrafish model was used 
in the identification of compounds which accelerated resolution of inflammation, and 
found that a natural product molecule called tanshinone IIA was highly active.36 This 
compound exhibited its effect by enhancing reverse migration of neutrophils, as well as 
resulting in a small increase in neutrophil apoptosis, yet without any significant effect 
on the number of neutrophils recruited to the site of injury. A related molecule called 
tanshinone I is also thought to exhibit an anti-inflammatory effect, although this has 
been only scarcely studied (Dr. Anne Robertson, The University Of Sheffield, Appendix 
10.1). 
As these tanshinones appear to display anti-inflammatory effects in zebrafish, effects 
of closely related structural analogues of these molecules in this model are also of 
interest. Little work has been done in this area (Appendix 10.1), and investigation of the 
effects of such molecules on neutrophil behaviour in a zebrafish model of inflammation 
is vastly underexplored. Many close derivatives have never been synthesised before, 
whilst others have not been investigated for anti-inflammatory activity, in particular, in 
relation to neutrophil-specific effects or in a zebrafish model. Therefore, synthesis of 
tanshinones, and their analogues, is of interest here.  
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2.3 Tanshinones 
2.3.1 Origin of tanshinones  
Tanshinones are a group of natural products found in Salvia miltiorrhiza (also known 
as danshen, tanshen or Chinese red sage), a plant traditionally used as a remedy in 
Chinese herbal medicine since as early as the first century AD.120 First isolated from the 
plant in 1934,121 these molecules are often referred to as abietane diterpenoids, and 
generally consist of four fused rings. Two of these rings form a naphthalene or 
tetrahydronaphthalene moiety, the third is usually an ortho- or para-quinone (or 
lactone), and the fourth ring is a furan or dihydrofuran. Particular tanshinones are 
differentiated by their different substituents, number of aromatic rings present in the 
molecule, or their stereochemical configuration: specific examples include tanshinone I 
(TI) 1, tanshinone IIA (TIIA) 2, tanshinone IIB (TIIB) 3, dihydrotanshinone I 4 and 
cryptotanshinone 5 (Figure 3). In particular, TI 1 and TIIA 2 are amongst the most widely 
investigated tanshinones. 
 
Figure 3. Exemplar tanshinones. 
 
Isolation of specific tanshinones directly from Salvia miltiorrhiza usually requires a 
series of extractions starting from the dried roots immersed in alcoholic solution,122–125 
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followed by chromatographic separation. Whilst this is sufficient for attaining milligram 
quantities of a particular compound for biological testing, the specificity and low-
yielding nature of this approach means that for obtaining practically useful quantities of 
various analogues, a synthetic organic chemistry approach is usually required, and is a 
necessity for the synthesis of any novel tanshinone derivatives.  
 
2.3.2 Biological effects of tanshinones  
Salvia miltiorrhiza has long been used as a remedy in traditional Chinese medicine, to 
treat a broad spectrum of conditions. These mainly comprise cardiovascular diseases 
including atherosclerosis and angina, and various inflammatory diseases such as arthritis 
and hepatitis, as well as other diseases including stroke, liver fibrosis, tuberculosis and 
leprosy, and anti-cancer activity.126–133 However, recent studies have sought to isolate, 
identify and investigate some of the biological effects of particular tanshinones found 
within Salvia miltiorrhiza. TI 1 and TIIA 2, as two of the more naturally abundant 
tanshinones in the herb, have been particularly well studied for various biological 
activities, especially TIIA 2. Many analogous effects have also been reported throughout 
the literature for the highly structurally similar molecules dihydrotanshinone I 4 and 
cryptotanshinone 5.  
Numerous studies have found that TI 1 induces apoptosis in various cell types, 
including in activated hepatic stellate cells,134 human colorectal cancer cells,135 and 
gastric cancer cells.136 Induction of apoptosis by TIIA 2 is also well-documented, in cells 
such as human leukaemia cells,137,138 human brain tumour (glioma) cells,139 
cardiomyocytes,140 and osteosarcoma cells.141 Such effects may occur as a result of 
various events, including activation of caspase-3 and/or caspase-12, events which likely 
have important implications in other biological effects such as anti-inflammatory 
activity.137,142,143,144  TIIA 2 is also a substrate of NAD(P)H quinone oxidoreductase 1 
(NQO1), resulting in apoptotic cell death in certain lung cancer cells.145 
These apoptotic effects are particularly relevant to the cytotoxic effects exhibited by 
tanshinones: in TI 1 this has been reported for human colon cancer cells,146,147 and for 
different types of leukaemia cells.142 Anti-cancer activity exhibited by TIIA 2 has similarly 
Page 32 of 246 
 
been observed against human breast cancer cells,148 as well as for various other cancer 
cells, and in other model organisms such as Drosophila.139,147,149–151  
Tanshinones have been reported to exhibit antioxidant effects, possibly by reacting 
with lipid free radicals and preventing lipid peroxidation products from binding with 
DNA.152 It was previously suggested that TIIA 2 did not act as an antioxidant, in contrast 
to other tanshinones such as TI 1,153,154 but TIIA 2 was later found to inhibit oxidation of 
low density lipoproteins, indicating a possible use for this molecule in preventing 
atherosclerosis development.155 
Both TI 1 and TIIA 2 have been found to demonstrate various protective effects. 
Beneficial cardiovascular effects have been reported for TI 1,156 as well as for TIIA 2,157–
160 including anti-atherosclerotic effects.161–165 TIIA 2 has shown protective effects 
against hepatic fibrosis and hepatotoxicity166–168 and diabetes,169,170 whilst TI 1 has 
exhibited beneficial effects for learning and memory-enhancement.171 Both TI 1 and TIIA 
2 have also shown antimicrobial activities, against a variety of bacterial and fungal 
strains.172–176 Neuroprotective effects of TIIA 2 have been reported in various mouse and 
rat models.177–181 Related effects including cardio-cerebrovascular protection are also 
well-documented, including protective effects against myocardial ischemia.156,182 In 
addition, TIIA 2 has been found to reduce inflammation in brain tissue in a rat model of 
Alzheimer’s disease,183 whilst TI 1 has shown an anti-inflammatory role in 
neuroprotection in gerbil hippocampus.184 
Various other anti-inflammatory effects have also been reported for TI 1 and TIIA 2. 
TI 1 exhibited an in vivo anti-inflammatory effect in rats,185 and it has been shown that 
TI 1 can inhibit production of inflammatory mediators such as IL-12 and interferon 
gamma,186 as well as cyclooxygenase-2-mediated production of prostaglandin E2 and 
inducible nitric oxide synthase- (iNOS) mediated synthesis of nitric oxide.187,188 TI 1 is 
also thought to exhibit an anti-inflammatory effect in a zebrafish model of inflammation, 
although this has not been fully explored (Dr. Anne Robertson, The University Of 
Sheffield, Appendix 10.1). Anti-inflammatory effects shown by TIIA 2 both in vivo and in 
vitro are relatively well documented. TIIA 2 inhibits the production of various 
inflammatory mediators, including the cytokines IL-1β, IL-6, IL-8, tumour necrosis factor 
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alpha (TNFα), and phospholipase A2,189–192 alongside other anti-inflammatory processes 
in other in vitro and in vivo studies,163,193–195 including in relation to NQO1.196 Anti-
inflammatory effects exhibited by TIIA 2 in vivo have been shown in vertebrate models, 
including a rat model of renal fibrosis and inflammation,197 a murine model of LPS-
induced lung injury,190,197 and murine models of colitis and chronic arthritis,198,199 where 
it was shown that the effects exhibited by TIIA 2 were due to modulation of neutrophil 
activity, including increased apoptosis and a reduction in NET formation. It was recently 
shown that TIIA 2 exhibited a profound anti-inflammatory effect in a zebrafish model of 
inflammation, modulating neutrophil activity to accelerate inflammation resolution. TIIA 
2 promoted increased reverse migration of neutrophils, as well as a small increase in 
neutrophil apoptosis, an effect which was conserved in treatment of human neutrophils 
with TIIA 2.36 
 
2.3.3 Chemical synthesis methods for TI and analogues 
The first synthesis of TI 1 was achieved in a semi-synthesis starting from the natural 
product podocarpic acid 6 (Scheme 1).200 The first step consisted of treatment with 
selenium, upon which dehydrogenation, demethylation and decarboxylation led to 
formation of 8-methyl-3-phenanthrol 7.201 This was coupled with diazotised sulfanilic 
acid, reduced to the amino-phenol, and converted to the corresponding 3,4-
phenanthraquinone 8 using the Fieser procedure.202 This was reduced to the ortho-
quinol and underwent autoxidation in the presence of potassium tert-butoxide and 
oxygen to form the hydroxy-quinone 9. Cyclisation with β-chloro-α-methylpropionyl 
peroxide gave racemic dihydrotanshinone I 4, which was oxidised using 2,3-dichloro-5,6-
dicyano-1,4-benzoquinone (DDQ) to yield TI 1 in seven steps. This was achieved in an 
overall yield of 34% from the 1,4-quinone 9; a yield for the first five steps was not 
reported. 
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Scheme 1. Synthesis of TI 1 from podocarpic acid 6.200–202  
 
In independent synthetic efforts, a Diels-Alder reaction was used to form the main 
part of the tanshinone structure, a strategy applicable for accessing several different 
tanshinones (Scheme 2).203,204 3-Methyl-4-benzofuranol 10 was first oxidised to 3-
methylbenzofuran-4,7-quinone 11 using potassium nitrosodisulfonate (Fremy’s salt). 
The para-quinone 11 underwent Diels-Alder reaction with 2-methylstyrene 12 to give 
the aromatised Diels-Alder product 13, albeit in low yield. This was reduced to the 
hydrogenated product 14 with platinum oxide, followed by hydrolysis with potassium 
hydroxide to give the diol 15. Acidification with sulfuric acid gave racemic 
dihydrotanshinone I 4, and final oxidation with DDQ yielded TI 1, in an overall yield of 
4% over six steps.  
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Scheme 2. Use of a Diels-Alder reaction to synthesise TI 1 in six steps.203,204 
 
A photochemical cyclisation reaction induced by base was utilised as a different 
approach to the synthesis of TI 1, starting with the dimethoxy-tricyclic compound 16 
(Scheme 3).205 A synthesis of this starting material 16 was later reported: an initial Suzuki 
coupling reaction between 2,3-dimethylphenylboronic acid 17 and 2-
bromoveratraldehyde 18 to give the coupled product 19 was followed by reaction with 
potassium tert-butoxide under irradiation, to form the cyclised product 16.206,207 For the 
synthesis of TI 1, the dimethoxy compound 16 was subjected to demethylation and 
oxidation to give the ortho-quinone 8, followed by acetylation to provide the tri-acetate 
20. Subsequent reaction with sodium methoxide formed the hydroxy-quinone 9, 
crotylation of which resulted in the alkylated product 21. This was followed by 
acetylation and oxidative olefin cleavage to give the aldehyde 22, and final hydrolysis 
and acid-promoted cyclisation to produce TI 1, in less than 1% overall yield.  
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Scheme 3. A photochemical cyclisation strategy for synthesis of TI 1.205–207  
 
A photochemical aromatic annulation method was later developed, which enabled 
the synthesis of TI 1 in nine steps and 32% overall yield from bromo-1-naphthoic acid 23 
(Scheme 4).208 This was first converted to the ketone 24 using a previously described 
quenching procedure with methyllithium,209 and was followed by a two-step 
‘detrifluoroacetylative’ diazo transfer method to give the corresponding diazo ketone 
25.210 The key aromatic annulation step between this diazo ketone 25 and a substituted 
alkyne gave the tricyclic product 26. This was followed by silyl deprotection with tetra-
n-butylammonium fluoride (TBAF) and treatment with oxygen to form the diol 15. 
Subsequent reaction with sulfuric acid gave enantiopure dihydrotanshinone I 4, and final 
oxidation with DDQ provided TI 1. 
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Scheme 4. Use of a photochemical aromatic annulation strategy to give TI 1 in nine 
steps.208–210 
 
A recently reported method outlined synthesis of TI 1 and closely related analogues 
in six steps and up to 19% overall yield, starting from 5-bromovanillin 27 (Scheme 5).211 
A two-step literature procedure proceeding via the 1,4-hydroquinone 28 was used to 
form the 1,4-bromoquinone 29 in high yield.212 This was coupled with a range of 
arylpropionic acids, with different substituents at the ortho- and para- positions of the 
phenyl ring, in a Minisci-type decarboxylative radical alkylation reaction. Intramolecular 
Heck reaction with a palladium catalyst, followed by direct treatment of the product 
with sodium hydroxide solution in the presence of oxygen, provided solely the fully 
aromatised, O-demethylated products. Finally, treatment of the alcohols 9 and 30 with 
bromo-2-propanone and ammonium acetate in a sealed tube gave the corresponding 
tanshinones 1 and 31. Unlike the methods previously discussed, this strategy was more 
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practical for synthesising analogues of TI 1, and did not appear to suffer from particularly 
low reaction yields or limited availabilities of starting material.  
 
Scheme 5. Synthesis of TI 1 from 5-bromovanillin 27.211,212 
 
Another route using a Diels-Alder reaction strategy led to synthesis of TI 1 in just three 
steps (Scheme 6).213 Diels-Alder reaction between para-benzoquinone 32 and 2-
methylstyrene 12 gave the tricyclic adduct 33 in moderate yield. Weitz-Scheffer 
epoxidation gave the epoxide 34, which was subjected to Feist-Bénary reaction 
conditions to form TI 1, in an overall yield of 15%.  
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Scheme 6. Synthesis of TI 1 in three steps using Diels-Alder, epoxidation, and Feist-
Bénary reactions.213 
 
In 2017, a three step multi-gram synthesis of TI 1 was reported (Scheme 7).214 A Diels-
Alder reaction between 2-methoxy-1,4-benzoquinone 35 and 2-methylstyrene 12 to 
give the tricyclic methyl ether 36 was followed by demethylation using ethanolic 
hydroxide solution to give the alcohol 9. Finally, a modified Feist-Bénary reaction using 
chloroacetone gave the desired TI 1 in 45% yield, and an overall yield of approximately 
18% across the three steps.  
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Scheme 7. Large scale synthesis of TI 1 in three steps using a Diels-Alder strategy.214 
 
In addition to syntheses of TI 1, there have been various reports detailing the 
preparation of different analogues of TI 1, often starting with the natural product itself 
(Figure 4). These have entailed exploration of various parts of the TI 1 structure, 
including modification of the ortho-quinone functionality,215–219 alteration of the furan 
ring to different heterocycles,220 addition of various substituents to the furan ring,175,221–
227 adjustment of the tanshinone core skeleton,227 modification of the phenyl ring,228–232 
and the addition of different phenyl ring substituents.211 
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Figure 4. Published syntheses of various TI analogues (modified parts shown in red). 
 
2.3.4 Chemical synthesis methods for TIIA and analogues 
TIIA 2 was first synthesised totally using a similar method to that of the first synthesis 
of TI 1 in the later steps (Scheme 8).200 7-Methoxy-1-tetralone 37 underwent a 
Reformatsky reaction with methyl γ-bromocrotonate, the product of which was oxidised 
over palladium on carbon, and hydrolysed to the carboxylic acid 38 for purification 
purposes. The acid 38 was converted to the methyl ester 39, which underwent Grignard 
reaction with methylmagnesium iodide, followed by cyclodehydration and 
demethylation to give the tricyclic phenol 40. This was converted to the 3,4-
phenanthraquinone 41 and then the hydroxy-quinone 42 using the same steps as in the 
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synthesis of TI 1. Treatment with β-chloro-α-methylpropionyl peroxide formed racemic 
cryptotanshinone 5, which was aromatised with DDQ to give TIIA 2 in a total of 13 steps. 
 
Scheme 8. Synthesis of TIIA 2 from 7-methoxy-1-tetralone 37.200 
 
In the same year, a stepwise cyclisation strategy was used to synthesise TIIA 2 in 
seventeen steps from 1,2,4-trimethoxybenzene 43 (Scheme 9).233,234 This underwent 
Friedel-Crafts acylation to give the aryl ketone 44, followed by catalytic hydrogenation 
to give the alkane 45, and further intramolecular Friedel-Crafts acylation to form the 
bicyclic product 46. Reformatsky reaction with ethyl γ-bromocrotonate and removal of 
a methoxy group, followed by concomitant dehydration, aromatisation, and alkene 
hydrogenation, produced the naphthylbutyric ester 47. Subsequent Grignard reaction 
and cyclodehydration using sulfuric acid formed the tricyclic product 48. A carboxylic 
acid moiety was then introduced, and used to form the corresponding methyl ester 49. 
This was converted to the methyl ketone 50 via a sulfoxide intermediate, and selective 
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demethylation. Further reaction steps consisted of reaction with ethyl bromoacetate 
and saponification to give the carboxylic acid 51, followed by an intramolecular Perkin 
reaction to construct the fourth ring, forming the furan 52. Finally, reaction with 
methylmagnesium iodide, attempted oxidation and subsequent autoxidation produced 
the desired TIIA 2. Catalytic hydrogenation was also used to convert this to racemic 
cryptotanshinone 5. 
 
Scheme 9. Synthesis of TIIA 2 in seventeen steps from 1,2,4-trimethoxybenzene 
43.233,234 
 
The Diels-Alder reaction sequence previously used to synthesise TI 1 was also 
employed by the authors to make TIIA 2 (Scheme 10).203,204 The para-quinone dienophile 
11 was again formed from Fremy’s salt-mediated oxidation of the benzofuranol 10. The 
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dienophile 11 underwent Diels-Alder reaction with 6,6-dimethyl-1-vinylcyclohexene 53 
to form the adduct 54, which was first aromatised in air, and then hydrogenated with 
palladium on carbon to give the unsaturated furan 55. Ring opening with potassium 
hydroxide to form the diol 56 was followed by acid-mediated cyclisation to form racemic 
cryptotanshinone 5, which was aromatised with DDQ to give TIIA 2 in a moderate overall 
yield.  
 
Scheme 10. TIIA 2 synthesis using a Diels-Alder reaction.203,204 
 
Later, it was found that a similar Diels-Alder reaction could be performed using a 
slightly different dienophile, and this could be promoted using ultrasound to increase 
both the yield and the proportion of desired product.229,230 This enabled the simplified 
construction of tanshinones in high yields (Scheme 11). Starting with propanal 57, 3-
Page 45 of 246 
 
methylbenzofuranol 58 was synthesised in three steps, and was converted into 3-
methyl-4,5-benzofurandione 59 by Fremy’s salt-mediated oxidation.228 This underwent 
Diels-Alder reaction with 6,6-dimethyl-1-vinylcyclohexene 53 and subsequent 
aromatisation to give TIIA 2 and its isomer 60. 
 
Scheme 11. Use of ultrasound to improve the outcome of the Diels-Alder reaction in 
the synthesis of TIIA 2.228–230 
 
The photochemical aromatic annulation strategy previously used in the synthesis of 
TI 1 was also applied to the synthesis of TIIA 2 (Scheme 12).235 Palladium-catalysed 
coupling of 2-bromoanisole 61 with a homoallylic organozinc compound gave the ortho-
substituted aryl ether 62, which upon treatment with aluminium trichloride underwent 
cyclisation to give the bicyclic compound 63. This was demethylated, and the phenol 
converted to the triflate 64. This underwent a carbonylative Stille reaction to give a 
ketone which was subjected to the diazo transfer conditions used previously in the 
synthesis of TI 1, to give the diazo compound 65. Photochemical aromatic annulation 
gave the phenol 66, which underwent silyl deprotection followed by reaction with 
oxygen to give the diol 56. Acid-mediated cyclisation produced (-)-cryptotanshinone 5, 
which was aromatised with DDQ to produce TIIA 2.  
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Scheme 12. Use of a photochemical aromatic annulation strategy to synthesise TIIA 2.235 
 
A different route to TIIA 2 was later reported, starting from 1,5-naphthalenediol 67 
(Scheme 13).236 Single methylation gave the mono-phenol 68, and was followed by 
formation of the diethyl phosphate 69, which underwent a nickel-catalysed coupling 
reaction, followed by aluminium trichloride-mediated cyclisation to give the tricyclic 
product 70. Demethylation, aromatic bromination, and reaction with allyl bromide gave 
the O-allyl tricycle 71. A key SmI2-promoted intramolecular cyclisation was used to form 
the fourth ring, yielding the cyclised product 72 in high yield. Nitration followed by 
reduction gave the amine 73, which upon treatment with Fremy’s salt, gave racemic 
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cryptotanshinone 5. Finally, reaction with DDQ provided TIIA 2, in an overall yield of 
approximately 7%. 
 
Scheme 13. A SmI2-promoted radical cyclisation approach to TIIA 2.236 
 
There have also been many reports detailing the synthesis of TIIA 2 derivatives (Figure 
5). These have included modification of the ortho-quinone functionality,217–219,237 
addition of furan ring substituents,147,175,238–249 addition of various cyclohexyl ring 
substituents,150,246,250–252 and alteration of the cyclohexyl ring itself.228–232 
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Figure 5. Published syntheses of various TIIA analogues (modified parts shown in 
red). 
 
2.4 Hypothesis and research aims 
It was hypothesised that various synthetic tanshinone analogues exhibit differing 
anti-inflammatory activities in vivo. Thus, such compounds could be used to manipulate 
and further explore the neutrophilic inflammatory response in vivo.  
The initial aim of this research was to synthesise various analogues of both TI 1 and 
TIIA 2, including previously unreported compounds. This would involve implementing 
previously reported synthetic routes for the syntheses of TI 1 and TIIA 2 as well as any 
structurally related compounds, optimising these routes where appropriate. The 
synthesised compounds would be used as probes to explore manipulation of the 
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inflammatory response, and to investigate any structure-activity relationships between 
the tanshinone structures and any anti-inflammatory effects. This would be done by 
testing the compounds in a zebrafish model of inflammation, to monitor the recruitment 
and resolution stages of inflammation, and analysing the number of neutrophils at 
various time points. Compound toxicity could also be evaluated using this model. 
Furthermore, a greater understanding of how molecules such as tanshinones reach their 
molecular target(s) in vivo was also sought, particularly in relation to neutrophil-specific 
effects. The long-term goal of this work was to work towards delivery of a safe and 
effective treatment for promoting resolution of inflammation, which might eventually 
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3. Materials and Methods 
3.1 Reagents and equipment 
All reagents were obtained from Sigma Aldrich/Merck (Darmstadt, Germany) unless 
stated otherwise. TIIA 2 was obtained from Generon (Slough, UK) and the c-Jun N-
terminal kinase inhibitor SP600125 (SP) 74 was obtained from StressMarq Biosciences 
(Victoria, Canada). All synthetic compounds were produced using chemistry as outlined 
in the Experimental section (Chapter 8). All compounds were dissolved in dimethyl 
sulfoxide (DMSO) for stock solutions prior to use in experiments.  
Zebrafish (Danio rerio) larvae were injured using a straight micro-scalpel blade (stab 
knife) with a 15 ° blade of 5.0 mm depth, obtained from MSP Surgical Specialties 
Corporation (Reading, PA, USA). Embryo selection and larval injury was performed using 
a Leica S6D Greenough stereo microscope and a Leica L2 light source (Milton Keynes, 
UK). Neutrophil counting was performed on a Leica MZ10F modular stereo microscope 
with fluorescent light source. 
 
3.2 Zebrafish husbandry 
Transgenic zebrafish which express GFP specifically in neutrophils, 
Tg(mpx:GFP)i114,86 were used for all biological experiments. Zebrafish were raised and 
maintained in Home Office-approved aquaria at the Bateson Centre at The University Of 
Sheffield, in accordance with standard protocols and procedures. Zebrafish were kept in 
a continuously recirculating closed system at 28 °C, and exposed to a cycle of 14 hours 
of light and 10 hours in the dark per day.  
Zebrafish embryos were obtained through either pair matings or ‘in-tank’ breeding. 
For pair matings, male and female adult zebrafish were placed in separate parts of small, 
covered plastic containers fitted with a plastic divider, and were kept separate 
overnight. The following morning, the dividers separating the pairs of fish were removed 
and mating was allowed to occur. After a few hours, the fish were returned to their 
original tank, and embryos were obtained by pouring the water from the mating 
containers through a small plastic tea strainer and then rinsing with aquarium water. For 
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‘in-tank’ breedings, in the evening, a plastic container holding a layer of marbles above 
a wire mesh sieve was placed into a tank containing up to 40 fish. Zebrafish mated when 
the lights came on the following morning, and embryos were obtained by pouring the 
water from the marble tank through a small plastic tea strainer and rinsing with 
aquarium water.  
Healthy, fertilised embryos were identified under a microscope and, using a plastic 
Pasteur pipette, sorted into Petri dishes containing approximately 40 mL embryo 
medium (E3) solution (Appendix 10.2), with approximately 60 embryos per dish. All 
dishes of embryos were incubated at 28 °C.  
After the completion of all biological experiments, and prior to 5.2 dpf, larvae were 
sacrificed by anaesthesia with the addition of approximately 1.5 mL 0.017% tricaine 
solution per Petri dish (Appendix 10.3), followed by immersion in bleach solution. All 
procedures performed were in accordance with United Kingdom Home Office 
legislation, and were carried out under Project Licence Number PPL 70_8178, Using 
Zebrafish to understand inflammation resolution. 
 
3.3 Larval tailfin transection 
Larvae at age 3 dpf were used for all experiments. Zebrafish larvae were 
anaesthetised by the addition of approximately 1.0-1.5 mL 0.017% tricaine solution to 
the Petri dish. Larvae were then transferred, using a plastic Pasteur pipette, onto a strip 
of masking tape adhered to the inside of a Petri dish lid, which had been pre-washed 
with deionised water to remove any tape residues. Excess liquid was removed prior to 
transection, to minimise movement of larvae. Larvae were then viewed under a 
standard biological microscope. A micro-scalpel blade was used to completely remove 
the caudal fin, initiating an inflammatory response. To ensure consistency, transection 
was performed as posterior as possible in the region where the pigment pattern was 
disrupted, as indicated by the red line (Figure 6). Injured larvae were transferred to a 
Petri dish containing approximately 40 mL fresh E3 solution which did not contain 
methylene blue, and incubated at 28 °C. 
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Figure 6. The larval tailfin was transected with a micro-scalpel blade at the position 
indicated by the red line, as viewed under the normal brightfield (top) and GFP (bottom) 
channels of a fluorescence microscope, thereby initiating an inflammatory response. 
 
3.4 Larval compound treatment 
Zebrafish larvae were immersed in aqueous compound solutions in 24-well plates. 
Larvae in E3 solution (which did not contain methylene blue) were added to compound 
solutions in such a way as to obtain the final experimental concentration indicated. 
Compounds were tested alongside a 0.5-1.0% DMSO solution which was used as a 
negative (vehicle) control in all experiments. In recruitment experiments, SP 74 (30 µM) 
or TI 1 (25 µM) was used as a positive control. For resolution experiments, TIIA 2 (25 
µM) was used as a positive control. Well plates were incubated with the lid on at 28 °C. 
In each experiment, 6-8 zebrafish larvae per treatment group were used, and each 
experiment was performed independently 3-4 times (unless otherwise stated), on 
different days. Results from each biological repeat were combined to give pooled 
datasets which were used for statistical analysis. All experiments were performed blind 
to treatment conditions for the duration of the experiment. 
 
3.5 Neutrophil recruitment experiments 
Zebrafish larvae were injured as previously described (Chapter 3.3). Injured larvae 
were treated immediately by immersion with the compound diluted in E3 solution 
(which did not contain methylene blue) at the concentration indicated, and incubated 
at 28 °C. At 4-6 hours post-injury (hpi), larvae were anaesthetised with one drop of 
tricaine solution per well, and for each larva, the number of neutrophils at the site of 
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injury was counted under a fluorescence microscope. The site of injury for neutrophil 
counting was defined as any neutrophils residing within the area of each larva containing 
disrupted pigment, as indicated by the blue box (Figure 7). Both compound treatment 
and neutrophil counting were performed blind to experimental conditions.  
 
Figure 7. All neutrophils in the blue box shown were included in counting. Larva shown 
as observed under the normal brightfield (top) and GFP (bottom) channels of a 
fluorescence microscope. 
 
3.6 Inflammation resolution experiments 
Larvae were injured as previously described (Chapter 3.3). At 3.5 hpi, larvae were 
anaesthetised with tricaine solution, and larvae that had mounted a good inflammatory 
response (around 20-25 neutrophils at the site of injury; termed ‘good responders’) 
were selected prior to any experimental procedures. At 4 hpi, selected larvae were 
subjected to compound treatment by immersion at the concentration indicated, and 
incubated at 28 °C. At 8 hpi, larvae were anaesthetised with tricaine solution and for 
each larva, the number of neutrophils at the site of injury was counted as previously 
described (Chapter 3.5). Both compound treatment and neutrophil counting were 
performed blind to experimental conditions.  
 
3.7 Statistical analysis 
All statistical analysis was carried out using Prism 7.0 (GraphPad, San Diego, USA), 
version 7.00. For all experiments, at least three biological repeats were performed 
(unless otherwise stated), from which data were pooled and then analysed. Statistical 
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significance was assessed at various levels:  * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, **** 
P ≤ 0.0001, ns not significant (P > 0.05).  
In resolution experiments where data comprised two experimental groups, an 
unpaired t-test was used to analyse data and determine statistical significance. For data 
from recruitment and resolution experiments comprising three or more experimental 
groups, analysis was performed using a one-way analysis of variance (ANOVA) test with 
Dunnett's multiple comparison post-test for comparing treatment neutrophil numbers 
to those of the DMSO negative control. For timecourse dynamics data, analysis was 
performed using a one-way ANOVA test with Tukey's multiple comparison post-test for 
comparing neutrophil numbers for each timepoint to those of every other timepoint. 
For the linear regression analysis performed in Chapter 6.4, the Spearman correlation 
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4. Synthesis and evaluation of tanshinone I analogues and 
isotanshinone I analogues 
4.1 Introduction 
In previous studies, TIIA 2 exhibited a highly significant effect in accelerating 
resolution in a zebrafish model of neutrophilic inflammation, an effect which was also 
conserved in human neutrophils.36 TIIA 2 did not significantly affect initial recruitment 
of neutrophils to the site of injury, although there was a trend towards lower numbers 
of neutrophils recruited at the higher concentrations tested, up to a concentration of 25 
µM.36 
TI 1 also had an effect in promoting inflammation resolution, although not to the 
same extent as TIIA 2 (Dr. Anne Robertson, The University Of Sheffield, Appendix 10.1). 
The effects of TI 1 on neutrophil recruitment have not previously been explored, and so 
were of interest in this work. In addition, the commercially available tanshinones 
cryptotanshinone 5 and dihydrotanshinone I 4, which are structurally very similar to TIIA 
2 and TI 1 respectively, were investigated for their effects on resolution of neutrophilic 
inflammation in the same model. Both cryptotanshinone 5 and dihydrotanshinone I 4 
accelerated resolution, although not with the same clear dose-response relationship 
observed for TIIA 2 (Dr. Anne Robertson, The University Of Sheffield, Appendix 10.1).  
Aside from these four known tanshinones, no previous tanshinones (or structurally 
similar molecules) have been investigated for their anti-inflammatory effects in this 
model. Furthermore, although these four tanshinones demonstrated observable anti-
inflammatory effects in vivo, their molecular mechanism of action is not currently 
understood. The target protein(s) of these molecules remains unknown, and may even 
comprise more than one target. Structure-activity relationships for these molecules 
have also not been constructed. Such relationships could aid in identification and an 
improved understanding of the molecular mechanism of action of tanshinones, and lead 
to an optimised potential drug molecule, working towards development of new clinical 
treatments for inflammatory diseases. 
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Therefore, the synthesis of analogues for both TI 1 and TIIA 2 was of interest. 
Synthesised molecules could then be evaluated in the zebrafish model of inflammation, 
and the results of such studies used to elucidate structure-activity relationships and 
guide future efforts. Several routes are reported in the literature for the synthesis of TI 
1 and TIIA 2, and at the start of this work (October 2014), all previously published 
methods for the synthesis of TI 1 and analogues were first reviewed, as this compound 
class was less explored. However, many of these were not suited for the cost-effective 
synthesis of a set of tanshinone analogues. The route adapted from the literature was 
one of the few published studies at the time which was amenable to synthesis of a range 
of TI analogues.211  
 
4.2 Hypothesis and aims 
It was hypothesised that analogues of tanshinones, in particular TI 1, would exhibit 
differing anti-inflammatory effects in vivo, depending on their structures. The first aim 
of this work was to prepare analogues of TI 1. The synthesised TI analogues could then 
be tested in vivo using a zebrafish model of inflammation, to identify which (if any) of 
the compounds affected neutrophil recruitment and/or resolution of neutrophilic 
inflammation. By analysing all of these data together, this could enable determination 
of structure-activity relationships and a greater understanding of which parts of the TI 1 
molecule were important for biological activity. This would help work towards 
identification of exactly how these compounds could be working at a molecular level. 
 
4.3 Initial synthesis of TI 
4.3.1 Initial steps 
A synthetic route previously employed in the literature for synthesising TI 1 and a 
closely related analogue 31 was initially used in this work,211 as it appeared to be the 
most amenable for the synthesis of a variety of functionalised TI analogues. The route 
was mainly dependent on the commercial availability of various substituted carboxylic 
acids in the third step of the synthesis, and their compatibility with the rest of the 
synthesis, which did not appear to be a major issue. It also comprised fewer steps than 
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most other syntheses, and was previously used in the synthesis of TI 1 and an additional 
tanshinone analogue 31 lacking the 6-methyl group, replaced with a hydrogen atom 
(Figure 8). However, besides these two tanshinones, no other tanshinones had 
previously been synthesised using this route. Use of this route would allow for the 
synthesis of tanshinone analogues with changes made to the structure which were 
situated away from the ortho-quinone moiety. This was important as it was 
hypothesised that this functionality was important for in vivo biological activity, as one 
of the few notable functional groups in the core tanshinone structure. 
 
Figure 8. Structures of the previously synthesised TI 1 and its 6-hydro derivative 
31.211 
 
Firstly, commercial 5-bromovanillin 27 was oxidised to the corresponding 1,4-
hydroquinone 28 using sodium percarbonate in a Baeyer-Villiger oxidation and 
subsequent ester hydrolysis (Scheme 14), modified according to Dakin and 
Kabalka.253,254 The percentage yield initially obtained (63%; 6 g scale) was lower than 
those obtained elsewhere for the same substrate,211,212 although this was without any 
further attempts at optimising the conditions used. The slightly modified work-up 
procedure used here (addition of sodium sulfite to quench any residual peroxide 
species, and subsequent extraction) may have had an effect on this yield. However, 
when this reaction was repeated on a much larger (19 g) scale, with slightly more careful 
extraction but otherwise using the same conditions, the yield obtained was significantly 
higher (82%). When the reaction was later repeated again on a 25 g scale to provide 
enough material for analogue synthesis, a further improved yield of 86% was obtained. 
This reaction also required no additional purification, making this a convenient process 
for larger quantities. 
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Scheme 14. Baeyer-Villiger oxidation of 5-bromovanillin 27. 
 
This oxidation was followed by a second oxidation step, in which iron(III) chloride was 
used to convert the 1,4-hydroquinone 28 into the corresponding 1,4-benzoquinone 29 
(Scheme 15). Originally, this reaction also proceeded in slightly lower yield (67%) than 
those published,211,212 although this was without any attempts at optimisation. As 
observed with the previous oxidation, when this reaction was scaled up yet with the 
same reaction conditions, the yield obtained (96%) was again a significant improvement, 
and on an even larger scale, a 99% yield was obtained. Isolation of the 1,4-benzoquinone 
product 29 also required no further purification. As previous syntheses have involved 
the use of chromatographic purification after this oxidation step,211,212 this method 
represented a more time- and cost-effective large-scale synthesis of the desired 
benzoquinone 29 compared to literature methods. 
 
Scheme 15. Oxidation of the 1,4-hydroquinone 28 to the 1,4-benzoquinone 29. 
 
4.3.2 Minisci-type radical decarboxylative alkylation reaction 
The next step in the synthesis was a Minisci-type radical decarboxylative alkylation 
reaction between the 1,4-benzoquinone 29 and a carboxylic acid. 3-(2-
Methylphenyl)propionic acid 75 was initially used as this would eventually provide TI 1. 
This would be a useful compound to synthesise, as a comparison could then be made 
between synthetic and commercially sourced TI 1 in terms of biological activity, as a 
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method of validating the biological effects of synthetic compounds. Similar carboxylic 
acids with different phenyl substituents could later be used to give derivatives of TI 1 for 
further biological evaluation. The reaction was first attempted using the conditions 
described in the literature (Scheme 16).211 
 
Scheme 16. Reaction of the 1,4-benzoquinone 29 with 3-(2-methylphenyl)propionic 
acid 75. 
 
However, this reaction only provided the desired alkylation product 76 in a 
disappointing 18% yield. This was especially low, given that the conditions used were 
those identified as being optimal in the literature, with yields of up to 65-79% previously 
reported.211 Therefore, the reaction conditions were investigated (Table 1). The results 
suggested that, compared to the initial reaction conditions used (entry 1), performing 
the reaction in the dark led to a slight improvement in the percentage yield (entry 2), 
likely due to the light sensitivity of the Ag(I) salt used. Greater improvements in the 
reaction yield were observed when the work-up procedure was modified (entry 3), and 
when the ammonium persulfate oxidant was added in twice the volume of water (entry 
4), corresponding to half of the original concentration of persulfate solution. A reduction 
in the number of equivalents of carboxylic acid 75 used (from 2 to 1.2) did not have any 
negative impact on the product yield (entry 5). This reduction may have minimised 
formation of any undesired side products such as the di-alkylated product or products 
from homocoupling reactions. Formation of small quantities (< 10%) of a by-product 
thought to be the di-alkylated product were observed throughout these reactions, so 
the reduction in number of equivalents of carboxylic acid 75 probably had a small 
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beneficial impact on reaction yield (although is not likely to have been the single main 
contributing factor to any noticeable increases). Interestingly, none of the alternative 
mono-alkylated product alkylated adjacent to the methoxide group was observed. This 
was consistent with previous reports,211,255 and appeared to be a directing effect as a 
result of the bromide substituent, the exact nature of which was unclear.  
 










H2O / mL 
% 
yield* 
1 Light 1 M NaOH (10 mL) 2 2 10 18 
2 Dark 1 M NaOH (10 mL) 2 2 10 25 
3 Light Ice (10 g); 1 M NaOH (3 mL) 2 2 10 33 
4 Light 1 M NaOH (10 mL) 2 2 20 42 
5 Light 1 M NaOH (10 mL) 1.2 2 10 35 
* Represents isolated product after chromatographic purification. 
 
A combination of all the modified reaction conditions was then used in an additional 
reaction with the same substrate 29 (Scheme 17). This delivered the desired alkylation 
product 76 in a 42% yield, a substantial improvement on the original reaction yield. 
Although this was still lower than the yields obtained in the literature for the same 
reaction, further optimisation was not considered here, as the quantity of the alkylation 
product 76 provided by this reaction was sufficient for later steps, which still required 
investigation. 
 
Scheme 17. Radical alkylation using optimised conditions. 
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4.3.3 Intramolecular Heck reaction 
The radical alkylation product 76 was subjected to intramolecular Heck reaction 
conditions to form the third ring of the tanshinone skeleton, initially using palladium(II) 
acetate as the catalyst and conditions previously used in the literature (Scheme 18).211 
This yielded a mixture of ring-closed products comprising predominantly the non-
aromatised product 77, consistent with the results obtained in the literature.211 This was 
determined by 1H nuclear magnetic resonance (NMR) spectroscopy, which indicated an 
80:20 ratio of non-aromatised:aromatised products 77:36. These compounds were 
inseparable by column chromatography, and so the crude mixture of the two products 
was taken forward to a following aromatisation step without any additional purification. 
 
Scheme 18. Palladium-catalysed intramolecular Heck reaction. 
 
Previously, a one-pot dehydrogenation-demethylation strategy using an oxygen 
balloon was employed to achieve complete aromatisation of the intramolecular Heck 
reaction products.211 However, aromatisation could be achieved with a safer reagent, 
followed by use of a conventional O-demethylation reagent. Thus, the aromatisation 
step was attempted by subjecting the crude mixture of non-aromatised 77 and 
aromatised 36 products to treatment with palladium on carbon (Scheme 19). Complete 
conversion of the mixture to solely the aromatised product 36 was successfully 
achieved, as indicated by 1H NMR spectroscopy, with complete disappearance of the 
peaks corresponding to the CH2 protons observed. However, when the preceding 
intramolecular Heck reaction was later repeated to provide more material, this 
surprisingly formed the aromatised product 36 as the only product, with no evidence for 
presence of the non-aromatised product 77 observed in the 1H NMR spectrum. This 
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thereby eliminated the need to carry out the aromatisation reaction with palladium on 
carbon again. This difference may have been due to variation in the quality of the 
nitrogen atmosphere used for the Heck reaction, and/or the quality of the palladium 
source, as the presence of more ‘palladium black’ may have catalysed oxidation. 
 
Scheme 19. Complete aromatisation using palladium on carbon. 
 
4.3.4 Demethylation reaction 
Different reagents for O-demethylation of the ether 36 were investigated. Use of 1.2 
equivalents of boron trichloride was first explored, as this was reported to be a 
particularly effective O-demethylation reagent when a carbonyl group is present in an 
ortho-position to the methoxide group (Scheme 20).256 
 
Scheme 20. Attempted O-demethylation using boron trichloride. 
 
However, this did not provide any of the desired demethylated product 9, and only 
starting material 36 was returned. Thus, several variations on this reaction were carried 
out (Table 2). As observed for the use of 1.2 equivalents (entry 1), use of 3 equivalents 
of boron trichloride gave no desired product 9 (entry 2). A combination of boron 
trichloride and tetra-n-butylammonium iodide (TBAI) was investigated (entry 3), as this 
has been used successfully in the cleavage of aromatic methyl ethers,257 but this also 
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returned only starting material 36. On the other hand, use of excess 2 M sodium 
hydroxide was very effective for the reaction, and enabled complete conversion of the 
methyl ether 36 to the desired alcohol 9. This reagent was also used previously in the 
literature,211 albeit under an oxygen atmosphere to achieve simultaneous 
aromatisation. The alcohol product 9 was isolated cleanly and meant that no further 
purification was required. Therefore, this was taken on to the final step of the synthetic 
route. 
 
Table 2. Reagents investigated for O-demethylation. 
Entry Reagent(s) Outcome 
1 BCl3 (1.2 eq.) No reaction 
2 BCl3 (3 eq.) No reaction 
3 BCl3 (3 eq.), TBAI (1.3 eq.) No reaction 
4 2 M NaOH (excess) Complete conversion 
 
 
4.3.5 Modified Feist-Bénary reaction  
With a successful demethylation procedure in hand, construction of the furan ring to 
give the final tanshinone 1 was explored. This transformation had previously been 
accomplished in a modest yield of 35%, with an additional 30% recovered starting 
material, using a modified Feist-Bénary reaction,211 by heating the alcohol 9 with 
bromoacetone and ammonium acetate in toluene in a sealed tube. However, 
bromoacetone could not be easily commercially sourced, and therefore, this reaction 
was first attempted using five equivalents of chloroacetone, with ammonium acetate 
and toluene under microwave conditions (Scheme 21). 
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Scheme 21. Attempted modified Feist-Bénary reaction. 
 
However, no reaction occurred, as predominantly starting material 9 was returned. 
One possible reason for this is that toluene was not an ideal solvent for this microwave 
reaction, due to it lacking a strong permanent dipole allowing for efficient absorption of 
microwaves. Therefore, the reaction was repeated using only the alcohol 9 and neat 
chloroacetone as both the reagent and a significantly more polar solvent. Again, only 
starting material 9 was returned, and this may have been due to the absence of weak 
base necessary for initial deprotonation of the alcohol 9 prior to reaction. Indeed, when 
the reaction was repeated using excess chloroacetone and a stoichiometric quantity of 
ammonium acetate, successful reaction occurred, and after chromatographic 
purification, two products were isolated. One of these was the desired TI 1 (a dark red 
solid), whilst the other product was identified as the isomer isotanshinone I (iso-TI) 13 
(an orange solid), which was formed in an approximately equal ratio (Scheme 22), with 
spectroscopic data matching the literature for both TI 1204,211,258 and iso-TI 13.203,204,259 
The two isomers were each isolated in approximately 20% yield, and this likely occurred 
either due to tautomeric intermediates, or due to the existence of the alcohol 9 as two 
possible tautomers under the reaction conditions. These tautomers could both react 
following deprotonation, with no preference for one tautomer over the other, thereby 
giving rise to the ortho- and para- quinone products 1 and 13 in approximately equal 
quantities. Although the yield of this reaction was fairly low, this provided a sufficient 
quantity of TI 1 for biological evaluation, as well as the additional isomer 13, which 
would likely be formed for each new tanshinone analogue generated. Isotanshinones 
are a class of compound for which only a few examples appear to be known, such as iso-
TI 13 and isotanshinone IIA (iso-TIIA) 78,203,204,259,260 isotanshinone IIB (iso-TIIB) 79,261 
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and only a small number of others (Figure 9).262 Related isotanshinones based on the 
isomeric parent compounds cryptotanshinone 5 and dihydrotanshinone I 4 are also 
known; these have recently been investigated as anti-cancer agents.263,264 However, this 
class of compounds is largely underexplored, both in terms of syntheses and biological 
studies, and may possess interesting biological properties. It was therefore of interest 
to evaluate any isotanshinones synthesised here in the same way as tanshinones, to 
explore whether any effects exhibited by tanshinones in vivo were also exhibited by the 
relevant isotanshinones.  
 
Figure 9. Structures of iso-TI 13, iso-TIIA 78 and iso-TIIB 79. 
 
 
Scheme 22. Synthesis of TI 1 and its isomer iso-TI 13. 
 
This meant that the complete synthetic route to TI 1 (and its isomer 13) was verified. 
Thus, synthesis of analogues of TI 1 (and their corresponding isomers) was undertaken, 
and further optimisation of particular reactions explored where appropriate. 
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4.4 Synthesis of TI analogues 
4.4.1 Radical decarboxylative alkylation reaction 
Firstly, reaction of the previously synthesised benzoquinone 29 with various 
substituted carboxylic acids in the radical decarboxylative alkylation step was to be 
carried out. The reaction was first performed using 3-phenylpropionic acid 80, on both 
250 and 500 mg scales, using the previously optimised reaction conditions (Scheme 23). 
Yields of 38% and 43% of the desired product 81 were obtained for the 250 and 500 mg 
scale reactions respectively. Whilst these were in line with the 42% yield obtained for 
the methyl-substituted product 76, these still represented relatively modest yields, 
especially compared to those obtained in the literature, and so further optimisation 
studies for this reaction were undertaken.  
 
Scheme 23. Radical alkylation of the benzoquinone 29 with 3-phenylpropionic acid 80. 
 
4.4.2 Use of Design of Experiments (DoE) studies in optimisation of the radical alkylation  
For these studies, the unsubstituted 3-phenylpropionic acid 80 was again used, in 
order to eliminate the possibility of an additional substituent having any electronic or 
steric impact on the reaction, allowing an unbiased assessment of the effect of changing 
various reaction conditions. Given the large number of different variables which could 
be investigated, a Design of Experiments (DoE) approach was utilised. DoE is a 
systematic method of exploring numerous parameters and their effects (and relative 
importance) on the reaction outcome, whilst minimising the number of individual 
experiments to be performed. It is an approach which has long been used in industry 
(especially process chemistry) and is becoming increasingly used in synthetic organic 
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chemistry reactions in academia.265–269 Using the Custom Design function in JMP 
software (JMP®, Version 12. SAS Institute Inc., Cary, NC, 1989-2007), the effects of 
changing the following reaction variables were investigated (Scheme 24): 
 
• Number of equivalents of carboxylic acid 80 (0.5 eq., 2 eq.) 
• Number of equivalents of the silver(I) salt (0.1 eq., 1 eq.) 
• Identity of the silver(I) salt (Ag3PO4, AgNO3, Ag2CO3) 
• Volume of acetonitrile (3 mL, 15 mL) 
• Volume of water (5 mL, 10 mL) 
• Reaction time (0.5 h, 3 h) 
• Reaction temperature (40 °C, 85 °C) 
• Method of addition of the aqueous persulfate solution to the reaction 
(dropping funnel, metal needle/syringe). 
 
Scheme 24. General radical alkylation reaction for optimisation studies using DoE. 
 
The indicated options for each variable were chosen for a number of reasons. Firstly, 
selecting two different numerical values for each quantitative variable, rather than three 
or more values, further reduced the number of required experiments to be performed. 
As each experiment required heating, work-up, and purification by column 
chromatography to accurately determine the reaction yield, this was highly desirable. 
The two values were generally chosen to represent high and low ‘extremes’ for each 
variable, based on previous data obtained for this reaction and evaluation of the 
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literature. For the reaction time, it was observed that although previous reactions 
carried out in this work had been performed for six hours, these reactions actually 
reached completion in two to three hours, and given the number of experiments to be 
performed, the higher value was set at three hours. Various silver(I) salts were selected 
based on those used previously, both in this work and in the literature. Finally, the 
method of addition of the aqueous persulfate solution was also chosen as an additional 
variable to investigate. With these input parameters, the software determined ten 
experiments to be performed, which were carried out within a short timeframe (Table 
3). 
 
Table 3. The ten radical alkylation experiments carried out, as determined by the 

























1 0.5 1 Ag3PO4 3 5 0.5 40 No 25% 
2 0.5 0.1 AgNO3 3 5 0.5 85 Yes 10% 
3 0.5 0.1 Ag3PO4 15 10 0.5 85 Yes 11% 
4 0.5 1 AgNO3 3 10 3 40 Yes 18% 
5 0.5 1 Ag2CO3 15 5 3 85 No 26% 
6 2 0.1 Ag2CO3 3 10 0.5 40 No 6% 
7 2 1 Ag2CO3 15 5 0.5 40 Yes 0% 
8 2 1 AgNO3 15 10 0.5 85 No 51% 
9 2 0.1 AgNO3 15 5 3 40 No 18% 
10 2 1 Ag3PO4 3 5 3 85 Yes 24% 
* Represents isolated product after chromatographic purification. 
 
Following completion of these reactions, as determined by the software, changing 
several of these parameters appeared to have only small effects on the reaction yield. 
However, the single most important factor identified was the method of persulfate 
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addition: addition of the persulfate solution via glass dropping funnel gave an elevated 
yield compared to addition via metal syringe. This observation has been noted 
elsewhere with aqueous persulfate solutions,270 and is thought to be because the metal 
syringe accelerates the rate of decomposition of the oxidant in solution, which is itself 
unstable at room temperature.271 Use of silver(I) phosphate or silver(I) nitrate also gave 
slightly higher yields than the use of silver(I) carbonate, whilst heating at 85 °C and 
increasing the number of equivalents of silver(I) salt both gave a mild increase in yield, 
with all other changes to the system identified as having minimal or no effect.  
In a small set of follow up experiments, changing the silver(I) salt to silver(I) acetate, 
silver(I) sulfate or silver(I) tetrafluoroborate also gave no increase in product yield. From 
analysis of these data, there seemed to be no obvious change which would boost 
product yields dramatically from those obtained already. Nonetheless, the combined 
optimal conditions from this study were used for the radical alkylation reaction with the 
hydrogen-substituted carboxylic acid 80, as well as other substituted carboxylic acids.  
 
4.4.3 Radical alkylation for analogue synthesis 
In addition to the methyl-substituted 75 and hydrogen-substituted 80 carboxylic 
acids used already, acids with trifluoromethyl 82, fluoro 83, and methoxy 84 
substituents in the same ortho-position on the phenyl ring were chosen. These were all 
commercially available and relatively inexpensive starting materials. These carboxylic 
acids and their corresponding products were all previously used in the radical alkylation, 
intramolecular Heck reaction, and demethylation steps of the synthesis, with no obvious 
compatibility issues reported,211 although none of the three heteroatom-substituted 
analogues were converted into the corresponding final tanshinone compounds. This 
small set of five carboxylic acids included a mixture of electron-donating, electron-
withdrawing, and neutral substituents on the phenyl ring, which would be interesting to 
explore in the biological evaluation of the final tanshinone compounds. Use of these 
acids in this route would also allow investigation of changes made some distance away 
from the tanshinone ortho-quinone moiety. In addition, comparison of the biological 
activities of the methyl- and hydrogen- substituted tanshinone compounds with their 
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trifluoromethyl- and fluoro-substituted counterparts were of interest in relation to in 
vivo metabolism. C-H bonds are often metabolised and functionalised in vivo,272,273 and 
replacement of particular C-H bonds with C-F bonds is a common strategy used in drug 
discovery and development. This is because this change can sometimes prevent or 
reduce metabolism as C-F bonds are not metabolically labile, thus often improving the 
metabolic stability of drug molecules.274,275 Other factors such as drug absorption, 
distribution, potency and target selectivity can also be affected, as the high 
electronegativity of fluorine can affect properties including pKa, conformation, hydrogen 
bonding and lipophilicity.274,275 
In the radical alkylation reaction using the newly optimised reaction conditions 
(Scheme 25), products bearing methyl 76, hydrogen 81, and fluoro 86 substituents were 
all formed in consistent yields of 46-54%, whilst the trifluoromethyl variant 85 was 
synthesised in a slightly lower yield of 38%. In some cases, dry column chromatography 
was found to be successful in the purification of reactions carried out on larger scales, 
which improved the time- and cost-effectiveness of this step. For the methoxy 
substituent, some benzoquinone 29 starting material remained, which despite all 
efforts, could not be separated from the product 87 by either chromatographic 
purification or recrystallisation on a large scale. Analysis of the 1H NMR spectrum of the 
mixture indicated a 60:40 ratio of the bromide 87 and the benzoquinone starting 
material 29, corresponding to an approximate 33% overall yield of desired product 87. 
These products were taken on to the intramolecular Heck reaction.  
Page 71 of 246 
 
 
Scheme 25. Radical alkylation reaction using various substituted carboxylic acids. 
 
4.4.4 Optimisation of the intramolecular Heck reaction  
With the alkylation products formed in reasonable yield, attention was turned to 
the intramolecular Heck reaction to form the tricyclic core. When the methyl-
substituted alkylation product 76 was previously subjected to the Heck reaction 
conditions used in the literature, the desired product was formed in moderate yield 
following purification, as a mixture of aromatised 36 and non-aromatised 77 
compounds. Given the very high quantities of palladium catalyst used (45 mol%), this 
was not a sufficiently high yield to justify repeating the reaction on moderate scales for 
multiple compounds using the same conditions. Therefore, optimisation of this reaction, 
with particular emphasis on efforts to considerably reduce the amount of catalyst 
required for the reaction, was explored.  
The unsubstituted bromide 81 was used as a model system (Scheme 26), again to 
determine the efficiency of the reaction in the absence of any phenyl substituents which 
could affect the reaction. 
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Scheme 26. General scheme for the intramolecular Heck reaction using the 
unsubstituted substrate 81. 
 
Reducing the amount of palladium catalyst from 45 mol% to 10 mol% gave a 
correspondingly low yield of 15% of the aromatised and non-aromatised products 88 
and 89, and changing the ligand from triphenylphosphine to tri(o-tolyl)phosphine had 
no obvious effect. This led to the hypothesis that the palladium catalyst might be 
working in a stoichiometric manner, whereby after first catalysing the intramolecular 
Heck reaction, it could then take part in a second reaction, aiding aromatisation of the 
initial product and thereby being consumed. Therefore, the reaction was repeated using 
10 mol% catalyst, but with the addition of either para-benzoquinone 32 or palladium on 
carbon as a co-oxidant to the reaction. However, in each case, the yield remained low 
at 10-15%, suggesting that there must be another reason for the poor product yields.  
The effect of concentration on this intramolecular reaction was then explored. When 
the reaction was performed at a three-fold lower concentration, again using 10 mol% 
catalyst, the combined yield of aromatised and non-aromatised products increased 
dramatically to 68% after purification. At a five-fold lower concentration (approximately 
0.01 M), a yield of 74% was obtained, and this was conserved when the catalyst loading 
was reduced to 5 mol%, with a 73% yield obtained (Scheme 27). Although it was not 
particularly surprising that the yield of this reaction was concentration-dependant, as 
this reaction is an intramolecular process, it appeared that this particular transformation 
was especially sensitive to concentration effects. These results were especially 
encouraging as they now represented a vast improvement on the conditions used in the 
literature for this transformation, mainly a nine-fold reduction in the amount of 
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palladium catalyst required in the reaction, whilst still achieving respectable product 
yields in line with those obtained previously.  
 
Scheme 27. Optimised intramolecular Heck reaction conditions. 
 
The optimised Heck reaction conditions were used to synthesise the corresponding 
substituted analogues 36, 77, 90-95 (Scheme 28). Whilst a comparable yield of 67% was 
obtained for the methyl variants 36 and 77, the yields were lower for the heteroatom-
substituted compounds. For the trifluoromethyl analogues 90-91, a yield below 47% was 
obtained, and a lower yield below 20% was attained for the fluoro analogues 92-93; 
precise yield values could not be determined due to the presence of an additional 
inseparable, unidentified component for these two substituents. For the methoxy 
compounds 94-95, the inseparable mixture of the alkylation product 87 and the 
benzoquinone 29 was subjected to the Heck reaction conditions but resulted in the 
return of mainly purified starting material 87. This suggested that the palladium 
underwent faster oxidative addition with the simple benzoquinone 29 than with the 
alkylated compound 87. After subjecting this recovered material to the Heck conditions 
for a second time, the mixture of desired aromatised and non-aromatised products 94 
and 95 was isolated in a combined yield of 28%. It was hypothesised that the reduced 
yields for these compounds may have been because the heteroatom was participating 
in the reaction mechanism, by co-ordinating to the palladium catalyst (Figure 9). Thus, 
the closer the heteroatom lone pair to the active catalyst site, the greater the 
interference with the reaction and hence the lower the yield of desired product 
obtained. The differing electronics of the phenyl ring may have also had an effect here. 
Although some of the yields were low, each of the required products were obtained in 
adequate yields to produce sufficient quantities of the final tanshinone products after 
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the remaining two reactions in the route. The ratios of aromatised:non-aromatised 
products varied for each of the reactions undertaken, with the fully aromatised product 
representing the major product in each case, and it was unclear as to whether this was 
related to the particular analogue in question, or some other reason such as variable 
quality of the nitrogen atmosphere or palladium source used for each reaction. 
However, this was relatively unimportant, as any of the non-aromatised product could 
be easily converted to the desired aromatised product. This could be achieved in a 
separate reaction with palladium on carbon as found previously, but it was also believed 
that such aromatisation might occur spontaneously in later reaction steps, thereby 
eliminating the need for an additional synthetic step. Thus, the isolated mixtures of 
aromatised and non-aromatised Heck reaction products for each analogue were taken 
on to the demethylation step without further reaction.  
 
Scheme 28. Intramolecular Heck reaction using various substituted analogues. 
 
 
Figure 10. Possible interaction of the heteroatom substituent with the inserted 
palladium. 
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4.4.5 Final demethylation and modified Feist-Bénary reaction steps 
Demethylation of the hydrogen-substituted ethers 88-89 to form the corresponding 
alcohol 30 using ethanolic 2 M sodium hydroxide solution under reflux conditions 
successfully yielded the desired alcohol 30 in near-quantitative yield (Scheme 29). 
During this reaction, the mixture of aromatised 88 and non-aromatised 89 starting 
materials was converted cleanly to the fully aromatised product 30, thereby avoiding 
the need for any use of palladium on carbon in a separate step. This worked well for the 
synthesis of all analogues 9, 30, 96-98 (Scheme 29), with complete conversion of the 
methyl ether products to the fully aromatised alcohol in each instance. Only the single 
desired demethylation was observed for the methoxy compound 98, with the methoxy 
substituent on the phenyl ring remaining intact. For the methyl- 9, hydrogen- 30 and 
methoxy- 98 substituted analogues, no further purification was required. However, for 
the trifluoromethyl- 96 and fluoro- 97 substituted compounds, the alcohol products 
were impure, and attempted purification by recrystallisation was unsuccessful with a 
variety of solvents. Efforts to purify these impure compounds by standard column 
chromatography were also unsuccessful, as the compounds were fairly polar, and in 
some cases, could only be removed from the silica using neat methanol. Therefore, in 
these cases, the crude alcohols 96 and 97 were taken forward to the final step without 
any further purification.  
 
Scheme 29. Aqueous hydroxide-mediated ether demethylation for various 
analogues. 
 
Finally, reaction of the various alcohols 9, 30, 96-98 with chloroacetone to give the 
desired tanshinones 1, 31, 100, 102, 104 and isotanshinones 13, 99, 101, 103, 105 was 
carried out (Scheme 30). The reaction was successful for each of the different analogues, 
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although the yields of products obtained after chromatographic purification were 
variable. Moderate yields of around 20-25% per isomer were achieved for the reactions 
of the methyl- 9, hydrogen- 30 and methoxy- 98 substituted alcohols, whilst the yields 
appeared to be lower for the reactions of the trifluoromethyl- 96 and fluoro- 97 
substituted alcohols, even accounting for the use of combined yields over three steps. 
This may be due to these substituents having a detrimental effect on this and/or 
preceding reactions. Nonetheless, in each case, sufficient quantities of the final 
tanshinones and isotanshinones were obtained for full characterisation and subsequent 
biological evaluation, and so no further optimisation of this reaction was attempted. 
This meant that five tanshinones (including TI 1) and five isotanshinones (including iso-
TI 13) had been successfully synthesised, in six steps from 5-bromovanillin 27, and could 
be evaluated in vivo in a zebrafish model of inflammation. 
 
Scheme 30. Reaction of various alcohols 9, 30, 96-98 with chloroacetone to produce 
tanshinones 1, 31, 100, 102, 104 and isotanshinones 13, 99, 101, 103, 105. 
 
Furthermore, a variant of this chloroacetone reaction was briefly investigated, using 
the unsubstituted alcohol 30 as a test substrate. Reactions to form the corresponding 
tanshinone lacking the 1-methyl group 106 and the isomeric isotanshinone 107 using 
either dimethyl chloroacetal (with addition of water or aqueous acid) or aqueous 
chloroacetaldehyde, instead of chloroacetone, were unsuccessful (Scheme 31). 
Although trace amounts of some products appeared to be formed, these were not 
sufficiently large to isolate and identify. Therefore, due to limited starting material 30 
availability, these reactions were not explored any further.  
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Scheme 31. Attempted microwave reactions with sources of chloroacetaldehyde. 
 
4.4.6 Synthesis of a TI-acetal 
It was hypothesised that the ortho-quinone moiety of TI 1 (and other tanshinones 
such as TIIA 2) was important for its biological activity, as this is a chemically interesting 
functional group common to most well-known tanshinones. Therefore, synthesis of a 
‘masked’ analogue lacking this functionality was explored. Synthesis of a dimethyl acetal 
analogue of TI 1 was accomplished in a two-step procedure (Scheme 32). Facile 
reduction of the ortho-quinone with sodium borohydride generated the diol 108. 
However, the diol 108 spontaneously decomposed back to TI 1 in solution and on 
exposure to air, matching similar observations made previously for TIIA 2 and TIIB 
3.237,244 Thus, quickly treating the diol 108 with 2,2-dimethoxypropane and acid led to 
formation of the acetal 109, which was stable in solution, in air, and to column 
chromatography. The acetal 109 was isolated in a moderate 34% yield over two steps, 
with some TI 1 also recovered. This acetal 109 was biologically evaluated in vivo in the 
same manner as the synthesised tanshinones and isotanshinones. 
 
Scheme 32. Synthesis of a dimethyl acetal 109 from TI 1. 
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4.5 Biological evaluation of TI, iso-TI and analogues 
4.5.1 Effect of TI on neutrophil recruitment 
Previous work carried out in the Renshaw laboratory showed that TIIA 2 promoted 
the resolution of neutrophilic inflammation in vivo but did not affect initial neutrophil 
recruitment.36 Meanwhile, TI 1 exhibited a smaller, yet still significant effect on 
inflammation resolution (Dr. Anne Robertson, The University Of Sheffield, Appendix 
10.1). The effect of TI 1 on recruitment of neutrophils to the site of injury was not 
previously investigated using this model, and was therefore of interest here.   
Firstly, commercial TI 1 was evaluated at concentrations of 1, 10 and 25 µM in 
neutrophil recruitment experiments, all of which were performed by myself. Zebrafish 
larvae at age 3 dpf were injured at the distal portion of the tailfin. The injured larvae 
were subjected to immediate treatment with one of the following: TI 1 (1, 10 or 25 µM 
concentrations), DMSO (negative vehicle control), or SP 74 (positive control). SP 74 is a 
commercially available, selective, cell-permeable inhibitor of c-Jun N-terminal kinase, 
which prevents activation of various inflammatory genes.276,277 The ability of SP 74 to 
significantly reduce neutrophil recruitment in both this and other zebrafish neutrophilic 
inflammation models has been well documented,36,114,119 and so this was used as a 
positive control for all recruitment experiments. The three concentrations of TI 1 were 
chosen as these were previously used for evaluation of the effect of TI 1 on the 
resolution of neutrophilic inflammation in the same zebrafish model (Dr. Anne 
Robertson, The University Of Sheffield, Appendix 10.1). These concentrations have been 
commonly used in this particular model for similar dose-response incubation studies of 
aqueous compounds, and in particular, a concentration of 25 µM is often used as an 
initial ‘screening’ concentration for new compounds which may be of interest. Larvae 
were incubated with the compounds for several hours (representing the recruitment 
stage of the inflammatory response), after which the number of neutrophils at the site 
of injury was counted.  
TI 1 significantly reduced the number of neutrophils recruited to the site of injury at 
concentrations of both 25 and 10 µM, compared to larvae treated with DMSO (Figure 
10). There was no difference in neutrophil recruitment at a TI 1 concentration of 1 µM. 
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Overall, the effect of TI 1 on neutrophil recruitment was much greater than that 
observed for TIIA 2,36 and may suggest the existence of different anti-inflammatory 
mechanisms of action for these two tanshinones. It should be noted that in these 
experiments, the positive control treatment SP 74 was in some instances used at a 
concentration of 30 µM, and at a 60 µM concentration in others. This was because 
different batches of the compound were used: the first batch was used at a 60 µM 
concentration as it was found to be ineffective at 30 µM in these experiments. It was 
later deduced that this batch had started to go off, having been kept for a long time. A 
second batch was purchased and used for later experiments, and was found to be 
effective at a 30 µM concentration, consistent with most previous experiments and 
those of other researchers.  
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Figure 11. TI 1 treatment significantly reduced neutrophil recruitment to a site of 
injury. 
DMSO used at 0.5% concentration, SP 74 used at a concentration of 30 or 60 µM, TI 1 
used at concentrations of 1, 10 and 25 µM. Data shown as mean ± SEM; n = 16-25 larvae 
from 3 independent experiments. * P < 0.01, **** P < 0.0001, ns not significant, in 
comparison to the DMSO control (one-way ANOVA with Dunnett's multiple comparison 
post-test). 
 
4.5.2 Comparison of commercial and synthetic TI 
Next, having found that TI 1 resulted in decreased neutrophil recruitment, 
commercially sourced TI 1 was compared with synthesised TI 1, to check that these 
different batches of the same compound had the same effect in vivo (Figure 11). These 
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experiments, as for all biological experiments performed herein, were carried out by 
myself. Both batches of TI 1 resulted in decreased neutrophil recruitment to the site of 
injury, and there was no difference in the effects observed between commercial and 
chemically synthesised TI 1. This was an encouraging result, and effectively validated the 
use of other chemically synthesised compounds in this model. Therefore, the entire set 
of synthesised tanshinone and isotanshinone analogues were evaluated in this way.  
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Figure 12. Commercial and chemically synthesised TI 1 both reduced neutrophil 
recruitment, and there was no difference between the two batches of TI 1. 
DMSO used at 0.5% concentration, SP 74 used at a concentration of 30 µM, TI 1 used at 
a concentration of 25 µM. Data shown as mean ± SEM; n = 14-16 larvae from 2 
independent experiments. ** P < 0.01, *** P < 0.001, **** P < 0.0001, ns not significant, 
in comparison to the DMSO control, or between indicated groups (one-way ANOVA with 
Dunnett's multiple comparison post-test). Comm TI = commercial TI 1, Synth TI = 
synthetic TI 1. 
 
4.5.3 Effects of TI analogues and isomers on neutrophil recruitment in vivo 
The series of synthesised TI analogues and isomers 1, 13, 31, 99-105, 109 were 
evaluated for any effects on neutrophil recruitment in the zebrafish inflammation 
model. Due to experimental constraints such as experiment timepoints and number of 
zebrafish larvae available, the whole set of 11 compounds (five tanshinones 1, 31, 100, 
102, 104, five isotanshinones 13, 99, 101, 103, 105, and the TI acetal 109) was split into 
three groups for biological evaluation. In each group, DMSO and SP 74 were used as the 
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negative and positive control treatments respectively, whilst TI 1 and iso-TI 13 were also 
included in each group for comparison.  
In the first group, TI 1, iso-TI 13, and 6-hydro-TI 31 were evaluated (Figure 12). TI 1 
again resulted in decreased neutrophil recruitment, and so too did the isomer iso-TI 13. 
The effect seen with iso-TI 13 treatment was notable, as neutrophil numbers 
approached those observed for treatment with the positive control compound SP 74.  
Replacement of the 6-methyl group of TI 1 with a hydrogen atom appeared to be 
detrimental to anti-inflammatory activity, as treatment with 6-hydro-TI 31 had no 
significant effect on neutrophil recruitment. 
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Figure 13. TI 1 and iso-TI 13 resulted in decreased neutrophil recruitment to a site of 
injury, yet 6-hydro-TI 31 did not. 
DMSO used at 0.5% concentration, SP 74 used at a concentration of 30 µM, all other 
compounds used at a concentration of 25 µM. Data shown as mean ± SEM; n = 31-39 
larvae from 4 independent experiments. * P < 0.05, **** P < 0.0001, ns not significant, 
in comparison to the DMSO control (one-way ANOVA with Dunnett's multiple 
comparison post-test). H = 6-hydro-TI 31.  
 
The second group of evaluated compounds comprised the remaining analogues 
based on TI 1: 6-trifluoromethyl-TI 100, 6-fluoro-TI 102, and 6-methoxy-TI 104, as well 
as the unsubstituted 4-hydro-iso-TI 99, in addition to the parent compounds TI 1 and 
iso-TI 13 (Figure 13). TI 1 resulted in decreased neutrophil recruitment, but surprisingly, 
iso-TI 13 did not in this set of experiments. However, iso-TI 13 did result in a significantly 
reduced number of recruited neutrophils in other sets of recruitment experiments 
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carried out using the same conditions. The particular result in this group may have 
reflected an anomalous result, compound-specific variability, or may have arisen from 
the inherent natural variability of this experiment, given the use of living organisms, 
despite all efforts to control for this. Treatment with 6-trifluoromethyl-TI 100, 6-fluoro-
TI 102, or 6-methoxy-TI 104 resulted in no significant effect on neutrophil recruitment, 
although there appeared to be a trend towards lower numbers of recruited neutrophils 
in each case. Treatment with 4-hydro-iso-TI 99 had no effect on neutrophil recruitment: 
the number of neutrophils at the site of injury was at least as high as those for the DMSO 
control treatment.  
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Figure 14. Neither 6-trifluoromethyl-TI 100, 6-fluoro-TI 102, 6-methoxy-TI 104, nor 4-
hydro-iso-TI 99 significantly affected neutrophil recruitment. 
DMSO used at 0.5% concentration, SP 74 used at a concentration of 30 µM, all other 
compounds used at a concentration of 25 µM. Data shown as mean ± SEM; n = 30-31 
larvae from 4 independent experiments. * P < 0.05, *** P < 0.001, ns not significant, in 
comparison to the DMSO control (one-way ANOVA with Dunnett's multiple comparison 
post-test). CF3 = 6-trifluoromethyl-TI 100, F = 6-fluoro-TI 102, OMe = 6-methoxy-TI 104, 
H = 4-hydro-iso-TI 99. 
 
In the third and final group of compounds, the remaining isotanshinones were 
evaluated: this comprised 4-trifluoromethyl-iso-TI 101, 4-fluoro-iso-TI 103, and 4-
methoxy-iso-TI 105, as well as the TI acetal compound 109, and also the parent 
compounds TI 1 and iso-TI 13 (Figure 14). As observed previously, both TI 1 and iso-TI 13 
resulted in decreased neutrophil recruitment. Treatment with either 4-trifluoromethyl-
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iso-TI 101 or 4-fluoro-iso-TI 103 also led to a decrease in the number of recruited 
neutrophils, whilst 4-methoxy-iso-TI 105 did not result in a significant difference, 
although there was a trend towards lower numbers of neutrophils. Furthermore, 
treatment with the TI acetal 109 also resulted in no significant difference. This was 
consistent with the hypothesis that the ortho-quinone moiety was important for 
biological activity, yet the activity shown by the para-quinone isotanshinones in this 
work appeared to somewhat disprove this hypothesis. However, a trend towards slightly 
lower neutrophil numbers could be seen for the TI acetal 109. One possible explanation 
for this is that the acetal 109 was hydrolysed, and then metabolised back to the parent 
TI 1 in vivo, which then exerted an effect on neutrophil recruitment. The lack of 
significant effect on neutrophil recruitment (compared to the clear effect shown by TI 
1) could be because hydrolysis and/or metabolism had only partially occurred by this 
point, or perhaps because TI 1 was only one of the products of hydrolysis and 
metabolism, with other products not exhibiting the same effect on neutrophil 
recruitment. 











































Figure 15. Trifluoromethyl- 101 and fluoro- 103 substituted isotanshinones resulted in 
decreased neutrophil recruitment, whilst neither 4-methoxy-iso-TI 105 nor the TI 
acetal 109 had any effect. 
DMSO used at 0.5% concentration, SP 74 used at a concentration of 30 µM, all other 
compounds used at a concentration of 25 µM. Data shown as mean ± SEM; n = 31-32 
larvae from 4 independent experiments. * P < 0.05, ** P < 0.01, **** P < 0.0001, ns not 
significant, in comparison to the DMSO control (one-way ANOVA with Dunnett's 
multiple comparison post-test). CF3 = 4-trifluoromethyl-iso-TI 101, F = 4-fluoro-iso-TI 
103, OMe = 4-methoxy-iso-TI 105, TI-ac = TI acetal 109. 
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Following completed analysis of the effects of these compounds on neutrophil 
recruitment, evaluation of any effects of the same compounds on resolution of 
neutrophilic inflammation was undertaken.  
 
4.5.4 Initial in vivo inflammation resolution experiments  
For experiments investigating any effects of the compounds on inflammation 
resolution in vivo, the same compounds groupings were used as for the neutrophil 
recruitment experiments. However, TI 1 and iso-TI 13 were only evaluated in the first 
group, and were omitted from the second and third groups, due to experimental 
constraints. Furthermore, a different positive control compound was used for these 
experiments: instead of SP 74, TIIA 2 was used, at a concentration of 25 µM. TIIA 2 has 
previously been shown to profoundly accelerate the resolution of neutrophilic 
inflammation in this zebrafish model,36 and use of this tanshinone as a positive control 
helped to link this work to previous research performed using this model.  
For initial resolution experiments carried out by myself, the same procedure as 
reported previously was used here.36,278 Zebrafish larvae at age 3 dpf were injured at the 
distal portion of the tailfin, then incubated in standard E3 solution for six hours. At 6 hpi, 
a time at which neutrophil numbers at the site of injury were typically thought to reach 
their peak, larvae which had mounted a good inflammatory response to the injury were 
identified. These typically comprised larvae with approximately 20 neutrophils at the 
site of injury, henceforth termed ‘good responders’. Good responders were selected and 
treated with a 25 µM concentration solution of the compound of interest, and incubated 
for a further six hours. At 12 hpi, a time at which inflammation had typically started to 
spontaneously resolve but had not yet completely resolved, neutrophil numbers at the 
injury site were recorded.  
However, when the first group of compounds was evaluated in such inflammation 
resolution experiments, none of the compounds had any significant effect on the 
number of neutrophils at the site of injury, including the positive control compound TIIA 
2 (Figure 15). The lack of any difference between the DMSO and TIIA 2 treatment groups 
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was a particular problem and suggested that there was an issue with either the 
compound or the experimental setup. The latter was considered more likely, especially 
as a relatively new batch of TIIA 2 was used for these experiments. Therefore, before 
proceeding any further with the evaluation of the synthesised tanshinones and 
isotanshinones, a series of experiments was carried out to optimise the experimental 
setup for inflammation resolution experiments.  
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Figure 16. Neither TIIA 2, TI 1, iso-TI 13, nor 6-hydro-TI 31 had any effect on 
inflammation resolution at 12 hpi. 
DMSO used at 0.5% concentration, all other compounds used at a concentration of 25 
µM. Data shown as mean ± SEM; n = 29-31 larvae from 4 independent experiments. ns 
Not significant, in comparison to the DMSO control (one-way ANOVA with Dunnett's 
multiple comparison post-test). 6-H-TI = 6-hydro-TI 31. 
 
4.5.5 Optimisation of inflammation resolution experiments and validation of new 
experimental timepoints using TI and TIIA 
One reason why TIIA 2 may not have worked as expected was because the timepoints 
for the inflammation resolution experiments were no longer the best ones to use. 
Therefore, to determine if this was the case (and if so, to then select new appropriate 
timepoints), timecourse experiments were carried out by myself on zebrafish larvae age 
3 dpf (Figure 16). Larvae were injured at their tailfin, and the number of neutrophils at 
the site of injury was counted at various timepoints following injury. The number of 
neutrophils at the injury site peaked at 4 hpi, before decreasing over time from this 
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point. The previous resolution experiments may therefore not have worked well 
because by 12 hpi, inflammation of the fish in the DMSO control group had already 
spontaneously resolved to such an extent that it was not possible to detect further 
significant decreases in neutrophil numbers as a result of treatments which accelerated 
resolution. Thus, in light of these data, it was more appropriate to count neutrophils 
(and therefore, treat the larvae) at an earlier timepoint. At 8 hpi, there was a significantly 
greater number of neutrophils at the injury site than at 12 hpi; resolution of neutrophilic 
inflammation had already started to occur (as indicated by a significant decrease 
between 4 hpi and 8 hpi), but not to the extent of that at 12 hpi. Resolution at this time 
had also not yet completed, as indicated by a significant difference between 8 hpi and 
24 hpi. Therefore, treatment of the good responders with compounds at 4 hpi, and 
counting the number of neutrophils at 8 hpi was investigated (rather than the 6 and 12 
hpi timepoints used previously for these respective steps). 
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Figure 17. The number of neutrophils at the site of injury reached a maximum at 
around 4 hpi, then resolved to pre-injury neutrophil numbers by 24 hpi. 
Data shown as mean ± SEM; n = 45 larvae from 3 independent experiments. * P < 0.05, 
** P < 0.01, **** P < 0.0001 (one-way ANOVA with Tukey's multiple comparison post-
test).  
 
To explore use of the new resolution timepoints, the effects of only the negative and 
positive control treatments, DMSO and TIIA 2 respectively, were investigated (Figure 
17). TIIA 2 significantly accelerated resolution of neutrophilic inflammation, which 
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indicated that the control treatments worked well using these timepoints. Compared to 
the lack of difference observed at 12 hpi, this appeared to confirm that the timepoints 
were indeed the issue previously.  








































Figure 18. TIIA 2 significantly accelerated inflammation resolution at 8 hpi. 
DMSO used at 0.5% concentration, TIIA 2 used at a concentration of 25 µM. Data shown 
as mean ± SEM; n = 32 larvae from 4 independent experiments. *** P < 0.001, in 
comparison to the DMSO control (unpaired t-test). 
 
To further validate the use of these new timepoints, the effects of TI 1 and TIIA 2 on 
resolution of neutrophilic inflammation were studied by myself in the same 
experiments. Neutrophil recruitment studies were also carried out by myself using the 
same treatment groups, again to compare the two different tanshinones within the 
same experiments, and ensure that previous individual findings for these two 
compounds could be replicated together (Dr. Anne Robertson, The University Of 
Sheffield, Appendix 10.1).36 Thus, resolution and recruitment experiments were carried 
out in which TI 1 and TIIA 2 were investigated concomitantly, at concentrations of 10 
and 25 µM.  
For the resolution experiments (Figure 18), TIIA 2 accelerated resolution at a 
concentration of 25 µM, and also resulted in decreased neutrophil numbers at a 10 µM 
concentration. These results were consistent with the dose-response effects seen for 
TIIA 2 previously in this model.36 Interestingly, TI 1 also resulted in decreased neutrophil 
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numbers at 8 hpi, at both 10 and 25 µM concentrations. Here, TI 1 worked just as well 
as TIIA 2 (if not better) in accelerating resolution of neutrophilic inflammation. The 
similar neutrophil numbers at the two different concentrations may suggest that the 
effect of TI 1 became ‘saturated’ at a concentration of 10 µM (or even lower), whether 
that be due to compound solubility, pharmacokinetics, pharmacodynamics, or some 
other reason.  
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Figure 19. Both TI 1 and TIIA 2 accelerated inflammation resolution. 
DMSO used at 0.5% concentration, TI 1 and TIIA 2 used at concentrations of 10 and 25 
µM. Data shown as mean ± SEM; n = 21 larvae from 3 independent experiments. * P < 
0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001, in comparison to the DMSO control 
(one-way ANOVA with Dunnett's multiple comparison post-test).  
 
TI 1 and TIIA 2 were then investigated in neutrophil recruitment experiments, in 
further validation studies (Figure 19). The 6 hpi timepoint for neutrophil counting was 
retained here, to keep these experiments consistent with recruitment experiments 
performed already in this work. This was not considered to be an issue, given that the 
appropriate control compounds had worked well with this experimental setup. TIIA 2 
did not significantly affect neutrophil recruitment at either of the two concentrations 
tested, although there was a trend towards a small decrease in neutrophil numbers at a 
25 µM concentration; this was consistent with previous studies of TIIA 2 in this model.36 
Treatment with TI 1 at a 25 µM concentration resulted in a reduced number of 
neutrophils recruited to the site of injury, although this was not the case at a lower 
concentration of 10 µM. This was generally consistent with previous experiments in this 
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work, and may suggest that TI 1 exhibited a dose response effect on neutrophil 
recruitment between these concentrations. 
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Figure 20. TI 1 resulted in decreased neutrophil recruitment, yet TIIA 2 did not. 
DMSO used at 0.5% concentration, SP 74 used at a concentration of 30 µM, TI 1 and TIIA 
2 used at concentrations of 10 and 25 µM. Data shown as mean ± SEM; n = 29-32 larvae 
from 4 independent experiments. * P < 0.05, ** P < 0.01, ns not significant, in 
comparison to the DMSO control (one-way ANOVA with Dunnett's multiple comparison 
post-test). 
 
The results for both inflammation resolution and recruitment using these timepoints 
indicated that the timepoints chosen for each of the two types of experiment were 
appropriate, and worked well for all the control treatments. Experiments using the two 
tanshinones TI 1 and TIIA 2 were also successful, and were consistent with previous 
experiments carried out in this model. Therefore, the synthesised library of tanshinones 
and isotanshinones was evaluated for any effects on resolution of neutrophilic 
inflammation using the new timepoints.  
 
4.5.6 Effects of TI analogues and isomers on resolution of neutrophilic inflammation in vivo 
Using the same groups of compounds and, except for the new timepoints, the same 
experimental conditions as previously (Chapters 4.5.3 and 4.5.4), resolution 
experiments were carried out for the synthesised TI analogues and isomers. The first 
group comprised TI 1, iso-TI 13, and 6-hydro-TI 31 (Figure 20). In contrast to previous 
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experiments (Chapter 4.5.5), TI 1 did not significantly accelerate resolution of 
neutrophilic inflammation, although there was a visible trend towards a lower number 
of neutrophils which approached significance (P = 0.063). Treatment with iso-TI 13 
resulted in a significantly lower number of neutrophils at the site of injury, and 
neutrophil numbers were close to those observed for the TIIA 2 positive control. As 
observed for neutrophil recruitment, replacement of the 6-methyl group of TI 1 with a 
hydrogen atom led to loss of biological activity of the compound, as 6-hydro-TI 31 had 
no effect on inflammation resolution.  
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Figure 21. Iso-TI 13 significantly accelerated inflammation resolution, whilst TI 1 and 
6-hydro-TI 31 did not. 
DMSO used at 0.5% concentration, all other compounds used at a concentration of 25 
µM. Data shown as mean ± SEM; n = 26-28 larvae from 4 independent experiments. ** 
P < 0.01, *** P < 0.001, ns not significant, in comparison to the DMSO control (one-way 
ANOVA with Dunnett's multiple comparison post-test). H = 6-hydro-TI 31. 
 
The second group of compounds comprised the remaining tanshinones 6-
trifluoromethyl-TI 100, 6-fluoro-TI 102, and 6-methoxy-TI 104, as well as the 
isotanshinone 4-hydro-iso-TI 99 (Figure 21). In this particular set of experiments, 
neutrophil numbers observed following treatment with the positive control compound 
TIIA 2 were not significantly different from those observed following DMSO treatment. 
However, there was a visible trend towards lower neutrophil numbers, and the results 
were very close to statistical significance (P = 0.052). In all other resolution experiments 
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carried out using these timepoints, larvae treated with TIIA 2 had significantly lower 
neutrophil numbers. Therefore, the neutrophil numbers for TIIA 2 observed here were 
not thought to be of concern. For the remaining compounds investigated, 6-methoxy-TI 
104 clearly accelerated inflammation resolution, whilst 6-trifluoromethyl-TI 100 and 6-
fluoro-TI 102 did not. However, for 6-fluoro-TI 102, there was a trend towards lower 
neutrophil numbers at the site of injury, whereas for 6-trifluoromethyl-TI 100, there 
appeared to be a trend towards a higher number of neutrophils, compared to larvae 
treated with DMSO. The unsubstituted 4-hydro-iso-TI 99 had no effect on resolution, 
and this was consistent with the previous lack of biological activity observed, both for 
recruitment with the same compound, and also for resolution with the unsubstituted 
tanshinone 6-hydro-TI 31.  
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Figure 22. 6-Methoxy-TI 104 significantly accelerated inflammation resolution, yet 6-
trifluoromethyl-TI 100, 6-fluoro-TI 102, and 4-hydro-iso-TI 99 did not. 
DMSO used at 0.5% concentration, all other compounds used at a concentration of 25 
µM. Data shown as mean ± SEM; n = 28-29 larvae from 4 independent experiments. ** 
P < 0.01, ns not significant, in comparison to the DMSO control (one-way ANOVA with 
Dunnett's multiple comparison post-test). CF3 = 6-trifluoromethyl-TI 100, F = 6-fluoro-TI 
102, OMe = 6-methoxy-TI 104, H = 4-hydro-iso-TI 99. 
 
Finally, the remaining isotanshinones – 4-trifluoromethyl-iso-TI 101, 4-fluoro-iso-TI 
103, and 4-methoxy-iso-TI 105 - and the TI acetal 109, were evaluated (Figure 22). None 
of the isotanshinones had any effect on resolution of neutrophilic inflammation, and 
neutrophil numbers at the site of injury were broadly comparable with the numbers for 
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DMSO treatment in each case. However, treatment with the TI-acetal 109 resulted in a 
significant reduction in neutrophil number. As suggested for the recruitment data 
obtained previously, one explanation for this could be that the acetal 109 was 
hydrolysed and then metabolised back to TI 1 in vivo, which then exerted a pro-
resolution effect, consistent with previous results for TI 1 (Chapter 4.5.5). 
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Figure 23. The TI acetal 109 significantly accelerated resolution of neutrophilic 
inflammation, yet the isotanshinones 4-trifluoromethyl-iso-TI 101, 4-fluoro-iso-TI 103, 
and 4-methoxy-iso-TI 105 all did not. 
DMSO used at 0.5% concentration, all other compounds used at a concentration of 25 
µM. Data shown as mean ± SEM; n = 29-30 larvae from 4 independent experiments. * P 
< 0.05, ** P < 0.01, ns not significant, in comparison to the DMSO control (one-way 
ANOVA with Dunnett's multiple comparison post-test). CF3 = 4-trifluoromethyl-iso-TI 
101, F = 4-fluoro-iso-TI 103, OMe = 4-methoxy-iso-TI 105, TI-ac = TI acetal 109. 
 
4.5.7 Summary of effects of TI analogues and isomers on neutrophil behaviour during the 
inflammatory response in vivo 
The effects of the compounds tested in both neutrophil recruitment and resolution 
of neutrophilic inflammation experiments were considered together (Table 4). For 
neutrophil recruitment, the patterns for compounds with each functional group broadly 
appeared to be consistent between tanshinones and isotanshinones. Compounds with 
a methyl substituent had a clear effect in reducing neutrophil recruitment, whilst 
analogues bearing trifluoromethyl, fluorine, or methoxy substituents exhibited some 
effect (although this was not always statistically significant). Removal of any 
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functionality at this position (by replacement with a hydrogen atom) led to a complete 
loss of biological effect. These results suggested that the presence of a substituent in 
this position was required for activity, but the nature of the substituent may not be too 
important. Tanshinones and isotanshinones were broadly similar in their behaviours in 
relation to neutrophil recruitment, and any difference between the families of 
compounds appeared to be fairly small.  
For effects on inflammation resolution, the trends for compounds with each 
functional group were less clear between tanshinones and isotanshinones. The 
compounds bearing a methyl group generally showed some effect (either significant, or 
a trend towards lower neutrophil numbers), and removal of any functionality at this 
position resulted in loss of activity in vivo. Compounds substituted with a trifluoromethyl 
group or a fluorine atom also showed no significant effect on resolution. When the 
substituent was a methoxy group, the tanshinone 104 had a clear pro-resolution effect, 
yet the isotanshinone 105 did not. The reasons behind this were not clear, and further 
investigation would be required in order to fully understand this. As for recruitment, 
these results suggested that a substituent in this position was required for any in vivo 
effects on inflammation in this model to be observed. However, in contrast to neutrophil 
recruitment, the nature of the substituent seemed to be more important for pro-
resolution activity.  
The effects of the compounds on recruitment were further compared with the effects 
on resolution. Some compounds affected both recruitment and resolution, whilst some 
affected neither, and others had an effect on only one of these inflammatory processes. 
This was not particularly surprising, as molecules which had an effect on neutrophil 
recruitment likely interacted with a different molecular target or set of molecular targets 
to those which affected resolution of neutrophilic inflammation. Both of the parent 
compounds TI 1 and iso-TI 13 significantly decreased neutrophil recruitment and 
accelerated inflammation resolution, whilst both of the unsubstituted molecules 6-
hydro-TI 31 and 4-hydro-iso-TI 99 had no effect on either process. The fluorine-
containing tanshinones 6-trifluoromethyl-TI 100 and 6-fluoro-TI 102 also had no 
significant effect on either process, although both resulted in a trend towards lower 
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neutrophil numbers in recruitment experiments. Similarly, the isotanshinones 4-
trifluoromethyl-iso-TI 101 and 4-fluoro-iso-TI 103 both resulted in decreased neutrophil 
recruitment, yet had no effect on resolution of neutrophilic inflammation. 6-Methoxy-
TI 104 exhibited no effect on neutrophil recruitment, yet significantly promoted 
inflammation resolution, which was analogous to the findings observed for TIIA 2. This 
suggested that this particular compound may be an interesting one to focus on, going 
forward in investigation of compounds which specifically target inflammation resolution 
processes. The same activity profile in these two types of experiment was also seen for 
the TI acetal 109, although as discussed previously, this may have been due to the 
formation of products arising from acetal hydrolysis and metabolism, and so could 
perhaps be considered a lower priority. In contrast to the corresponding tanshinone, 4-
methoxy-iso-TI 105 had no effect on either the recruitment or resolution stages of 
neutrophilic inflammation. 
Comparison of the fluorine-containing compounds with their non-fluorine-containing 
analogues was also of interest, as this could provide insights into how in vivo metabolism 
may have affected biological activity. Whereas TI 1 had an effect on both neutrophil 
recruitment and resolution, 6-trifluoro-TI 100 did not significantly affect either process 
(although there was a trend towards fewer recruited neutrophils). Similarly, iso-TI 13 
also affected both recruitment and resolution, whilst the analogous 4-trifluoromethyl-
iso-TI 101 reduced neutrophil recruitment yet had no effect on resolution of neutrophilic 
inflammation. This could suggest that in vivo C-H metabolism (or some other factor 
relating to C-F bond substitution) was important for acceleration of inflammation 
resolution, but not for neutrophil recruitment. 6-Hydro-TI 31 did not affect either 
recruitment or resolution, and neither did 6-fluoro-TI 102, although there were trends 
towards lower neutrophil numbers for both processes. Meanwhile, the unsubstituted 4-
hydro-iso-TI 99 also had no effect on neutrophil numbers for either recruitment or 
resolution, yet treatment with 4-fluoro-iso-TI 103 resulted in decreased neutrophil 
recruitment, but did not affect resolution. Conversely to the results for the 
trifluoromethyl variants, this may suggest that replacement of a hydrogen atom with a 
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fluorine atom here had more effect on neutrophil recruitment than on resolution of 
neutrophilic inflammation.  
 
Table 4. Summary of the effects of various tanshinones and isotanshinones on 
neutrophil recruitment and resolution of neutrophilic inflammation in vivo. 
Entry Compound Effect on recruitment Effect on resolution 
1 TIIA 2 No effect Enhanced 
2 TI 1 Reduced Enhanced 
3 Iso-TI 13 Reduced Enhanced 
4 6-hydro-TI 31 No effect No effect 
5 6-trifluoromethyl-TI 100 No effect No effect 
6 6-fluoro-TI 102 No effect No effect 
7 6-methoxy-TI 104 No effect Enhanced 
8  4-hydro-iso-TI 99 No effect No effect 
9 4-trifluoromethyl-iso-TI 
101 
Reduced No effect 
10 4-fluoro-iso-TI 103 Reduced No effect 
11 4-methoxy-iso-TI 105 No effect No effect 
12 TI-acetal 109 No effect Enhanced 
 
4.5.8 Aqueous solubilities and in vivo toxicities of TI analogues and isomers  
The aqueous solubilities of the various tanshinones and isotanshinones were 
qualitatively examined via visual observations of the treatment solutions under the 
microscope whilst neutrophils were counted (and still blinded to identities of the various 
treatment groups). At a concentration of 25 µM, precipitation was consistently observed 
for TI 1 in both recruitment and resolution experiments, whilst minimal precipitation 
was seen at a 10 µM concentration. This indicated that the aqueous solubility of TI 1 (in 
E3 solution) was likely between these two values. For iso-TI 13, there was also 
precipitate at a 25 µM concentration, although this was noticeably less than for TI 1. 
Considerable precipitation was observed for 6-hydro-TI 31 at the same concentration, 
which often appeared to be greater than that observed for TI 1. For the remaining 
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tanshinones, there was minimal or no precipitation at a 25 µM concentration. A small 
amount was seen for 4-hydro-iso-TI 99, whilst slightly more was observed for both 4-
trifluoromethyl-iso-TI 101 and 4-methoxy-iso-TI 105. The TI-acetal 109 produced 
minimal amounts of precipitate at the same dosage, whilst none was observed for 4-
fluoro-iso-TI 103. Unsurprisingly, these observations suggested that the least water-
soluble compounds were those without heteroatom substituents, whilst those with 
these groups tended to be more soluble. Aqueous solubility is an important 
consideration for any compounds taken forward for further study, and future drug 
development, and so was useful to gauge at a qualitative level at this stage. 
Concomitantly, observations of the health of the treated zebrafish larvae were made 
for all experiments. At a concentration of 25 µM (or lower), none of the evaluated 
tanshinones and isotanshinones exhibited any larval toxicity; larvae were generally 
healthy in all treatments, as determined by general body shape, tail shape, presence of 
circulation, and heartbeat. This was useful information to obtain, as in vivo toxicity is 
another very important consideration in drug discovery and development, and so this 




In this work, synthesis of a series of analogues of TI 1, and its isomer iso-TI 13, was 
achieved in six steps from the commercially available compounds 5-bromovanillin 27 
and various substituted carboxylic acids. Whilst this synthesis used the same strategy to 
access the final tanshinones as previous literature precedence,211 a number of 
advantages were presented in this work. The first two oxidation steps were carried out 
on large (25 g) scales without the requirement for chromatographic purification. The 
radical decarboxylative alkylation step was also performed on moderate (1-2 g) scales, 
and purification was often carried out effectively using dry column chromatography as 
a more time- and material-efficient alternative to standard column chromatography. 
One of the more notable achievements of this work was the nine-fold reduction in the 
quantity of palladium catalyst required for the intramolecular Heck reactions. These 
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reactions were carried out using 5 mol% palladium(II) acetate, rather than the 45 mol% 
used previously in the literature, and yields of up to 74% were achieved. Complete 
aromatisation of the ring-closed products was observed using mild demethylation 
conditions, and did not require the use of an oxygen balloon, representing a safer and 
more convenient method. Furthermore, the modified Feist-Bénary reaction using 
chloroacetone and microwave conditions resulted in consistent production of both 
tanshinones and isotanshinones; there are generally very few reported syntheses of 
isotanshinones in the literature. Thus, the various optimisations carried out led to an 
improved synthesis of tanshinones and isotanshinones.  
One particular set of optimisations involved the use of design of experiments (DoE) 
software. DoE has been used in industry for many years, particularly in process 
chemistry, but has only recently started to attract more attention in academic scenarios. 
In this work, although the optimised conditions as a result of the DoE study were not 
vastly differently from those used before the study, use of DoE allowed a range of 
different reaction parameters to be explored quickly using a minimal number of 
experiments. Significantly fewer experiments were performed than would otherwise 
have been required to investigate all of these factors without the use of DoE. The custom 
design function in the DoE software enabled identification of the most important 
contributing factors to overall reaction yield as well as investigation of any obvious 
improvements to the reaction conditions which had not previously been implemented. 
This particular DoE approach was relatively simplistic, in the absence of any specialist 
knowledge, and future studies of this type could involve the use of more complex, yet 
efficient, designs in the DoE software. Overall, this approach was useful for evaluating 
numerous reaction variables, and its use could be considered in similar situations in the 
future. 
Throughout the synthesis, yields of isolated products obtained were often 
respectable, although in some cases, depended on the phenyl ring substituent. This was 
particularly true for the intramolecular Heck reaction, and to a lesser extent, the radical 
alkylation and modified Feist-Bénary reactions. The best yields were generally achieved 
for compounds with electron-neutral substituents, such as a methyl group 36, 77 or 
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hydrogen atom 88-89. Lower yields were obtained for heteroatom substituents, 
particularly where the heteroatom was directly bound to the phenyl ring, as for 
compounds with fluorine 92-93 and methoxide 94-95 substituents. For the Heck 
reaction, other than the differing electronics of the phenyl ring, this could be because in 
these cases, due to rotation around a single bond, the heteroatom could become closely 
positioned to and interact with the palladium catalyst, possibly interfering with the 
reaction mechanism and thereby resulting in reduced product yields. With the 
trifluoromethyl-substituted compounds 90-91, the heteroatoms were perhaps further 
away from this active site, and so may have had less of an effect, resulting in an 
intermediate yield. Attempts to investigate this hypothesis were not carried out here 
due to time constraints, but could be further investigated using other substituents, such 
as by adding a bulky tert-Butyldimethylsilyl (TBDMS) group, and in different positions 
around the phenyl ring. This approach would also lead to the synthesis of other 
tanshinone analogues, which could be biologically evaluated to construct further 
structure-activity relationships.  
Synthesis of further functionalised tanshinones using this synthetic route is also of 
interest. Such tanshinones could be used in various applications, but would be 
particularly useful for synthesising molecules which could be used to probe the 
molecular target of tanshinones in vivo, for example using photoaffinity labelling.279 A 
desirable tanshinone would be the 6-hydroxy-substituted variant, as the phenol could 
be functionalised whilst avoiding functionalisation close to the ortho-quinone moiety. 
Various alcohol protecting groups could be explored (such as a TBDMS group), but one 
particular approach would be to use an allyl protecting group. This would have the 
advantage of likely compatibility with the various reaction conditions throughout the 
synthesis (although careful analysis of the Heck reaction might be required). Reaction 
with chloroacetone to form the corresponding tanshinone and isotanshinone would 
produce new analogues which could be evaluated in vivo. Furthermore, the key part of 
this strategy would be that the allyl group could then undergo ozonolysis to reveal a 
terminal carbonyl group, which could be functionalised in various ways to produce other 
derivatives. Careful consideration of the quantities and yields of each step required to 
Page 99 of 246 
 
produce enough material for functionalisation would be needed, but this approach is 
worth considering in future studies.  
Synthesis of the TI acetal 109 was undertaken to explore the hypothesis that the 
ortho-quinone moiety of tanshinones was essential for their biological activity. 
However, following analysis of the recruitment and resolution data for the TI acetal 109, 
it was thought that hydrolysis of the acetal 109 and subsequent metabolism of 
hydrolysis products might have occurred in vivo. Therefore, the original hypothesis may 
not have been tested as originally hoped. Synthesis of a similar compound with greater 
in vivo stability, which ‘masks’ the ortho-quinone functionality of the tanshinone but is 
otherwise structurally similar, could be considered in future work. This would enable 
more rigorous investigation of the importance of the ortho-quinone moiety for 
biological activity.  
For evaluation of the synthesised tanshinones and isotanshinones in inflammation 
resolution experiments, it was necessary to change the experimental timepoints, from 
the 6 and 12 hpi timepoints used previously, to the 4 and 8 hpi timepoints used in this 
work. The neutrophil timecourse data for the populations of zebrafish larvae indicated 
that the number of neutrophils at the site of injury peaked at around 4 hpi, rather than 
6 hpi as found previously.36,86,278 These data suggested that the zebrafish inflammatory 
response dynamics had changed, and this was likely due to zebrafish strain inter-
variability, and a lack of inbred strains. The generation of adult zebrafish used to produce 
larvae for these experiments were changed every 18 to 24 months, so it is likely that the 
adult zebrafish used here were also a different age to those used previously, and that 
these differences explained the different experimental timepoints required for these 
experiments. Furthermore, it is possible that this shift in the time of readout for 
resolution experiments to an earlier timepoint could have consequences for recruitment 
assays, since neutrophil counting was still performed at 6 hpi for recruitment 
experiments. However, the difference in neutrophil numbers in untreated, injured 
larvae at 4 and 6 hpi was small (Figure 16). In addition, treatment of larvae with a 25 µM 
concentration of TIIA 2 had no significant effect on neutrophil recruitment at 6 hpi 
(Figure 19), yet use of TIIA 2 at the same concentration consistently resulted in a 
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significantly lower number of neutrophils at the site of injury at 8 hpi in resolution 
experiments. Therefore, it is considered to be rather unlikely that the results from 
recruitment experiments were significantly affected by any effect of the compound on 
resolution of neutrophilic inflammation. As both recruitment and resolution 
experiments were carried out separately anyway, these results can be considered 
together for individual treatments.  
Tanshinones, which contain an ortho-quinone moiety, and isotanshinones, bearing a 
para-quinone moiety, exhibited similar effects on both neutrophil recruitment and 
resolution of neutrophilic inflammation. However, the two classes of compounds are 
somewhat structurally different, thus the two types of compound may not have acted 
at the same binding region of the same protein target(s). For example, the slightly 
greater variability in neutrophil recruitment upon treatment with iso-TI 13 compared to 
TI 1 may be related to a difference in targets and/or polymorphisms in target genes. 
Furthermore, compounds which resulted in decreased neutrophil recruitment likely 
acted at a different protein target to those which accelerated resolution of neutrophilic 
inflammation, as these are different processes in the inflammatory response. Therefore, 
it may be that there was more than one protein target involved in the biological activities 
of these compounds observed here. Given the complex biological nature of the 
inflammatory response, it is possible that the compounds operated at more than one 
protein target for recruitment alone, and also at more than one target for resolution.  
One alternative possibility is that compounds which significantly reduced neutrophil 
recruitment did not act at a particular protein target or targets, but instead exhibited an 
antioxidant effect, by reacting with reactive oxygen species (ROS) generated at the site 
of injury, such as hydrogen peroxide. Hydrogen peroxide has been found to rapidly 
promote the accumulation of neutrophils at a wound following injury,280 thus, reaction 
of a compound with hydrogen peroxide could affect neutrophil recruitment. Previous 
work found that using the same zebrafish model of inflammation, treatment of larvae 
with the natural product isopimpinellin led to decreased neutrophil recruitment, yet this 
was highly unlikely to be due to antioxidant activity, as shown using in vivo and in vitro 
methods.278 Thus, it is possible that the same was true for the tanshinone compounds 
Page 101 of 246 
 
evaluated in this work. Future in vivo experiments could be carried out with the ROS dye 
used previously,281 alongside in vitro methods, to determine if the tanshinones 
evaluated here were likely to be working in this way, although this is thought to be 
unlikely. This possibility is also very unlikely to be true for compounds which accelerated 
inflammation of resolution, as hydrogen peroxide is released very early in the process 
of inflammation, thus likely only affecting neutrophil recruitment. This may therefore 
explain the results for neutrophil recruitment effects, possibly leaving a single target 
responsible for the observed effects on resolution of neutrophilic inflammation. 
Observed differences in recruitment and resolution effects may also be due to delayed 
penetration of compounds into larvae, with compounds being able to penetrate the 
larvae quicker and more easily in recruitment experiments than in resolution 
experiments. Thus, one possibility is that TI 1 was able to quickly get into the larvae and 
act to decrease neutrophil recruitment, whereas, possibly due to structural differences, 
TIIA 2 was not able to access the required target quickly enough to have an effect on 
neutrophil recruitment, but was able to penetrate the larvae sufficiently to have an 
effect on resolution.  
Going forward with any of these compounds which resulted in a significant decrease 
in the number of neutrophils at the injury site (either in the recruitment or resolution 
stages of inflammation), it may be wise to carry out neutrophil whole body counts for 
larvae which have been treated with these compounds. This would involve incubation 
of the larvae for the same duration as used in the previous experiments, and then 
counting the number of neutrophils in the whole body, to determine whether the 
observed decreases in neutrophil numbers at the site of injury were due to overall 
neutrophil number decreases in the body upon drug treatment, or not. It was previously 
shown that TIIA 2 accelerated resolution of neutrophilic inflammation in the zebrafish 
inflammation model without affecting the total number of neutrophils in the larval 
body;36 thus it is likely that this would also be true for the structurally similar tanshinones 
investigated in this work, though it would be wise to evaluate this with at least some of 
the compounds tested here. 
Page 102 of 246 
 
Overall, the results from this work suggested that there were some structural-activity 
relationships between the compounds tested and their in vivo biological activities, as 
discussed previously. However, these were not completely clearly defined, and there 
remained some ambiguity. In general, this phenotypic screening approach enabled 
identification of new compounds which demonstrated significant effects on neutrophil 
behaviour in the inflammatory response in vivo, and provided some areas for further 
investigation. The compounds evaluated in this work (especially the ortho-quinone 
tanshinones) were structurally very similar, with only small changes made to one 
particular part of the molecule. Next, evaluation of molecules which were more 
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5. Synthesis and evaluation of other tanshinone analogues and 
related compounds 
5.1 Introduction 
The results from the biological evaluation of the TI and iso-TI analogues indicated that 
there were some clear patterns, yet there appeared to be some ambiguity in structure-
activity relationships between the various compounds and their effects on neutrophil 
behaviour during the inflammatory response in vivo. Although some of the compounds 
exhibited significant effects on neutrophil recruitment and/or resolution of neutrophilic 
inflammation, prediction of the precise chemical identity of these particular compounds 
prior to synthesis and evaluation would not have been possible. In light of these results, 
more broadly-related tanshinone analogues were explored, as well as other structurally 
related compounds. Compounds bearing some, but not all, of the structural features of 
tanshinones were of interest, as were compounds with a more interesting three-
dimensional component, given the complete planarity of TI 1 and many of the related 
analogues studied. 
Firstly, a general route for synthesising different broadly-related tanshinone 
analogues was explored. A Diels-Alder reaction strategy, followed by aromatisation, was 
previously used to synthesise various tanshinones and related compounds, including 
TIIA 2 and others such as TIIB 3, nortanshinone 110, and tanshindiol B 111 (Scheme 
33).229,230 By using different dienes, a range of analogues could be synthesised and 
evaluated. The particular compounds synthesised would be mainly dependent on the 
availability or ease of synthesis of the various dienes and the dienophile 59, the 
efficiency of the Diels-Alder reaction, and the reaction selectivity, where relevant. Using 
the same dienophile 59 in each reaction would enable both the ortho-quinone moiety 
and the furan ring found in most tanshinones to be maintained in each synthesised 
compound. However, the particular Diels-Alder reaction using the dienophile 59 was 
previously reported to only work efficiently with reactive dienes. Less reactive dienes 
required more forceful conditions to generate moderate yields, although the use of 
ultrasound was found to improve both the yield and regioselectivity of the 
reaction.229,230   
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Scheme 33. Use of a Diels-Alder reaction to synthesise various tanshinone 
analogues. 
 
Two interesting compounds encountered in the literature were β-lapachone 112 and 
nor-β-lapachone 113 (Figure 23). These compounds satisfied both of the desired criteria 
mentioned previously, comprising three of the four rings common to most tanshinones, 
including the ortho-quinone moiety on the middle ring, an adjacent benzene ring in the 
same position as in all tanshinones, and an oxygen-containing five- or six- membered 
ring, with the oxygen atom in the same position as found in tanshinones. In particular, 
nor-β-lapachone 113 contains a five-membered ring, the same ring size as the 
tanshinone furan ring. The dimethyl-substituted carbon atom adjacent to the oxygen 
atom in both compounds 112 and 113 would allow some exploration of three-
dimensional space. Similarly, the different levels of saturation of the remaining one (nor-
β-lapachone 113) or two (β-lapachone 112) sp3 hybridised carbon atoms in this 
unsaturated ring, in comparison to the sp2 hybridised carbon atoms in the furan ring of 
tanshinones, were of interest. The absence of the fourth ring in these structures could 
also affect biological activity. 
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Figure 24. Structures of related compounds β-lapachone 112 and nor-β-lapachone 
113, and their structural similarity, shown in red, with TI 1 and TIIA 2. 
 
β-Lapachone 112 is a naturally-occurring ortho-quinone compound obtained from 
the bark of the lapacho tree, Tabebuia avellanedae in Brazil, a plant used as a traditional 
medicine for centuries for various treatments, including as an analgesic, as an anti-
inflammatory agent, an antineoplastic agent, and as a diuretic.282,283 In more recent 
work, β-lapachone 112 has been considered as a candidate drug for cancer treatment, 
demonstrating significant anti-cancer activity in various studies.284–288 Other reported 
effects include anti-angiogenesis activity,289,290 antimicrobial effects,291–293 and wound 
healing properties.294 
Some anti-inflammatory effects exhibited by β-lapachone 112 have also been 
reported. β-Lapachone 112 inhibited iNOS in the alveolar macrophages and aorta of 
rats,295 whilst anti-inflammatory effects in LPS-stimulated microglia have been 
described.296 β-Lapachone 112 is also a known substrate of NAD(P)H quinone 
oxidoreductase 1 (NQO1), found to modulate the metabolism of NAD and lead to an 
increase in cellular NAD(+).297 Such inhibition led to anti-inflammatory effects in 
macrophages, via protein kinase activation.298 Anti-inflammatory effects of β-lapachone 
112 (as well as anti-arthritic activities) were also shown in rats.299 In this study, β-
lapachone 112 inhibited neutrophil migration and led to reduced concentrations of pro-
inflammatory cytokines including TNFα, IL-6, and nitric oxide. A synthetic derivative of 
β-lapachone 112 also inhibited production of TNFα and nitric oxide in LPS-induced 
murine macrophages.300,301 Furthermore, suppression of neuroinflammation by β-
lapachone 112 was recently observed.302 
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In contrast to β-lapachone 112, reports of previous studies involving nor-β-lapachone 
113 are scarce. Although nor-β-lapachone 113 (and its derivatives) is considered an anti-
cancer drug candidate,303,304 there are no studies involving nor-β-lapachone 113 in 
relation to inflammation, neutrophils, or zebrafish in the literature. This may be because 
β-lapachone 112 is a naturally occurring compound, whereas nor-β-lapachone 113 is 
not.  
In recent studies, both TIIA 2 and β-lapachone 112 were shown to act as NQO1 
inhibitors.145,305 The structural and pharmacological similarities of these two molecules 
meant that they both exhibited a synergistic anti-cancer effect when used in conjunction 
with the drug paclitaxel.305 Although a formal connection between the lapachones and 
tanshinones has not been greatly established elsewhere, this recent finding may suggest 
that these two classes of compounds could exhibit common biological activities in vivo. 
The fact that both of these molecules have been shown to act as inhibitors of NQO1 
could mean that this is considered a possible molecular target with regards to any anti-
inflammatory activities of these molecules (although such investigation is outside of the 
scope of this work).   
Both β-lapachone 112 and nor-β-lapachone 113 were previously synthesised from 
the commercially available natural product lapachol 114, and its one carbon homologue 
norlapachol 115, respectively (Figure 24).306,307 β-Lapachone 112 was obtained from 
lapachol 114 in a single step, whilst nor-β-lapachone 113 was synthesised from lapachol 
114 in two steps, via the intermediate nor-lapachol 115.306,307 
 
Figure 25. Structures of related compounds lapachol 114 and norlapachol 115. 
 
Lapachol 114 is a para-quinone compound and, like β-lapachone 112, is naturally 
present in the lapacho tree, Tabebuia avellaneda.283 Another similarity with β-lapachone 
Page 107 of 246 
 
112 is that lapachol 114 is also an inhibitor of NQO1, with an IC50 value of 150 nM.308 In 
the same study, lapachol 114 caused melanin defects in zebrafish embryos, as well as a 
range of other abnormalities.308 Lapachol 114 has also been shown to exhibit 
cytotoxicity against a range of different cancer cells,309,310 amongst other biological 
effects including anti-metastatic and antimicrobial activities.283,291,311–313 Furthermore, 
lapachol 114 previously exhibited anti-inflammatory activity, including in a rat model of 
inflammation.314 However, lapachol 114 has also presented significant toxicity issues, 
including in rat models.315–317 
Analogously to β-lapachone 112 and nor-β-lapachone 113, whereas lapachol 114 has 
previously been investigated in numerous studies, few such investigations have been 
carried out on the closely related norlapachol 115. In particular, no studies on 
norlapachol 115 could be found in relation to inflammation, neutrophils, or zebrafish. 
This may again be because lapachol 114 is a known natural product, whereas 
norlapachol 115 is not, instead requiring synthesis from lapachol 114.  
Overall, the relative similarities of these compounds, especially the lapachones 112 
and 113, to tanshinones, their known biological activities, and their ease of synthesis, 
merited investigation of these compounds in this work. This would enable wider 
exploration of the structure-activity relationships of tanshinones and related 
compounds in the zebrafish model of inflammation, compared to the more closely 
related compounds explored in the previous chapter.  
 
5.2 Hypothesis and aims 
It was hypothesised that other tanshinones, as well as compounds with some degree 
of structural similarity to tanshinones, such as β-lapachone 112 and nor-β-lapachone 
113, would exhibit anti-inflammatory activity in vivo, according to structure-activity 
relationships. Such activity would allow for a greater understanding of the biologically 
active part(s) of tanshinones including TI 1 and TIIA 2.   
The first aim of this work was to synthesise various tanshinone analogues using a 
previously reported Diels-Alder reaction strategy. This would require use of different 
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dienes, which could either be synthesised or bought as required, as well as synthesis of 
a significant quantity of the required dienophile. Any synthesised tanshinones could be 
evaluated in vivo, utilising the zebrafish model of inflammation used previously. 
The second aim of this work was to synthesise compounds more broadly related to 
tanshinones, namely β-lapachone 112 and nor-β-lapachone 113, using literature 
precedents. These compounds, alongside any intermediates, would also be tested for 
any anti-inflammatory activity using the zebrafish inflammation model, and the results 
used to explore any further structure-activity relationships more widely. 
 
5.3 Towards the synthesis of TIIA and analogues 
5.3.1 General strategy 
Using the route previously documented in the literature,229,230 formal disconnection 
of the TIIA general structure led back to the dienophile 59 and various dienes, the exact 
structures of which could be modified to give various tanshinone analogues (Figure 25). 
The dienophile 59 could be produced by selective oxidation of 3-methyl-5-benzofuranol 
58 using Fremy’s salt, as previously described,228,230 and this phenol 58 could be 
synthesised in three steps from simple and cheap starting materials. This route was 
previously used for the synthesis of a range of TIIA derivatives,150 as well as for the 
synthesis of other tanshinones and related compounds.318,319 
 
Figure 26. Disconnection of the general TIIA structure to the phenol 58 and various 
dienes. 
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5.3.2 Dienophile synthesis 
The route to synthesising 3-methyl-5-benzofuranol 58 employing enamine 
formation, subsequent reaction with para-benzoquinone 32, and acid-mediated 
elimination was attempted.228,230 Enamine formation from propanal 57 and excess 
piperidine 116 (Scheme 34) initially seemed to be unsuccessful, based on analysis of the 
1H NMR spectrum, even with slower addition of the aldehyde 57 to piperidine 116. 
However, analysis of the starting materials by 1H NMR spectroscopy indicated that 
propanal 57 used directly from the bottle was impure. When freshly distilled propanal 
57 was used immediately in the reaction, formation of the enamine 117 occurred 
successfully, and complete conversion of the aldehyde was observed when excess amine 
116 (1.5 equivalents) was used, confirmed by 1H NMR spectroscopy. The data were 
consistent with only the sterically expected (E)-isomer formation,320,321 based on the 
coupling values of the alkene protons (J = 13.9 Hz, indicating a trans- relationship 
between the two protons) as well as the absence of any additional peaks corresponding 
to the (Z)-isomer.  
 
Scheme 34. Enamine formation from propanal 57 and piperidine 116. 
 
Due to the expected volatility of the enamine product 117 (relative to the residual 
piperidine 116), as well as its sensitivity towards acid, purification of the enamine 117 
was not trivial. Distillation under reduced pressure has previously been used for 
this,150,230,319 and this led to an improved purity of product, although still not pure. In an 
attempt to circumvent this issue, the quantity of piperidine 116 used in enamine 
formation was varied. Both stoichiometric (1 equivalent) and sub-stoichiometric (0.8 
equivalents) quantities of piperidine 116 were used, to ensure complete reaction of the 
piperidine 116. However, although the enamine 117 was formed, both aldehyde 57 and 
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piperidine 116 remained, even with varied reaction times. Use of anhydrous ether as 
solvent resulted in the same outcome. Thus, following re-synthesis on a multi-gram scale 
using the initial reaction conditions, the crude enamine 117 was taken forward, with 
excess piperidine 116 as the main contaminant. 
The crude enamine 117 was reacted with para-benzoquinone 32, in an effort to form 
the piperidine-substituted benzofuranol 118 (Scheme 35). Initial formation of a wine-
red solution in this reaction was observed, as reported previously.230,319 The literature 
also reported isolation of a white solid product, simply upon removal of solvent in vacuo, 
possibly following gradual decolouration of the reaction solution over time. However, 
this decolouration was not observed here, and the resulting concentrated residue 
resembled a deep red/amber-coloured gum. The reaction was repeated both with a 
slower rate of addition of the crude enamine 117 and a longer reaction time, yet still 
gave the same result, and so too did swapping the order of addition of reagents. Analysis 
by 1H NMR spectroscopy indicated formation of a complex mixture of products, with no 
desired product 118 formed. 
 
Scheme 35. Attempted reaction of the enamine 117 with para-benzoquinone 32. 
 
Addition of a Lewis acid to this reaction was also investigated, to promote formation 
of the desired product 118. Simultaneous reactions were performed, using no additive, 
0.1, and 1.0 equivalents of aluminium trichloride, respectively. However, in each 
instance, no significant quantities of desired product 118 were observed in the 1H NMR 
spectra of the crude products. In addition, attempts to further purify all reagents and 
substrates prior to use in this reaction still did not deliver the desired product 118. 
An alternative reaction was investigated, utilising distilled propanal 57 directly with 
para-benzoquinone 32 in the presence of L-proline (Scheme 36). L-Proline has previously 
Page 111 of 246 
 
been found to act as an effective catalyst in a variety of (asymmetric) reactions, including 
the Hajos–Parrish–Eder–Sauer–Wiechert reaction, aldol reactions, Michael reactions, 
and Mannich reactions.322–324 However, synthesis of the required benzofuranol product 
58 was unsuccessful, and only propanal 57, para-benzoquinone 32, and 1,4-
hydroquinone were present, even after the mixture was left to stir for several days. This 
particular reaction was therefore abandoned without further exploration. 
 
Scheme 36. Attempted benzofuranol 58 formation from propanal 57 and para-
benzoquinone 32 in the presence of L-proline. 
 
In light of these unsuccessful reactions using the piperidine-derived enamine 117, use 
of morpholine 119 instead of piperidine 116 was investigated, following precedence for 
such reactions.228,230 Enamine formation from propanal 57 and morpholine 119 
proceeded successfully (Scheme 37), albeit again with residual starting materials 
remaining. The crude enamine 120, again consistent with being the E-isomer,230,325,326 
was then reacted with para-benzoquinone 32 (Scheme 37). This produced a deep 
red/amber-coloured gum, as for the piperidine variant, yet analysis by 1H NMR 
spectroscopy appeared to indicate successful formation of the desired product as the 
trans-isomer 121, based on comparison with literature data.230,325 Attempted 
purification by column chromatography successfully removed major impurities, but 
appeared to result in isolation of the epimeric cis-isomer 122, as determined by the 
shifting of various peaks in the 1H NMR spectrum of the product. Nonetheless, the 
isolated material was taken forward to the next step.  
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Scheme 37. Enamine 120 formation using morpholine 119 followed by reaction with 
para-benzoquinone 32 and chromatographic purification. 
 
The next step comprised gentle heating with aqueous acid, to eliminate morpholine 
119 and form the desired 3-methyl-5-benzofuranol product 58 (Scheme 38), as 
previously achieved.230,327 Following work-up, analysis by both 1H NMR spectroscopy 
and thin layer chromatography (TLC) indicated that a mixture of products was present, 
and the desired product 58 appeared to be one of these. Purification by column 
chromatography led to the successful isolation of the desired benzofuranol 58, albeit in 
small quantities. Starting material 122 was also isolated, and analysis of the respective 
product masses suggested that the reaction had occurred with around 10% conversion. 
However, this indicated that the previous reaction with para-benzoquinone 32 was 
successful. This also suggested that the morpholine-containing phenol starting material 
122 was much more stable to both acid and chromatographic purification on silica than 
originally thought. Also, a longer reaction time and/or higher reaction temperature 
could be required for the complete reaction of this starting material 122 with acid. Thus, 
heating at reflux with aqueous 1 M hydrochloric acid for 4.5 hours provided greater 
conversion to the benzofuranol product 58, although still not complete.  
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Scheme 38. Acid-mediated elimination to give 3-methyl-5-benzofuranol 58. 
 
As the morpholine-containing phenol 122 appeared to be completely stable to silica, 
the compound was resynthesised in two steps from propanal 57 (Scheme 39). The crude 
product from the reaction of the enamine 120 with para-benzoquinone 32 was again 
subjected to chromatographic purification, and provided the desired phenol 122. The 
purified product 122 was then heated at reflux overnight with aqueous acid (Scheme 
39), and following chromatographic purification, yielded 3-methyl-5-benzofuranol 58 in 
a 33% yield across the three steps. Although this was a significantly lower yield than 
those obtained in the literature, this may be due to the lack of complete purification of 
the enamine 120, with residual morpholine 119 contaminating the following reaction 
and lowering the yield. However, a sufficient quantity of 3-methyl-5-benzofuranol 58 
was produced using these conditions, and in light of time considerations, this synthesis 
was not optimised any further. Overall, use of the morpholine-derived enamine 120 was 
much more successful than use of the piperidine-derived enamine 117, as supported 
both by reaction success, and results of attempted chromatographic purifications for 
both variants.  
 
Scheme 39. Synthesis of 3-methyl-5-benzofuranol 58 in three steps from propanal 57. 
 
The next step in this synthesis required the selective oxidation of 3-methyl-5-
benzofuranol 58 to the ortho-quinone dienophile 59. This transformation was previously 
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carried out using potassium nitrosodisulfonate, [(KO3S)2NO·], commonly known as 
Fremy’s salt.328,329 Following the literature procedure,228,230 oxidation of 3-methyl-5-
benzofuranol 58 was first attempted on a small (100 mg) scale using three equivalents 
of commercial Fremy’s salt (Scheme 40). 
 
Scheme 40. Selective oxidation of 3-methyl-5-benzofuranol 58 using Fremy’s salt to 
form the ortho-quinone 59. 
 
Upon addition of the Fremy’s salt solution to the phenol 58, a relatively quick change 
in colour from beige to deep red was observed. This suggested that the reaction had 
worked, as the product was known to be a dark red solid,228,230 and reactions using 
Fremy’s salt are reported to occur rapidly.328,329 Following work-up, analysis of the crude 
product by 1H NMR spectroscopy indicated the presence of a mixture of both the desired 
ortho-quinone product 59, and the phenol starting material 58. This lack of complete 
conversion was somewhat consistent with previous reports in which instability of the 
ortho-quinone 59, particularly in halogenated solutions, was observed.228,230 Attempts 
to use non-halogenated solutions for spectroscopic analysis were similarly unyielding, 
as were longer reaction times. Characterisation of the solid product by infrared (IR) 
spectroscopy also indicated a mixture of the ortho-quinone 59 and the phenol 58, and 
melting point determination further supported a product mixture. This was possibly due 
to the use of dichloromethane (DCM) in the work-up procedure, where decomposition 
of the ortho-quinone 59 may have already started to occur. Therefore, the crude ortho-
quinone product 59 was taken on to the Diels-Alder reaction, without any further efforts 
at either characterisation or purification.  
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5.3.3 Attempted synthesis of dienes 
With the synthesis of the required dienophile 59 in hand, albeit not optimal, attention 
then turned to synthesis of appropriate dienes. Initially, two particular dienes were 
considered (Figure 26). Use of the dimethyl diene 53 in the Diels-Alder reaction would 
lead to synthetic TIIA 2, which could be a useful control compound to synthesise. A 
second, simplified diene 123 was also considered, for two reasons. Firstly, this would 
produce a TIIA analogue 124 without the two methyl groups, allowing for exploration of 
the importance of these substituents for biological activity. Secondly, synthesis of this 
diene 123 appeared to be easier than that of the dimethyl diene 53, and so was explored 
first, to determine the feasibility of this chemistry. Should the chemistry be successful, 
the dienes could then be varied (within the limits of reaction tolerances and starting 
material availabilities) to provide various tanshinone analogues. 
 
Figure 27. The dimethyl diene 53 and the simplified diene 123 would give TIIA 2 and 
a tanshinone analogue 124, respectively. 
 
The simplified diene 123 could be formed from dehydration of the tertiary alcohol 
125, which could be synthesised from a Grignard reaction between cyclohexanone 126 
and vinylmagnesium bromide (Scheme 41). The Grignard reaction between 
cyclohexanone 126 and commercial vinylmagnesium bromide was carried out 
successfully to produce the tertiary alcohol 125. Analysis of the 1H NMR spectrum 
indicated that the product 125 was present yet slightly impure,330,331 with small amounts 
of residual cyclohexanone starting material 126 still present, as well as other low-level 
impurities. Purification by column chromatography successfully yielded a much cleaner 
alcohol product 125 in 54% yield. This was considered respectable, as the product 
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alcohol 125 appeared to be somewhat volatile, meaning that mass returns were likely 
diminished with each attempted work-up and purification step. The purified product 
125 was then taken on to the dehydration step. 
 
Scheme 41. The diene 123 could be synthesised from cyclohexanone 126 in two 
steps, comprising a Grignard reaction followed by dehydration. 
 
Dehydration of the tertiary alcohol 125 to give the desired diene 123 was first 
attempted by heating the alcohol 125 to reflux with aqueous hydrochloric acid (1 M) for 
several hours. However, this did not yield any of the desired diene 123, and analysis of 
the 1H NMR spectrum indicated a mixture of compounds. Therefore, a different method 
of dehydration was attempted, where the alcohol 125 was heated to reflux in pentane 
with a catalytic amount of para-toluenesulfonic acid, for a shorter time of two hours 
(Scheme 41). Analysis of the product by 1H NMR spectroscopy indicated that the diene 
123 was present,331,332 but as part of a mixture with other unidentified components, and 
so purification by column chromatography was attempted. However, when fractions 
containing the least polar product were concentrated under reduced pressure, no 
desired compound 123 was isolated. Analysis of other eluted products indicated that 
these also did not correspond to the desired diene 123. This may have resulted from 
decomposition of the product 123 on silica, but was probably due to the volatility of the 
diene 123, which may have been lost during rotary evaporation. The reaction was 
therefore repeated, using an increased quantity of para-toluenesulfonic acid (1.5 
equivalents), and again purified by column chromatography. This time, pentane was 
used as the eluent, and the first product-containing fractions were concentrated more 
carefully, to minimise loss of volatile product. This resulted in isolation of a very small 
quantity (11 mg) of the desired diene 123, which was significantly cleaner than 
previously, but still not pure.  
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Therefore, a different method of purification was considered. The reaction was 
repeated using the same conditions, and purification by distillation was attempted. 
However, this was not successful in isolating the desired diene 123. The reaction scale 
was possibly not large enough to enable effective purification by conventional 
distillation, and other techniques such as Kugelrohr distillation may have been more 
effective. However, due to time constraints associated with this work, this synthesis was 
not explored any further; this would be an obvious area to explore in any future studies. 
Instead, commercially available dienes were explored in the Diels Alder reaction with 
the ortho-quinone dienophile 59. Any products isolated from these reactions would still 
exhibit significant structural similarities with tanshinones, and would therefore be 
worthy of biological evaluation. Given the previous results obtained from small changes 
made to the TI 1 structure (Chapter 4), evaluation of tanshinone analogues with more 
broader changes, yet still maintaining key structural features of tanshinones, was 
considered worthwhile. 
 
5.3.4 Diels-Alder reactions using commercially available dienes 
Previous studies found that this Diels-Alder reaction worked well with reactive 
dienes, but was not so effective with less reactive dienes.228,230 Therefore, 
cyclopentadiene 127 was chosen as a highly reactive diene to explore this reaction with, 
as this had previously been used successfully in this reaction.228,230 Cyclohexadiene 128 
and isoprene 129 were also considered due to some previous literature 
precedence,229,230 leading to formation of two tanshinone analogues (or more, 
depending on Diels-Alder reaction selectivity) possessing common structural similarity 
to both TI 1 and TIIA 2. Danishefsky’s diene 130 was also used.   
Selective oxidation of the benzofuranol 58 to the ortho-quinone dienophile 59 was 
performed using Fremy’s salt (Scheme 42), using the same procedure as earlier in this 
work (Chapter 5.3.2). Again, reaction success was crudely determined by the observed 
colour changes which were in agreement with the literature.230 The crude ortho-quinone 
dienophile 59 was reacted with an excess of freshly cracked and distilled 
cyclopentadiene 127, using low temperature conditions as employed in the literature.230 
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Initially, this reaction was unsuccessful, as determined by 1H NMR spectroscopy. 
However, this was because the ortho-quinone starting material 59 had completely 
decomposed prior to use, as there was a significant amount of time between generation 
of the first batch of crude ortho-quinone 59, which was used here, and the Diels-Alder 
reaction being carried out. Therefore, for all further reactions, the oxidation was carried 
immediately before the Diels-Alder reaction utilising the freshly synthesised ortho-
quinone dienophile 59. When the Diels-Alder step was repeated using freshly generated 
unpurified dienophile 59, the reaction was successful. The reaction changed colour as it 
proceeded, from dark red to a pale yellow, consistent with literature observations and 
the reported yellow solid expected for the product 131.230 Analysis of the crude product 
by 1H NMR spectroscopy indicated successful formation of the desired product 131 as 
the single endo isomer, consistent with that reported in the literature.230 Additionally, a 
substantial amount of 3-methyl-5-benzofuranol 58 was present, in an approximate 
67:33 ratio of phenol 58:Diels-Alder product 131. This likely resulted from 
decomposition of the ortho-quinone dienophile 59 before it had chance to react with 
cyclopentadiene 127.  
 
Scheme 42. Formation of the ortho-quinone dienophile 59 and subsequent Diels-
Alder reaction with cyclopentadiene 127. 
 
Purification to remove the remaining phenol 58 was first attempted by treating the 
crude product with aqueous sodium hydroxide, which resulted in formation of a purple 
solid after work-up. The 1H NMR spectrum indicated that the desired product 131 was 
still present, and that the phenol was successfully removed. However, some additional 
peaks were present in the aromatic region of the spectrum, as well as two broad singlets 
further upfield. Due to a low mass return at this stage, the reaction was repeated using 
the same conditions, and again the desired product 131 and residual phenol 58 were 
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formed, although this time in a much improved ratio of 80:20 in favour of the Diels-Alder 
product 131. Purification of the crude product was attempted by column 
chromatography. Formation of a purple solid was again observed, yet the 1H NMR 
spectrum of this product matched the data reported in the literature (with small levels 
of impurities present), even though the appearance clearly did not. Attempted 
purification by recrystallisation was also unsuccessful. However, this particular bicyclic 
product 131 was not a high priority target compound for biological evaluation, and so 
due to the different compound appearances as well as low mass returns, purification of 
this compound was not explored any further. Nonetheless, formation of this product 
indicated that the ortho-quinone dienophile 59 was successfully produced from 
oxidation of the phenol 58, and that this dienophile 59 had undergone a Diels-Alder 
reaction with cyclopentadiene 127. Therefore, Diels-Alder reactions using other dienes 
were explored. 
Firstly, freshly generated ortho-quinone dienophile 59 was reacted with 
cyclohexadiene 128 (Scheme 43). Instead of employing low temperature conditions as 
were used with cyclopentadiene 127, the reaction was heated at reflux for a longer 
period of time, due to the lower reactivity of cyclohexadiene 128 compared to 
cyclopentadiene 127. However, there was no evidence of desired Diels-Alder reaction 
product 132 formation, based on analysis of the 1H NMR spectrum of the crude product. 
In the interests of time, and again as this bicyclic compound 132 was not a high priority 
for biological evaluation, this particular substrate was therefore abandoned.   
 
Scheme 43. Formation of the ortho-quinone dienophile 59 and attempted Diels-
Alder reaction with cyclohexadiene 128. 
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Next, the Diels-Alder reaction using isoprene 129 as the diene was explored (Scheme 
44). Although isoprene 129 is a considerably less reactive diene than cyclopentadiene 
127, this particular transformation has been successfully carried out previously, using 
ultrasonication to promote the cycloaddition.229,230 Therefore, this Diels-Alder reaction 
was carried out in an ultrasound bath, and was then heated to reflux overnight with 
chloranil, to achieve full aromatisation of the initial Diels-Alder reaction products. After 
crude purification through a silica plug, analysis by 1H NMR spectroscopy indicated that 
the Diels-Alder reaction and subsequent aromatisation had been successful, forming the 
two product isomers 133 and 134 in a 67:33 ratio. The reaction was relatively low 
yielding, although a low yield was also reported in the literature,229,230 and was not 
surprising given the poor reactivity of isoprene 129. In addition, as observed with the 
reaction involving cyclopentadiene 127, a significant quantity of the phenol starting 
material 58 was returned, corresponding to an approximate 70:30 ratio of phenol 58 to 
the combined product isomers 133 and 134. Analysis of the crude product mixture by 
TLC indicated that although the phenol 58 could be easily removed from the mixture, 
separation of the two product isomers 133 and 134 was very difficult, an observation 
which was consistent with the purification difficulties observed in the literature.230 
Whereas Diels-Alder reactions of this type (with different dienes) have previously been 
achieved with high regioselectivity, in favour of the isomer more closely resembling 
natural tanshinones where relevant,229,230 such regioselectivity was not achieved here 
with isoprene 129. As the quantities of products involved were very small, and the 
separation appeared to be quite challenging, efforts to isolate pure products were not 
taken any further.  
 
Scheme 44. Use of an ultrasound-promoted Diels-Alder reaction to synthesise a 
mixture of tanshinone analogues 133 and 134. 
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Finally, the Diels-Alder reaction was attempted using Danishefsky’s diene 130, a 
diene known to possess high reactivity (Scheme 45). Ultrasonication was again used to 
promote both reactivity and regioselectivity. In this reaction, a colour change was 
observed, as the reaction mixture turned from dark red to pale yellow, in a similar 
manner to the successful reaction using cyclopentadiene 127 as the diene. However, 
analysis of the crude product mixture by 1H NMR spectroscopy indicated the presence 
of a single predominant compound which vastly ‘swamped’ the quantities of all other 
compounds present. This was deduced to be the unsaturated ketone 135 (Scheme 45), 
formed by loss of the trimethylsilyl group from the excess Danishefsky’s diene 130, 
followed by enol-keto tautomerisation. This ketone 135 was not volatile and so could 
not be removed from the reaction mixture easily, making spectroscopic determination 
of the quantities of other products present in the mixture difficult. In addition, analysis 
by TLC revealed approximately seven different spots. These likely consisted of the two 
Diels-Alder reaction products, the phenol starting material 58, the ketone 135, and 
possibly residual Danishefsky’s diene 130, alongside impurities which originated from 
the bottle of diene 130 initially obtained, as determined by 1H NMR spectroscopy, which 
was purchased as 94% purity. This analysis suggested that purification to provide the 
pure desired Diels-Alder reaction products would not be trivial, especially given the 
quantities involved. Quantities of reagents and crude product mixtures were generally 
small (less than 100 mg), mainly because these reactions all required 2.5-3 equivalents 
of Fremy’s salt for the formation of the ortho-quinone dienophile 59. This reagent was 
not particularly cheap, meaning that this oxidant was the limiting reagent for reaction 
scale.  
 
Scheme 45. Formation of the ortho-quinone dienophile 59 and subsequent Diels-
Alder reaction with Danishefsky’s diene 130. 
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Due to the various difficulties encountered with these Diels-Alder reactions and 
purification of the resultant product mixtures, alongside time constraints, this approach 
to synthesis of tanshinone analogues was not taken any further, although this work did 
leave significant scope for future work. Instead, synthesis of the lapachone compounds 
was explored (Chapter 5.4), since these compounds were previously synthesised easily 
in multiple studies in just 1-2 steps from a cheap, commercially starting material. This 
would allow investigation of more broadly related tanshinone analogues, whilst still 
retaining many of the key structural elements of tanshinones. 
 
5.3.5 Summary 
This work showed that 3-methyl-5-benzofuranol 58 could be synthesised in three 
steps from simple starting materials, and converted into the ortho-quinone 59 using 
Fremy’s salt. This ortho-quinone 59 could act as a dienophile and successfully 
participated in Diels-Alder reactions with reactive dienes such as cyclopentadiene 127 
(low temperature conditions) and Danishefsky’s diene 130 (ultrasonication conditions). 
Ultrasonication conditions were also employed for the Diels-Alder reaction using the 
less reactive isoprene 129, although this reaction gave little regioselectivity. Reaction 
with cyclopentadiene 127 gave a single Diels-Alder product 131, although attempts to 
purify this compound were not completely successful. Purification issues were also 
encountered for the remaining Diels-Alder reaction product mixtures, and would require 
further efforts to enable isolation of tanshinone analogues suitable for biological 
evaluation. Synthesis of non-commercially available dienes was attempted, and 
appeared to be a feasible strategy using a Grignard/dehydration strategy. However, the 
reaction conditions may require optimisation to maximise product yields, and the 
purification steps for this route merit further investigation before use of this route to 
synthesise various related dienes. Optimisation of ortho-quinone dienophile 59 
formation from 3-methyl-5-benzofuranol 58, as well as of the conditions needed to 
ensure most efficient Diels-Alder reaction, could also be explored to address difficulties 
associated with cost and product purification encountered in this route.  
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5.4 Lapachone and lapachol compounds 
5.4.1 Chemical synthesis 
Synthesis of β-lapachone 112 was carried out as described in the literature (Scheme 
46).306,307 Acid-mediated cyclisation of the commercially available lapachol 114 
selectively formed the desired β-lapachone 112 in a good yield of 85% after 
chromatographic purification, and the isomer α-lapachone 136 was not observed. 
Mechanistically, exclusive formation of β-lapachone 112 under these conditions likely 
occurred via an intermediate epoxide, as proposed in the literature for similar reaction 
conditions.333 Previous studies have shown that the proportion of each isomer obtained 
can be varied depending on the conditions used, including the use of various Lewis acids, 
the reaction time, and the temperature at which the reaction is carried out.333–335  
 
Scheme 46. Synthesis of β-lapachone 112 from lapachol 114. 
 
Norlapachol 115 was synthesised from lapachol 114 in an unoptimized yet moderate 
yield of 52% after recrystallisation by a Hooker oxidation (Scheme 47), the mechanism 
of which has still not been conclusively elucidated. It has been suggested that the first 
step involves epoxidation of the quinone alkene under basic conditions to form an 
intermediate epoxy-alcohol 137 (Scheme 47).336 Subsequent epoxide opening and 
benzilic acid rearrangement steps have been proposed, to give the well-established 
Hooker intermediate 138.336 This vicinal diol 138 is then believed to undergo oxidative 
cleavage, followed by intramolecular aldol reaction to give the α-hydroxy acid 
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intermediate 139. Finally, decarboxylation followed by oxidation results in the 
production of norlapachol 115.336–338 
 
Scheme 47. Synthesis and proposed mechanism for the formation of norlapachol 
115 from lapachol 114 by a Hooker oxidation. 
 
Finally, nor-β-lapachone 113 was synthesised from its corresponding precursor 
norlapachol 115, in an analogous manner to the synthesis of β-lapachone 112 (Scheme 
48). Sulfuric acid-promoted cyclisation again provided the desired product 113 as a 
single isomer in a near-quantitative yield of 95%, after simple purification by trituration 
with cold hexane. No formation of the nor-α-lapachone 140 isomer was observed, likely 
for the same reasons as for the selective formation of β-lapachone 112 discussed 
previously. 
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Scheme 48. Synthesis of nor-β-lapachone 113 from norlapachol 115. 
 
With the synthesis of β-lapachone 112, norlapachol 115, and nor-β-lapachone 113 
completed, these three compounds, alongside the parent compound lapachol 114, were 
taken forward for biological evaluation in the zebrafish model.  
 
5.4.2 Biological evaluation – recruitment experiments 
Lapachol 114, β-lapachone 112, norlapachol 115, and nor-β-lapachone 113 were first 
evaluated in neutrophil recruitment experiments, again all of which were performed by 
myself. Zebrafish larvae at age 3 dpf were injured at the distal portion of the tailfin and 
immediately treated with a solution of the compound being investigated. To explore 
possible dose-response effects, norlapachol 115 was tested at concentrations of 0.1, 1, 
and 10 µM. A higher dose of 25 µM was toxic to the larvae. The remaining three 
compounds were all evaluated at a single concentration of 1 µM; higher doses were also 
toxic. This stood in stark contrast to the use of the various tanshinones at a 25 µM 
concentration previously (Chapter 4.5), in which larvae were generally all healthy, with 
no signs of toxicity observed.  
Firstly, norlapachol 115 was investigated for effects on neutrophil recruitment, at 0.1, 
1 and 10 µM concentrations (Figure 27). Alongside the DMSO vehicle control, two 
positive controls were used: SP 74 (30 µM), the standard positive control compound 
used in all recruitment experiments so far, and also TI 1 (25 µM). The latter was included 
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based on findings from the previous work (Chapter 4), to provide a synthetic control 
compound to compare the effects of the synthetic norlapachol 115 to.  
Norlapachol 115 significantly reduced the number of neutrophils recruited to the site 
of injury (in comparison to the vehicle control-treated larvae), at concentrations of both 
10 µM and 0.1 µM. Given the structural differences between norlapachol 115 and 
tanshinones, norlapachol 115 may have worked in a different way to tanshinones such 
as TI 1, for example by acting on a different protein target. Recruitment was not 
significantly reduced at a concentration of 1 µM, although there was a trend towards 
slightly lower neutrophil numbers. The difference between the effects observed at 1 and 
0.1 µM concentrations was slightly surprising, but may reflect the natural variability in 
this type of in vivo experiment, despite all efforts to control for this as far as reasonably 
practicable.   
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Figure 28. Norlapachol 115 significantly reduced neutrophil recruitment to a site of 
injury at 0.1 and 10 µM concentrations, but not at a 1 µM concentration. 
DMSO used at 0.5% concentration, SP 74 used at a concentration of 30 µM, TI 1 used at 
a concentration of 25 µM. Data shown as mean ± SEM; n = 30-32 larvae from 4 
independent experiments. ** P < 0.01, *** P < 0.001, **** P < 0.0001, ns not significant, 
in comparison to the DMSO control (one-way ANOVA with Dunnett's multiple 
comparison post-test). 
 
Next, the remaining three compounds were evaluated in the same way but at a 
concentration of 1 µM (Figure 28). This time, as the synthetic TI 1 control had worked 
just as well as the commercial control compound SP 74 in the previous norlapachol 115 
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recruitment experiments and had generally worked reliably in all recruitment 
experiments to date, the SP 74 control was omitted. Instead, TI 1 was used at both 25 
µM (as a known positive control) and 1 µM concentrations, to compare the effects of 
this compound to the other compounds tested at the same dosage. This might reveal 
different ‘activity ranges’ for sets of compounds with differing safety profiles.  
β-Lapachone 112 led to a significant reduction in the number of neutrophils recruited 
to the site of injury. In addition, larvae treated with nor-β-lapachone 113 showed a trend 
towards lower neutrophil numbers at the wound which approached significance (P = 
0.08, in comparison to the DMSO control group). However, treatment with lapachol 114 
at the same concentration did not reduce neutrophil recruitment, nor did TI 1 at this 
concentration, although treatment with TI 1 with the control dosage of 25 µM led to the 
usual reduction in neutrophil number. No signs of toxicity or unhealthiness were 
observed amongst the larvae of any of the treatment groups.  
These results were particularly interesting, as β-lapachone 112 and nor-β-lapachone 
113 are both ortho-quinone compounds which are structurally similar to TI 1, and these 
both led to reduced neutrophil numbers (significant for β-lapachone 112 only, at a 1 µM 
concentration), as observed with TI 1 at a 25 µM concentration. However, TI 1 showed 
no significant effect when used at a concentration of 1 µM (although did show a trend 
towards slightly decreased neutrophil numbers), suggesting that β-lapachone 112 (and 
possibly also nor-β-lapachone 113) may have been more efficacious than TI 1 in vivo. 
This would clearly require further investigation, but is of interest given the toxicity issues 
observed with the β-lapachones 112-113 yet not with TI 1 at the concentrations 
investigated. 
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Figure 29. β-Lapachone 112 significantly reduced neutrophil recruitment at a 
concentration of 1 µM, whilst at the same concentration, neither TI 1, lapachol 114, 
nor nor-β-lapachone 113 significantly affected neutrophil recruitment. 
DMSO used at 0.5% concentration, TI 1 used at concentrations of 25 and 1 µM. Data 
shown as mean ± SEM; n = 29-32 larvae from 4 independent experiments. * P < 0.05, ** 
P < 0.01, ns not significant, in comparison to the DMSO control (one-way ANOVA with 
Dunnett's multiple comparison post-test). Lap = lapachol 114, β-lap = β-lapachone 112, 
nor-β-lap = nor-β-lapachone 113. 
 
5.4.3 Biological evaluation – resolution experiments 
The same four compounds were evaluated for any effects on resolution of 
neutrophilic inflammation in vivo. As with previous resolution experiments, all carried 
out by myself, injured 3 dpf zebrafish larvae identified as good responders (those 
mounting a good inflammatory response to injury, as determined by neutrophil number 
at the site of injury at 4 hpi) were treated with a solution of the compound of interest, 
and then incubated for a further four hours. Norlapachol 115 was evaluated at a range 
of different concentrations from 0.1 up to 25 µM, as the compound was not toxic to 
larvae at a 25 µM concentration in these experiments. Lapachol 114, β-lapachone 112 
and nor-β-lapachone 113 were each tested at a concentration of 1 µM, as higher doses 
were again found to be toxic. 
Norlapachol 115 was first evaluated for any effects on resolution of neutrophilic 
inflammation at concentrations of 0.1, 1, 10 and 25 µM (Figure 29). TIIA 2 (25 µM 
concentration) was again used as a positive control, as in previous resolution 
experiments. Norlapachol 115 had no significant effect on the number of neutrophils at 
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0.1 and 1 µM concentrations. However, a significant reduction in neutrophil number was 
observed at a 10 µM concentration, and a highly significant effect was seen at a 
concentration of 25 µM, although some of the larvae did show opaqueness and slow or 
absent circulation at this concentration.  
The difference in toxicities between recruitment and resolution experiments could 
be attributed to the longer treatment times and less healed injury wounds associated 
with the recruitment experiments, perhaps allowing easier penetration of the 
compound into the zebrafish larvae. Overall, the resolution data for norlapachol 115 
showed a good dose-response trend. It is unclear if the reduced neutrophil numbers 
observed at the 10 µM concentration were a genuine effect on inflammation resolution, 
or whether they may have been a function of incipient drug toxicity; further experiments 
may need to be undertaken in the future to determine which of these explanations is 
most likely.  
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Figure 30. Norlapachol 115 significantly accelerated resolution of neutrophilic 
inflammation at 10 and 25 µM concentrations, but not at 0.1 or 1 µM concentrations. 
DMSO used at 0.5% concentration, TIIA 2 used at a concentration of 25 µM. Data shown 
as mean ± SEM; n = 29 larvae from 4 independent experiments. * P < 0.05, *** P < 0.001, 
**** P < 0.0001, ns not significant, in comparison to the DMSO control (one-way ANOVA 
with Dunnett's multiple comparison post-test). 
 
Finally, the remaining compounds lapachol 114, β-lapachone 112, and nor-β-
lapachone 113 were analysed in similar resolution experiments, at a concentration of 1 
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µM (Figure 30). However, none of these compounds had any significant effect on 
resolution of neutrophilic inflammation, as only the control treatment of TIIA 2 at a 25 
µM concentration gave a significant reduction in neutrophil number. 
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Figure 31. Neither lapachol 114, β-lapachone 112, nor nor-β-lapachone 113 
significantly enhanced resolution of neutrophilic inflammation at a concentration of 1 
µM. 
DMSO used at 0.5% concentration, TIIA 2 used at 25 and 1 µM concentrations. Data 
shown as mean ± SEM; n = 24 larvae from 3 independent experiments; ** P < 0.01, ns 
not significant, in comparison to the DMSO control (one-way ANOVA with Dunnett's 
multiple comparison post-test). Lap = lapachol 114, β-lap = β-lapachone 112, nor-β-lap 
= nor-β-lapachone 113. 
 
5.4.4 Biological evaluation – summary 
All biological evaluation results for norlapachol 115, lapachol 114, β-lapachone 112, 
and nor-β-lapachone 113 were considered together (Table 5). Norlapachol 115 was toxic 
at a concentration of 25 µM for recruitment, yet significantly enhanced inflammation 
resolution at this concentration, although this may have been a result of early signs of 
toxicity (entry 1). At a 10 µM concentration, norlapachol 115 both significantly reduced 
the number of neutrophils recruited, and enhanced inflammation resolution (entry 2). 
Both of these effects were lost at a lower concentration of 1 µM (entry 3), although a 
reduction in the number of recruited neutrophils was also observed at the lowest 
concentration of 0.1 µM (entry 4). There was no effect on resolution at this 
concentration, and it is unclear whether the effect on recruitment was a genuine dose-
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response effect, or may have been a result of the natural biological variability of this 
type of experiment. Taken together, the results for norlapachol 115 treatment for both 
recruitment and resolution experiments suggest that this compound may warrant 
further investigation. 
Lapachol 114 induced larval toxicity at a 10 µM concentration, in both types of 
experiment (entry 5). No effect on either neutrophil recruitment or resolution of 
neutrophilic inflammation was observed at a 1 µM concentration (entry 6). Like lapachol 
114, β-lapachone 112 also led to toxicity at a 10 µM concentration (entry 7). However, 
treatment of larvae with β-lapachone 112 at a concentration of 1 µM led to a significant 
reduction in the number of neutrophils recruited to the site of injury (entry 8). No effect 
on inflammation resolution was detected at the same concentration. Nor-β-lapachone 
113 produced similar results, having also led to larval toxicity at a 10 µM concentration 
(entry 9). Although its effect on neutrophil recruitment at a concentration of 1 µM was 
not significant, a trend towards fewer recruited neutrophils was observed, which 
approached statistical significance (entry 10). Again, this compound had no effect on 
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Table 5. Summary of the effects of norlapachol 115, lapachol 114, β-lapachone 112, 
and nor-β-lapachone 113 on neutrophil recruitment and resolution of inflammation in 
vivo. 






1 Norlapachol 115 25 Toxic Enhanced (***) 
2 Norlapachol 115 10 Reduced (***) Enhanced (*) 
3 Norlapachol 115 1 No effect No effect 
4 Norlapachol 115 0.1 Reduced (**) No effect 
5 Lapachol 114 10 Toxic Toxic 
6 Lapachol 114 1 No effect No effect 
7 β-Lapachone 112 10 Toxic Toxic 
8 β-Lapachone 112 1 Reduced (*) No effect 
9 Nor-β-Lapachone 
113 
10 Toxic Toxic 
10 Nor-β-Lapachone 
113 




Overall, norlapachol 115 affected both neutrophil recruitment and resolution at 
higher concentrations, yet this could possibly be targeted towards only affecting 
neutrophil recruitment at a lower concentration. Lapachol 114 exhibited no observable 
effect on either recruitment or resolution, whilst both β-lapachone 112, and nor-β-
lapachone 113 at low concentrations appear to affect only recruitment of neutrophils, 
and not resolution of neutrophilic inflammation. 
 
5.5 Discussion 
This work showed that synthesis of a variety of tanshinone analogues using a key 
Diels-Alder reaction to assemble the tanshinone skeleton was not trivial. Use of Fremy’s 
salt to synthesise the required dienophile 59 from the phenol precursor 58 was 
successful, but was not without difficulties. Although it has previously been shown to be 
highly selective for the required transformation as well as similar examples,228,230,329 
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Fremy’s salt is not a cheap reagent, and the requirement of at least 2.5-3 equivalents of 
this reagent to obtain a meaningful yield, as determined by mass return and 1H NMR 
spectroscopy, meant that this was not a particularly economical oxidation. The known 
instability of the dienophile 59 also meant that detailed analysis of this product was 
difficult. Future work could look at optimising this step further, by exploring which 
oxidation reagents have not previously been used for this step. Other reagents may give 
selectivities as good as those observed for Fremy’s salt, but may be significantly cheaper. 
Synthesis of required dienes for the Diels-Alder reaction was also non-trivial, mainly 
due to the careful purification steps required for such volatile compounds. Due to time 
constraints, this meant that the synthesis of various dienes could not be completed here. 
Studies in the future could explore synthesising particular dienes on larger gram scales, 
to facilitate easier purification (for example, using Kugelrohr distillation) and sufficient 
quantities of dienes for use in the Diels-Alder reaction.  
Whilst the key Diels-Alder reaction was carried out successfully (to some extent), this 
reaction also merits further study. Previous work showed that this reaction worked well 
for reactive dienes,228,230 and this was observed here, as both cyclopentadiene 127 and 
(seemingly) Danishefsky’s diene 130 reacted with the dienophile 59. Return of 
significant quantities of the phenol precursor 58 made effective purification more 
difficult, and ideally this reaction would be optimised to ensure that minimal quantities 
of this starting material were returned. Carrying out this reaction with less reactive 
dienes has been found to be difficult, and has required the use of heat, high pressures, 
and/or ultrasonication to achieve moderate yields and selectivities.228–230 In this work, 
reaction with cyclohexadiene 128 was unsuccessful, and this could be the case for other 
dienes required for the synthesis of tanshinones and analogues. One possibility for 
future study would be to explore the use of microwave conditions for this reaction. This 
does not seem to have been well examined in the literature, and the use of microwave 
conditions may give rise to the high temperatures and pressures which appear to be 
required for successful reaction. Use of additives such as Lewis acids was previously 
found to lead to unsuccessful reaction, thought to be due to promoting decomposition 
of the dienophile 59.228,230 However, a more thorough solvent screen could be explored, 
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as solvent choice is well known to have an effect on the efficiency, selectivity and 
mechanism of Diels-Alder reactions.339–341  
Overall, this work on the synthesis of TIIA analogues showed that this was an 
accessible route to tanshinone compounds, but requires further optimisation to ensure 
that various dienes can be used to generate required compounds effectively. The route 
used to synthesise various TI analogues was not used here due to difficulty in easily 
obtaining the required carboxylic acids, but could be explored (Figure 31). Alternatively, 
methods for forming the required carbon-carbon bond from the appropriate sp3 carbon 
atom and the bromide could be considered (Figure 31). Functionalisation reactions for 
forming carbon-carbon bonds from sp3 carbon atoms are becoming increasingly 
popular,342–345 and as the desired six-membered ring formation is likely to be 
thermodynamically favoured compared to other possibilities in this system, there may 
be a method of achieving this transformation. This may work particularly for dienes 
where both R2 and R3 are groups other than hydrogen atoms. This would also depend 
on the identity of the attached R groups and commercial or synthetic availability of the 
required carboxylic acids for the previous radical alkylation reaction, but is a possibility 
which could be explored.  
 
Figure 32. Possible routes to tanshinone analogues using an intramolecular Heck 
reaction (top) or C(sp3)-H activation chemistry (bottom). 
 
The desired lapachone and lapachol compounds were synthesised much more easily, 
using commercially available lapachol 114 and known, good-yielding 
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transformations.306,307 This work was the first study of the effects of both nor-β-
lapachone 113 and norlapachol 115 on zebrafish larvae. It is also the first report of the 
evaluation of these compounds for anti-inflammatory effects. Furthermore, although 
both β-lapachone 112 and lapachol 114 have previously been investigated for effects on 
zebrafish larvae and on inflammation in separate studies, these compounds have not 
been evaluated in a zebrafish model of inflammation. 
 β-Lapachone 112, lapachol 114, and nor-β-lapachone 113 all resulted in zebrafish 
larval toxicity at a 10 µM concentration. For β-lapachone 112, this observation was 
found to be broadly consistent with those of previous studies, including a zebrafish drug-
repurposing screening study, in which β-lapachone 112, at a screening concentration of 
34 µM, was categorised as one of 48 ‘toxic compounds and compounds with adverse 
effects’.94 An earlier study also reported toxicity associated with β-lapachone 112, and 
lethal concentration (LC50) values of approximately 1.90 µM were reported for zebrafish 
larvae at both 56 and 80 hours post fertilisation (hpf).308 Furthermore, β-lapachone 112 
has been shown to induce heart defects and morphogenesis in zebrafish larvae, via 
induced apoptosis of endocardium cells and erythrocytes, possibly through an NQO1-
containing pathway.346 Similarly, at a 10 mM concentration, lapachol 114 has previously 
been found to induce abnormalities in the vast majority of zebrafish embryos at 56 hpf, 
leading to a mortality rate of over 50% at 80 hpf.308 The LC50 concentration for lapachol 
114 with embryos at 80 hpf has also been reported as around 9 µM.308 However, nor-β-
lapachone 113 has never been studied before in this way. Variations in such toxicity 
thresholds may be due to factors such as strain of zebrafish used, method of injury, and 
method of compound administration. Taken together, these findings indicate the 
importance of determining the optimal dosage of compounds administered to living 
organisms, and the utility of in vivo models such as zebrafish in allowing quick 
determination of obvious compound toxicity.  
At a concentration of 10 µM, larvae treated with norlapachol 115 remained healthy, 
in contrast to the structurally similar compound lapachol 114. This suggests that making 
a subtle change such as removing a single carbon atom from the hydrocarbon chain of 
the molecule can lead to a profound difference in the safety profile of the molecule in 
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vivo. This could be due to various reasons; for example, the change in molecular 
structure could lead to the molecule binding to a different target protein or receptor, or 
it could affect how much of the drug is able to enter and/or exit different cells via 
passage across the cell membrane (see Chapter 6). 
At a concentration of 1 µM, β-lapachone 112 led to a significant reduction in the 
number of neutrophils recruited to the site of injury, whilst treatment with nor-β-
lapachone 113 at the same concentration showed a trend towards lower neutrophil 
numbers which approached significance. These reductions in neutrophil numbers 
mirrored similar reductions observed when larvae were treated with the structurally 
similar TI 1. However, use of the latter at a concentration of 25 µM (or 10 µM; see Figure 
10) was required to observe a significant effect, and no significant reduction was seen 
at a TI 1 concentration of 1 µM. This suggests that β-lapachone 112 (and perhaps also 
nor-β-lapachone 113) was more active than TI 1 in reducing neutrophil recruitment. One 
possible explanation is that these compounds were all acting at the same molecular 
target, in accordance with their high structural similarities. However, their structural 
differences may have affected their absorption, metabolism and/or distribution around 
the zebrafish larval body, meaning that there was a difference in the incubation 
concentrations required to observe a significant reduction in the number of neutrophils 
recruited to the site of injury. 
A change in any one or more of these processes may also help to explain why the 
tanshinones were not toxic at a concentration of 25 µM, yet the lapachones 112-113 
and lapachols 114-115 were, and at even lower doses, despite their structural 
similarities. The extra aromatic ring of tanshinones, or the furan ring in these molecules 
(compared to the unsaturated oxygen-containing ring of the lapachones 112-113, or the 
absence of this ring in the lapachol compounds 114-115) may have reduced their 
toxicity. This could relate to target effects, such as an altered target binding efficiency 
or a different binding profile for other proteins (off-target effects), or transport into or 
out of the neutrophil or even the zebrafish larva itself. Further work could involve 
investigating one or more of these aspects in more detail. The differing toxicity profiles 
and ‘activity windows’ of these compounds are also of interest. β-Lapachone 112 and 
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nor-β-lapachone 113 both led to toxicity at a concentration of 10 µM, yet were active at 
a 1 µM concentration with no obvious signs of toxicity; the 1-10 µM concentration range 
could be further explored. This is in contrast to TI 1, which has been used regularly at a 
concentration of 25 µM in this type of experiment with no observable signs of toxicity.  
Furthermore, it is possible, although unlikely, that any effects on neutrophil 
recruitment and resolution of neutrophilic inflammation observed here were due to 
effects on the number of neutrophils in the whole body of the larvae, and/or effects 
relating to generation of ROS such as hydrogen peroxide at the site of injury, as 
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6. How tanshinones access neutrophils – expression of drug 
transporter molecules in human and zebrafish neutrophils 
6.1 Introduction 
In order to fully understand how a drug exhibits its desired in vivo effect, it is 
important to consider not only the identity of the molecular target or targets, relating 
to pharmacodynamics, but also the journey taken by the drug through the body to 
access the target(s), relating to pharmacokinetics. This includes entry to cells of interest, 
as well as exit from these cells: timely elimination of the drug from the body after it has 
exhibited its effect is important in preventing undesired toxicity. Before this can be 
considered for specific molecules such as tanshinones, it is desirable to have a 
generalised understanding to enable future rational anti-inflammatory drug 
identification and design. 
For many years, it was widely assumed that drug molecules entered cells via diffusion 
across the phospholipid bilayer of the cell membrane, and until recently, this theory 
remained largely unchallenged. However, within the last twenty years, it has become 
apparent that transporter proteins embedded in the cell membrane, which are 
responsible for the transfer of ions and metabolites into and out of the cell, are also 
utilised by drug molecules for cell entry and exit.347–352 Such transporters, herein termed 
‘drug transporters’, have been the subject of much recent work; in particular, several 
studies by Kell and co-workers have led to formation of the ‘phospholipid bilayer 
diffusion is negligible’ (PBIN) hypothesis, which is supported by significant evidence.353–
356 It is thought that most successful drugs in their active form are somewhat similar in 
structure to that of an endogenous metabolite, which itself is transported by one or 
more specific transporter proteins; thus, the drug ‘hijacks’ the same transporter(s) and 
uses this to cross the cell membrane.357–360 It is now believed that drug transport across 
cell membranes is mostly comprised of this hijacking of transporter proteins rather than 
passive diffusion, and so drug transporters appear to be vital for absorption, distribution 
and excretion of drug molecules. 
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Drug transporters are comprised of two main families: solute carrier (SLC) and ATP-
binding cassette (ABC) transporters. According to the HUGO Gene Nomenclature 
Committee, in humans there are 395 members of the SLC family (April 2017),361 and the 
main physiological function of these proteins is to transport ions and metabolites into 
cells (influx). One of the best reported examples of drug transport via an SLC transporter 
protein is that of gemcitabine 141 (Figure 32), which is mainly transported by the 
SLC29A1 transporter, and is used in the treatment of pancreatic cancer,362,363 whilst 
many other SLC transporter proteins are emerging as potential drug targets.364 The ABC 
family is made up of 52 proteins,361 and these are mainly responsible for the transport 
of ions and metabolites out of cells (efflux). There are some reports in the literature of 
drugs presenting toxicity issues in patients with particular mutations in ABC proteins, 
and many ABC transporters are known to be involved in active drug transport, 
suggesting an important role for these proteins in drug treatment.365–367  
 
Figure 33. Structure of the pancreatic cancer drug gemcitabine 141. 
 
Although expression of SLC and ABC transporter proteins has been broadly 
determined both in humans and other models,368,369 there is no published analysis of 
these transporters in neutrophils, in either humans or zebrafish.  
 
6.2 Hypothesis and aims 
It was hypothesised that tanshinones specifically target neutrophils to exhibit anti-
inflammatory effects, and utilise SLC and ABC transporters expressed in neutrophils to 
get into and out of the cell. It was also hypothesised that there was a level of 
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conservation of SLC and ABC transporter protein expression between human and 
zebrafish neutrophils. 
The aims of this work were to: 
• Determine evolutionary relationships between different drug transporters 
and their sub-families within each of the SLC and ABC families in both humans 
and zebrafish, via the production of phylogenetic trees. 
• Determine expression of SLC and ABC transporters in both unstimulated 
primary human and zebrafish neutrophils, using previously published RNA-
sequencing (RNAseq) data. 
• Analyse the effects, if any, of granulocyte macrophage colony-stimulating 
factor (GM-CSF) and tumor necrosis factor alpha (TNFα) stimuli on drug 
transporter expression in primary human neutrophils. 
• Use publically available human neutrophil proteomics datasets to determine 
the level of consistency between RNAseq and proteomics approaches for drug 
transporter expression in human neutrophils. 
• Determine if there was any conservation in SLC and ABC transporter 
expression between primary human and zebrafish neutrophils. 
 
6.3 Methods 
6.3.1 Identification of relevant genes and protein sequences 
Lists of the human SLC and ABC transporter genes were obtained from the HUGO 
Gene Nomenclature Committee (HGNC) database (April 2015).361 The Ensembl database 
(human data: version GRCh38.p2, release 79; zebrafish data: version Zv9, release 79) 
was manually searched for each human SLC and ABC gene identifier,370 and orthologous 
genes present in the zebrafish (Danio rerio) database (version Zv9, release 79) were 
identified. Due to some observed discrepancies in the naming of the zebrafish 
orthologues, such as where two different genes had identical names in the database, 
the unique numerical identifier (for example, ENSDARG00000000001) was used to 
search for orthologues in each case, to avoid ambiguity. Gene names as returned from 
Ensembl were generally retained for all further analysis. Genes with identical names 
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were arbitrarily given suffixes of _first and _second to enable distinction. Where genes 
were identified as being a ‘novel gene’ in the Ensembl database with no additional 
annotation, the corresponding name for the same gene was obtained from an earlier 
release of the same version of Ensembl (version Zv9, release 75) in accordance with the 
RNAseq data used [accessed via the NCBI Gene Expression Omnibus (GEO), under 
accession number GSE78954].  
For both human and zebrafish datasets, the longest corresponding protein-coding 
sequence (highest number of amino acids) for each individual gene was obtained from 
the Ensembl database. Any non-protein-coding genes, regulatory genes and 
pseudogenes were excluded from the analysis. Files containing protein sequence data 
used in this work were deposited at The University Of Sheffield Research Data Catalogue 




6.3.2 Production of phylogenetic trees 
      Clustal Omega (version 1.2.3) was used for multiple sequence alignment of protein 
sequences.371,372 The ‘Phylogenetic Tree’ output (.ph file) was converted to a Newick 
tree format using the Phylogeny.fr resource.373 This was input into the Interactive Tree 
of Life (iTOL) programme (version 3.3) to produce phylogenetic trees displaying the 
evolutionary relationships in the human and zebrafish SLC and ABC families.374 The 
phylogenetic trees were annotated with the corresponding expression and proteomics 
data.  
 
6.3.3 Expression and regulation of human transporter proteins 
Published transcriptomics datasets (GEO accession number GSE40548) were 
downloaded and used for analysis.375 A gene was said to be expressed if it had a 
‘fragments per kilobase of exon per million fragments mapped’ (FPKM) value greater 
than or equal to 1, a conservative value chosen due to its relationship to expression of 
the well-validated neutrophil protein myeloperoxidase (MPO), expression level 0.98 
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FKPM. Genes with a FPKM value less than 1 were said to be unexpressed in this analysis. 
Any genes with expression observed to be significantly up- or down-regulated in the 
presence of either of the inflammatory stimuli GM-CSF or TNFα in this dataset were 
annotated on the phylogenetic trees accordingly. 
To cross-reference expression of human transporter proteins with findings from 
proteomics studies, human neutrophil proteomics data from eight different studies 
were manually searched for any SLC and ABC transporter proteins identified therein.376–
383 These were annotated on the relevant phylogenetic trees. 
For expression validation, each SLC and ABC gene was searched for in a second 
published dataset, generated by Chatterjee et al. (GEO accession number GSE59528).384 
Mean FPKM values for each identified gene were plotted against the corresponding data 
from the initial dataset from Wright et al. following logarithmic transformation of both 
datasets.375  
All human genes and proteins were referred to according to HGNC conventions 




6.3.4 Expression and regulation of zebrafish transporter proteins. 
Previously generated zebrafish larval RNAseq data were downloaded and used for 
this work (GEO accession number GSE78954).385 For both neutrophil and background 
(non-neutrophil) cell expression levels, any gene with a FPKM value greater than or 
equal to 1 was said to be expressed, and any with a FPKM value less than 1 was said to 
be unexpressed, in line with the definitions used for expression of human genes here. 
All zebrafish genes and proteins were referred to in accordance with the Zebrafish 
Information Network (ZFIN) naming conventions as far as practicably possible. Raw data 
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6.4 Analysis of expression and regulation of drug transporters in human 
neutrophils 
To display the expression data most clearly, whilst also allowing for visualisation of 
the evolutionary relationships between different drug transporters and their sub-
families, the transporter proteins were displayed as phylogenetic trees for each of the 
SLC and ABC families. Production of the trees first required the protein sequences for 
each individual SLC and ABC family member to be found. The longest coding protein 
sequence for each transporter gene was obtained from the Ensembl database,370 and 
following alignment, was used in tree construction.371–374 Any genes which did not code 
for functional proteins, or which were pseudogenes or regulatory genes, were removed 
from the dataset. 
Expression analysis was carried out using a publically-available RNAseq dataset.375 
Here, any gene with a FPKM value greater than 1.0 was said to be expressed, with all 
lower values corresponding to genes not expressed. This conservative value was chosen 
due to its relationship to MPO expression, which is a well-validated neutrophil protein 
with a FPKM value of 0.98 in this human neutrophil dataset. Each branch on the tree, 
corresponding to a different protein, was annotated with its expression in primary 
human neutrophils: the presence of a black dot denoted that the gene was expressed, 
whilst the absence of a black dot indicated that the gene was not expressed.  
This resulted in annotated phylogenetic trees for both SLC (Figure 33) and ABC (Figure 
34) transporter proteins. Two trees were displayed for each of the families, 
corresponding to two different display modes of the same data: the circular mode 
showed all the annotations in a more easily understood form, and the unrooted mode 
gave a more accurate indication of the individual sub-families of proteins and how they 
were related. For these trees, the lengths of the branches were not proportional to the 
genetic distances. However, trees containing branches proportional to genetic 
relationship were also produced for the SLC (Appendix 10.4.1) and ABC (Appendix 
10.4.2) families; whilst perhaps not as clear as the non-proportional trees, these trees 
were important in allowing an accurate visualisation of evolutionary relationships 
between genes for drug transporter proteins. Furthermore, whilst labels for specific 
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branches in some of the larger trees are fairly small, fully scalable electronic versions of 
these trees were produced and made accessible.386 
In addition to unstimulated expression data, data were also available for the 
expression status of the same genes in the presence of two important regulators of 
neutrophil function and survival: GM-CSF and TNFα. These data were displayed as 
annotations around the relevant trees, with a green box corresponding to significant up-
regulation of the gene in the presence of the regulator, and a red box denoting 
significant down-regulation of the gene. All other genes showed no significant change in 
regulation in the presence of the regulator. 
Furthermore, to investigate the relationship between RNAseq analysis and proteomic 
approaches, human neutrophil proteomics datasets from eight different publically 
available studies were analysed manually.376–383 Any SLC or ABC transporter protein 
which was identified in one or more of these proteomics studies was annotated on the 
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Figure 34. Subsets of SLC transporter proteins were expressed and regulated in resting 
primary human neutrophils. 
Annotated phylogenetic trees in (a) circular and (b) unrooted display modes indicate 
evolutionary relationships between SLC transporter proteins in human neutrophils 
(branch lengths not proportional to genetic distance; see Appendix 10.4.1 for trees with 
proportional branch lengths). In (a), for resting primary human neutrophil expression 
data (inner circle), expressed proteins were marked with a black dot, whereas proteins 
not expressed were denoted with a white dot. For GM-CSF (second circle from centre) 
and TNFα (third circle from centre) regulation data, significant up-regulation of a gene 
was denoted with a green box, significant down-regulation was denoted by a red box, 
and a lack of significant change in regulation unmarked. For human neutrophil 
proteomics data (outer circle), any proteins identified in one or more of the analyses 
were denoted with a blue box, and any not identified were denoted with a white box. 
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Figure 35. Subsets of ABC transporter proteins were expressed and regulated in resting 
primary human neutrophils. 
Annotated phylogenetic trees in (a) circular and (b) unrooted display modes indicate 
evolutionary relationships between ABC transporter proteins in human neutrophils 
(branch lengths not proportional to genetic distance; see Appendix 10.4.2 for trees with 
proportional branch lengths). In (a), for resting primary human neutrophil expression 
data (inner circle), expressed proteins were marked with a black dot, whereas proteins 
not expressed were denoted with a white dot. For human neutrophil proteomics data 
(outer circle), any proteins identified in one or more of the analyses were denoted with 
a blue box, and any not identified were denoted with a white box. 
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As can be seen from the SLC phylogenetic trees (Figure 33), around 34% of the SLC 
protein-coding genes (134 of 389) were expressed above threshold values in human 
neutrophils. In the presence of GM-CSF, nine genes showed a significant change in 
regulation, all of which were expressed in human neutrophils. Of these nine genes, two 
were up-regulated (SLC1A5 and SLC25A25) and seven were down-regulated (SLC10A3, 
SLC15A3, SLC15A4, SLC16A14, SLC16A6, SLC19A1 and SLC25A51). In the presence of 
TNFα, six genes exhibited significant regulation change, of which three were expressed 
in human neutrophils (SLC1A5, SLC35B2 and SLC7A5) and three were not expressed 
(SLC11A2, SLC2A6 and SLC30A4). Notably, all six of these genes were up-regulated, 
whilst no SLC genes were found to be down-regulated in the presence of TNFα. Only one 
gene, SLC1A5, was common to both of these sets, showing significant up-regulation in 
both cases. SLC1A5, previously referred to as Alanine Serine Cysteine Transporter 2, is a 
neutral amino acid transporter, and is ubiquitously expressed. However, overexpression 
of this gene has been reported in various cancers,387,388 and is currently being explored 
as a drug target in cancer treatment.389 This does not by any means suggest that this 
transporter is used by molecules such as tanshinones; rather, this is simply a transporter 
of interest in relation to inflammatory processes. Across the human neutrophil 
proteomics datasets, only 33 SLC proteins were identified (some in a single set, others 
across several studies), and of these, 20 were identified as being expressed in the 
RNAseq data presented here. 
Approximately 35% of the ABC protein-coding genes (17 of 48) were expressed above 
threshold values in primary human neutrophils (Figure 34). Interestingly, the proportion 
of drug transporters expressed in human neutrophils was approximately the same for 
the SLC and ABC families respectively. However, a noteworthy difference between the 
two families was that, in the presence of either GM-CSF or TNFα, none of the ABC 
transporters showed a significantly increased or decreased change in expression. This 
may reflect a particular need for the SLC transporters to transport molecules into 
activated neutrophils. When the various human neutrophil proteomics datasets were 
interrogated, a total of six ABC transporter proteins were identified, and of these, three 
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had been identified as being expressed in human neutrophils according to the RNAseq 
data. 
Thus far, all of the analysis was carried out using a single RNAseq dataset.375 To 
determine the validity of this approach and the quality of the dataset, a second more 
recent publically available human neutrophil RNAseq dataset was identified,384 and the 
same analysis of SLC and ABC drug transporters expressed in unstimulated primary 
human neutrophils was carried out. The results from the two separate datasets were 
compared, and displayed in graphical form for both SLC and ABC transporters (Figure 
35; tables showing raw data given in Appendices 10.5.1 and 10.5.2). The two datasets 
exhibited a highly significant positive correlation, both for the SLC transporters (r = 
0.9157, P < 0.0001) and for the ABC transporters (r = 0.8368, P < 0.0001). This helped to 
validate the approach used, and provided confidence in the methodology used thus far. 
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Figure 36. Expression levels of human SLC and ABC transporter proteins across two 
different datasets showed highly significant positive correlation. 
Scattergraphs show comparison of expression of (a) SLC and (b) ABC transporter 
proteins in datasets by Wright et al. and Chatterjee et al.375,384 Data points represent the 
mean of replicate values. Any genes in the Wright et al. dataset which could not be 
identified in the Chatterjee et al. dataset were not shown. For (a), r = 0.9157, P < 0.0001 
(Spearman correlation, n = 368 pairs). For (b), r = 0.8368, P < 0.0001 (Spearman 
correlation, n = 47 pairs). Corresponding tables provided in Appendices 10.5.1 and 
10.5.2. 
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6.5 Expression analysis of drug transporters in zebrafish neutrophils 
As discussed previously, the zebrafish is an excellent in vivo model for anti-
inflammatory drug screening, and analysis of neutrophil function.86,90,103 Indeed, just 
one example of the practicality of this approach was shown in the identification of the 
SGK1 inhibitor GSK650394 142 (Figure 36).76 This compound has been shown to induce 
apoptosis, both in zebrafish models of inflammation in vivo, and in human neutrophils 
in vitro. Analysis by mass spectrometry has also provided evidence that this molecule 
was able to penetrate zebrafish larvae in order to induce its effect.76 However, analysis 
of published data regarding the accumulation of drug-like compounds within zebrafish 
larvae showed that there was not a simple correlation between the lipophilicity of a 
compound (measured as cLogP, the calculated logarithm of the compound’s partition 
coefficient between n-octanol and water) and its concentration in the larvae.386 This is 
supportive of the hypothesis that cLogP alone is not sufficient to predict larval 
penetration and access into cells, consistent with much work done by Kell and others,348–
350,355 suggesting that transport across membranes via drug transporter proteins is also 
very important in zebrafish. 
 
Figure 37. Structure of the SGK1 inhibitor GSK650394 142. 
 
To begin investigation of the hypothesis that drug transporter expression in zebrafish 
was an important factor in larval drug penetration, and specifically, expression in 
zebrafish neutrophils, which was hypothesised to be particularly relevant to 
inflammatory disease, phylogenetic trees for both SLC and ABC transporter expression 
were produced. This again allowed for the visualisation of relationships between 
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different individual drug transporters and between sub-families, as well as clear display 
of expression data. 
For each individual human SLC and ABC transporter gene, the Ensembl database was 
manually searched for orthologous genes present in the zebrafish.370 Paralogues of each 
of these zebrafish genes were then identified in a similar manner, and any genuine SLC 
or ABC paralogues not already in this set were included. This was to ensure that the set 
of zebrafish genes used in this analysis was as comprehensive and complete as possible. 
In some cases, it was not clear from inspection of the gene name alone whether the 
paralogue was actually a ‘true’ paralogue or not, especially since some returned genes 
were clearly not ‘true’ paralogues and were related to different protein families, 
according to their name. In these ambiguous cases, the corresponding gene tree in 
Ensembl was examined. The gene was included in this dataset if it had a clear 
evolutionary relationship to one or more annotated zebrafish drug transporter genes. 
Any returned paralogues which could not be identified as having such a relationship 
were excluded from this analysis.  
Once the two sets of zebrafish transporter genes were considered to be complete, 
the longest coding protein sequence for each individual gene was identified using the 
Ensembl database,370 in the same manner as for the human genes previously. 
Pseudogenes, regulatory genes, and genes not coding for functional proteins were again 
excluded, and the remaining sequences were aligned and used in the construction of 
the phylogenetic trees.371–374 
For zebrafish drug transporter analysis, expression analysis was carried out using 
RNAseq data from transgenic Tg(mpx:GFP)i114 zebrafish at 5 dpf (GEO accession 
number GSE78954), obtained as described previously.385 As this involved sorting cells 
into GFP-positive cells (corresponding to neutrophils only) and GFP-negative cells (all 
other non-neutrophil cells, termed background cells), this meant that analysis of drug 
transporters expression in neutrophils and in background cells could be carried out here. 
Again, any gene with a FPKM value greater than or equal to 1.0 was said to be expressed, 
and any gene with a value less than 1.0 was not considered expressed. This limit was 
chosen to maintain consistency with the expression definitions used in the analysis of 
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drug transporter expression in human neutrophils previously. As for earlier trees, each 
branch (protein) on the tree was annotated with its expression status in both 
neutrophils and background cells; in both cases, a black box meant that the gene was 
expressed, whilst a white box meant that the gene was not expressed.  
This enabled production of annotated phylogenetic trees for SLC (Figure 37) and ABC 
(Figure 38) transporter proteins in zebrafish larval neutrophils, in both circular and 
unrooted display modes, as utilised for the human neutrophil data. Like in the human 
trees, the branches in the zebrafish trees did not correspond to genetic distance; trees 
containing proportional branch lengths were also generated for both SLC (Appendix 
10.6.1) and ABC (Appendix 10.6.2) families. Scalable electronic versions of all the 
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Figure 38. Zebrafish larval neutrophils and non-neutrophil cells expressed distinct 
subsets of SLC transporter proteins. 
Annotated phylogenetic trees in both (a) circular and (b) unrooted display modes 
indicate evolutionary relationships between SLC transporter proteins in zebrafish 
(branch lengths not proportional to genetic distance; see Appendix 10.6.1 for trees with 
proportional branch lengths). In (a), for both neutrophil (inner circle) and background 
cell (outer circle) expression data, expressed proteins were marked with a black box, 
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Figure 39. Zebrafish larval neutrophils and non-neutrophil cells expressed distinct 
subsets of ABC transporter proteins. 
Annotated phylogenetic trees in both (a) circular and (b) unrooted display modes 
indicate evolutionary relationships between ABC transporter proteins in zebrafish 
(branch lengths not proportional to genetic distance; see Appendix 10.6.2 for trees with 
proportional branch lengths). In (a), for both neutrophil (inner circle) and background 
cell (outer circle) expression data, expressed proteins were marked with a black box, 
whereas proteins not expressed were unmarked. 
 
Analysis of the SLC phylogenetic trees (Figure 37) revealed that approximately 27% 
of the SLC protein-coding genes (142 of 533) were expressed above threshold values in 
zebrafish larval neutrophils. In non-neutrophil ‘background’ cells, a slightly higher 
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proportion (41%, 219 of 533) were expressed. Of these, 130 were found to be expressed 
in both neutrophil and background cells, meaning that 89 were expressed solely in 
background cells and not in neutrophils. Out of the 142 genes expressed in neutrophils, 
12 were only expressed in neutrophils: slc2a3b, slc2a8, slc2a12, slc2a15a, slc3a2_4of4, 
slc4a2b, slc13a1, slc13a5b, slc34a2b, slco3a1, rhcgl1, and CR352249.1. This may suggest 
that some (or all) of these corresponding proteins have specific roles in modulating 
neutrophil function.  
Similar consideration of the ABC phylogenetic trees (Figure 38) found that 25% of the 
ABC protein-coding genes (16 of 64) were expressed in zebrafish neutrophils at this 
developmental stage. A similar proportion, 27%, of the ABC genes (17 of 64) were 
expressed in background cells, and 12 of these were expressed in both neutrophils and 
background cells. Five genes were expressed only in background cells, and four genes 
were expressed solely in neutrophils: abca2, abcb4, abcb9, and si:dkey-57h18.2. Again, 
it is possible that the relevant proteins have more neutrophil-specific roles than other 
ABC transporters.  
 
6.6 Comparison of drug transporter expression between human and zebrafish 
neutrophils 
The zebrafish model for study of inflammatory diseases has many advantages, 
including high homology to humans.  Thus, it was hypothesised that there was a level of 
conservation in the neutrophilic drug transporter expression of these two species. To 
address this hypothesis, the expression patterns of SLC and ABC transporters in primary 
human and zebrafish larval neutrophils were compared. 
Firstly, the overall proportion of drug transporters expressed in the neutrophils of 
each species was determined. For the SLC family of transporters, 34% of the total human 
SLC genes were expressed in human neutrophils, whilst for zebrafish, 27% of the SLC 
genes were expressed in larval neutrophils. Similarly, for the ABC family, 35% of the ABC 
genes in humans were expressed in neutrophils, compared to 25% of the ABC genes 
expressed in zebrafish neutrophils. When the various technical differences between the 
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datasets were considered, the overall level of drug transporter expression in humans 
and zebrafish was approximately equal.  
In addition, the median SLC and ABC expression values, given as FPKM values, were 
also compared to the median expression level of all genes identified in the relevant 
datasets. For the human genes, the median FPKM value for the SLC transporters was 
0.22, and for the ABC transporters, this value was 0.34. These values compared with a 
median FPKM value of 0.26 for the entire set of genes (drug transporters and all other 
genes) identified across all cells. In the zebrafish dataset, the median FPKM value was 
0.16 for SLC transporters and 0.12 for ABC genes, compared with a median of 0.10 for 
all genes in this set. Thus, within both human and zebrafish neutrophil datasets, the 
median FPKM values of the SLC and ABC transporter genes were similar both to each 
other, and to the median expression value of all genes. Comparing between human and 
zebrafish datasets, the median values were of the same order of magnitude and were 
reasonably similar, again providing some validation of the approach used here. 
Finally, when the set of 134 SLC transporters identified as expressed in human 
neutrophils were considered, around half of these (65 out of 134, 49%) had at least one 
orthologous gene in zebrafish which was also expressed in zebrafish neutrophils (see 
Appendix 10.7.1 for a full list of these genes). Similar analysis for the set of ABC 
transporters expressed in human neutrophils revealed that the same proportion (8 out 
of 17, 47%) also had an orthologous gene expressed in zebrafish neutrophils (full list in 
Appendix 10.7.2). These data again suggested a level of conservation in the expression 
of SLC and ABC drug transporters in primary human and zebrafish larval neutrophils. 
 
6.7 Discussion 
Biological evaluation of synthesised TI analogues was carried out in a zebrafish model 
of inflammation (Chapter 4), and the results from this work indicated that some of the 
analogues, including TI 1 itself, led to reduced neutrophil recruitment to an injury site, 
and/or accelerated inflammation resolution. Other analogues appeared to have no 
effect, and structure-activity relationships for the whole set of data were not entirely 
straightforward. This was despite the fact that for the synthetic tanshinones, and also 
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the isotanshinones, only a single change to the parent TI 1 structure or parent 
isotanshinone I structure 13 was made. Similarly, treatment with lapachones 112-113, 
compounds with structural similarity to tanshinones, in the same model led to reduced 
neutrophil recruitment (Chapter 5). However, these compounds were used at a much 
lower concentration than the tanshinones, due to toxicity of the lapachones 112-113 at 
higher concentrations. 
There are several possible explanations for these differences in observed activities. 
Changing the structure of the tanshinones may have led to reduced target specificity, 
with the modified part of the molecule perhaps interacting differently (or not at all) with 
a particular protein residue or binding site of the protein target. Alternatively, this 
structural modification may have perhaps reduced the cell penetration of the 
compound, and resulted in the molecule no longer being able to cross the cell 
membrane and enter the neutrophil, or even the larva more generally. Furthermore, 
changing the structure of the molecule may have increased its cell permeability, which 
may be one possible explanation for the differing toxicity profiles observed between TI 
analogues and lapachones. It is now increasingly accepted that drugs mimic the 
structures of endogenous metabolites and hijack the relevant transporter protein(s) to 
cross the cell membrane.357–360 Therefore, it may be that changing the tanshinone 
structure meant that the modified compound no longer resembled the relevant 
metabolite sufficiently to be able to hijack the corresponding transporter(s) and enter 
the neutrophil. Clearly, in order to completely optimise potential drug treatments, and 
design and synthesise effective compounds which are more likely to reach their target, 
it is important to understand not only the molecular target of the drug 
(pharmacodynamics), but also how the drug accesses and penetrates the cell 
(pharmacokinetics). Knowledge of which protein transporter(s) the drug uses to cross 
the cell membrane would thus be very useful: if the specific transporter(s) used by the 
drug was known or determined, then a drug (in this case, a tanshinone) could be 
designed to optimise cell penetration, thereby increasing the likelihood of a greater 
quantity of the drug reaching its target and exhibiting a desired effect on inflammation. 
For this reason, much research has recently been carried out in this area, including into 
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drug-metabolite likenesses, and how this information can be used more widely to 
inform future drug design and development.357–360 
At present, the required software does not exist to be able to quickly and accurately 
identify the drug transporter protein(s) used by any particular molecule to cross the cell 
membrane. However, various approaches are being utilised to work towards this goal. 
In this regard, the work on drug transporters herein was carried out to provide a useful 
resource to the field. Prior to this work, identification of the drug transporters present 
in neutrophils of both humans and zebrafish larvae had not been carried out. 
Identification of the drug transporters in human neutrophils which were significantly up-
or down-regulated in the presence of inflammatory stimuli such as TNFα or GM-CSF may 
indicate that these transporters play a particular role in the inflammatory response. 
Similarly, transporters enriched in zebrafish neutrophils compared to non-neutrophil 
(background) cells may suggest that these transporters are particularly important in co-
ordinating neutrophil function and response. This may contribute towards explaining 
relative activities exhibited by different compounds on neutrophils in the zebrafish 
model.  
One limitation of the zebrafish expression data used here is that these data 
corresponded to zebrafish larvae at an early stage of development (5 dpf), and such 
expression is likely to change as zebrafish mature. Nevertheless, these data were useful 
in allowing overall examination of transporter expression in zebrafish neutrophils at a 
stage of development commonly used in zebrafish models of disease, including the 
zebrafish model of inflammation already used in this work (Chapters 4 and 5).  
Human neutrophil proteomic datasets were also analysed to compare identification 
of SLC and ABC transporter proteins to these analyses, and this found that only a small 
fraction of proteins were identified in the mass spectrometric studies. This represented 
a substantial difference between the approaches, and perhaps highlights how current 
proteomics datasets are somewhat incomplete. Indeed, a published comparison of 
some of these datasets showed the vast differences between human neutrophil protein 
samples:380 the studies analysed detected a combined total of 1895 proteins, with 
overlap ranging from 4% to 40% - this is only a small subset of the total number of 
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proteins in neutrophils. This is possibly because proteomic analysis of neutrophils is 
notoriously difficult due to the large numbers of proteases within the cell, and the 
stochastic nature of protein mass spectrometry, including technical limits in sensitivity 
of protein detection. Thus, whilst mRNA expression and protein expression themselves 
may not always correlate, differences in datasets obtained via different approaches may 
be exacerbated due to these practical limitations. Furthermore, ongoing development 
of more advanced proteomics methods continues to reveal more identified proteins in 
cells such as neutrophils; a recent proteomics study identified over 7000 proteins in 
human neutrophils, including 89 SLC and 19 ABC proteins.390 Future work in this area 
might continue analysis of these more recent datasets, alongside further development 
and utilisation of different proteomics methods to give further insight into the 
expression of drug transporter proteins in neutrophils, and indeed other cell types of 
interest. 
A more detailed knowledge of the relative expressions of drug transporters in various 
organisms and cells of interests will certainly be of wider use to the field. For example, 
large compound screens are often carried out successfully using organisms such as 
zebrafish, to identify new molecules which could potentially become future 
drugs.36,90,115,119 However, such screens can overlook particular compounds which may 
in fact be effective, due to the ‘false negative’ rates of these methods.391 It is possible 
that such compounds are effective once they reach their intracellular target, but simply 
may not be able to reach this target; this may be due to differential drug transporter 
expression.  
In addition, in both the human and zebrafish datasets, resting neutrophils (rather 
than inflammatory neutrophils) were studied. In the human dataset, some transporters 
showed regulation in the presence of an inflammatory stimulus, perhaps suggesting that 
transporter expression may be modified in inflammatory states. However, extracting 
neutrophils from inflammatory sites is technically complex, particularly in zebrafish, and 
may represent a limitation of this work.  
Looking forward, experiments which could make use of these resources might involve 
identification of the SLC and ABC transporters used by particular metabolites. This 
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knowledge could then inform compound design to more closely mimic metabolites, 
where possible. In silico comparison of drugs and their metabolite-likenesses would help 
to form hypotheses of potential transporters which could be tested in the zebrafish 
model. One possible experimental approach would be to mutate a family of SLC 
transporters using CRISPR/Cas9 genome editing, or use CRISPR interference (CRISPRi), 
which would allow a greater number of transporters to be screened.392,393 The effect of 
this change on drug penetration into neutrophils or zebrafish larvae could then be 
determined, using a well-defined phenotypic readout. There is not currently a model 
system for rational dissection of drug transporters and their effects on inflammation, 
but it is anticipated that these resources will provide the first step towards constructing 
such a system in vivo. It is hoped that this, in turn, would help towards optimising 
potential drug treatments, such as tanshinones, working towards identification of new, 
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7. Discussion 
In this work, an improved synthetic route was used to synthesise TI 1, the isomer iso-
TI 13, and a set of analogues based on both of these compounds, in six steps starting 
from 5-bromovanillin 27 and various phenyl-substituted carboxylic acids 75, 80, 82-84. 
An acetal variant of TI 109 which lacked the characteristic ortho-quinone functionality 
was also synthesised from TI 1, to explore the importance of this functional group for in 
vivo anti-inflammatory activity. Synthesis towards TIIA 2 and related analogues was 
attempted using a key Diels-Alder reaction to assemble the tanshinone framework, and 
although this reaction worked with dienes of varying reactivity, low mass returns and 
purification issues limited further study of reaction products. Furthermore, two 
lapachones 112-113, with structural similarity to tanshinones, were synthesised from 
the natural product lapachol 114 and its homologue norlapachol 115. 
Biological evaluation of these compounds in vivo using a zebrafish model of 
inflammation was undertaken, to investigate the effects of these compounds on 
neutrophil recruitment and resolution stages of the inflammatory response. This 
revealed that, at an aqueous concentration of 25 µM, the parent compounds TI 1 and 
iso-TI 13 both reduced initial neutrophil recruitment to a site of injury, and accelerated 
resolution of neutrophilic inflammation, whilst analogous compounds lacking the 
methyl group at the 6- or 4-position respectively had no effect on either process. 
Tanshinones and isotanshinones with other substituents had various effects, and 
structure-activity relationships arising from these results could not be completely clearly 
defined, although some interesting trends were observed.  In particular, 6-methoxy-TI 
104 accelerated resolution of neutrophilic inflammation yet did not affect initial 
neutrophil recruitment. This may make this compound a more attractive candidate for 
investigation as a pro-resolution therapeutic, since compounds which accelerate 
resolution without affecting recruitment are more likely to function without 
compromising host-defence, an important justification for the study of both neutrophil 
recruitment and resolution. The TI acetal 109 also exhibited some in vivo activity, 
although it was not clear whether this was as a function of the compound itself, or as a 
result of in vivo hydrolysis and metabolism. Evaluation of the lapachones 112-113 was 
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carried out at a concentration of 1 µM, as larval toxicity was observed at higher doses, 
despite the structural similarity of these compounds to tanshinones. Lapachones 112-
113 resulted in reduced numbers of recruited neutrophils to the site of injury, yet did 
not affect resolution. Norlapachol 115 also reduced neutrophil recruitment and 
accelerated inflammation resolution at higher doses, yet the homologous lapachol 114 
had no effect on recruitment or resolution.  
Thus, making small point changes to the tanshinone structure did not affect their 
toxicity, yet affected their biological activity, giving rise to non-trivial structure-activity 
relationships. The equivalent isotanshinones, in which two of the aromatic rings were 
kept the same, and the other two were oriented differently, with a para-quinone instead 
of an ortho-quinone, were also non-toxic and exhibited some structure-activity 
relationships. Evaluation of lapachones 112-113 allowed the effect of making broader 
changes to the tanshinone structure to be explored: the middle two rings of the 
tanshinone framework were kept the same, whilst the additional phenyl ring was 
removed completely, and the furan ring dearomatised. This had a substantial effect on 
the toxicity of the compounds, which were consequently evaluated at a much lower 
dosage than for tanshinones. The evaluated lapachones 112-113 exhibited some effects 
in reducing neutrophil recruitment, yet did not affect resolution of neutrophilic 
inflammation at this concentration. This may suggest that retention of the core ortho-
quinone moiety of tanshinones was sufficient to retain effects on neutrophil 
recruitment, yet these broader changes were detrimental to pro-resolution activity.  
In addition to those provided by use of zebrafish models in general, the zebrafish 
model for inflammatory disease presented several advantages, including the reliable 
and replicable modelling of acute, spontaneously resolving inflammation in living 
organisms. Synthesised compounds were evaluated for in vivo biological effects in this 
model at an early stage of the drug discovery and development process, which allowed 
efficacious compounds to be identified (and possibly prioritised for future studies). 
Going forward, such compounds could be tested for effects on human neutrophils, in a 
similar manner to that undertaken for TIIA 2 previously.36  Any compounds which also 
exhibited observable effects on human neutrophils would be of particular interest, 
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having shown both in vivo and in vitro efficacy, with translatable activity. Another 
advantage of the zebrafish model of inflammation is that compound toxicity can be 
detected quickly, using various methods such as analysis of tail shape, circulation, and 
heartbeat. Toxicity was observed for the lapachones 112-113 and lapachols 114-115 at 
certain doses, in contrast to the tanshinones and isotanshinones at the same 
concentrations, which exhibited no observable toxicity. This raised interesting questions 
about why these differences in safety profiles existed, despite the respective 
compounds bearing many structural similarities. These data indicated that the presence 
of the furan ring and the additional phenyl ring likely contributed to the compounds’ 
lack of toxicity. This may have been due to differences in pharmacokinetics (how the 
compounds accessed their molecular target, for example due to differences in cell 
membrane permeability), pharmacodynamics (differences in target interaction and/or 
binding), or both. Detection of both compound efficacy and toxicity at this early stage 
of drug development is highly advantageous, as lack of efficacy and safety concerns are 
two of the most common reasons for attrition in the drug discovery and development 
process in the pharmaceutical industry.95–98   
Use of the zebrafish model was an effective phenotypic screening approach for 
identification of tanshinones, isotanshinones, and structurally similar compounds which 
exhibited anti-inflammatory effects in vivo. Manipulation of either the initial neutrophil 
recruitment or resolution of neutrophilic inflammation stages of the inflammatory 
response as a result of treatment with any of these synthetic tanshinone analogues was 
easily visualised. However, the molecular mechanism and target(s) of these tanshinone 
analogues in achieving these effects was not known. Furthermore, the route taken by 
these compounds through the zebrafish larvae to reach their cellular target was not 
known. An improved understanding of both of these processes would enable further 
drug optimisation and development to be undertaken.  
To address broad gaps in knowledge regarding drug transport, and to work towards 
exploration of how molecules such as tanshinones reach their molecular target in 
neutrophils, identification and analysis of the SLC and ABC drug transporters expressed 
in primary human and zebrafish larval neutrophils was carried out. This resulted in 
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corresponding phylogenetic trees which were presented as useful resources to the 
wider field. The data indicated that approximately one third of all known SLC and ABC 
drug transporters were expressed in human neutrophils, and one quarter of identified 
SLC and ABC transporters were expressed in zebrafish neutrophils. Drug transporter 
expression profiles exhibited a good level of conservation between human and zebrafish 
neutrophils, consistent with the high gene homology between zebrafish and humans 
more generally, another important advantage of the use of zebrafish models. In addition 
to representing a general resource, this work identified a number of drug transporters 
expressed in both primary human and zebrafish larval neutrophils, some of which are 
likely used by tanshinones to cross the neutrophil cell membrane and reach their cellular 
target. Further studies in this area would ideally work towards acquiring knowledge of 
which particular drug transporters are used by tanshinones (and more widely, any 
particular drug) to access, and later be removed from, the neutrophil (or other cell types 
of interest). This would enable more targeted rational design in the drug discovery and 
development process.  
The zebrafish model for inflammatory disease is not without its limitations. Firstly, 
automation of the in vivo experiments undertaken in this work would not be trivial, 
especially as operations such as tailfin injury need to be performed manually. Although 
some work in this area has been carried out previously, scaling this process up to analyse 
large numbers of larvae for many different compounds and concentrations would be 
difficult. Furthermore, zebrafish larvae were used at an early stage of development, 
both for in vivo experiments and drug transporter analysis, and this may not provide a 
completely accurate representation of inflammatory conditions or drug transporter 
expression, either in older zebrafish or in human patients. Using this model, acute and 
spontaneously resolving inflammation was investigated; different effects may be 
observed for chronic and/or non-resolving inflammation, and these types of 
inflammation are often more clinically relevant. In addition, some compounds which 
were actually active at the relevant biological target may not have been identified, due 
to inefficient penetration of the neutrophil, or the larva more generally, although this 
may mean that compounds which were identified were particularly effective. There are 
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also difficulties in translating some of the zebrafish experimental approaches used 
across into human studies. Nonetheless, the advantages of using this in vivo model for 
inflammatory disease far outweigh the limitations, and in conjunction with other 
approaches such as in vitro studies using human neutrophils, this is a powerful model 
for the identification and development of potential new anti-inflammatory therapeutics. 
In addition to experimental approaches suggested already, future studies could 
include in silico approaches. There are a number of readily available pieces of software 
which allow prediction of likely protein targets of a particular compound, simply upon 
input of the compound structure: tanshinones could be input into such software, to 
compile a list of possible molecular targets. Some of these targets would likely be more 
relevant to inflammatory processes than others, and as such could be prioritised for 
further study. Although these pieces of software are unlikely to be comprehensive, or 
indeed entirely accurate, they may be useful to complement ongoing approaches. This 
could be combined with other approaches such as molecular docking, RNAseq data, and 
microarrays, and could also be carried out in conjunction with practical approaches 
including in vitro studies, knockdown experiments for possible targets, mass 
spectrometry techniques such as phosphoproteomics or thermal shift profiling, and/or 
methods involving further functionalised analogues, such as photoaffinity labelling. A 
combination of these approaches, perhaps alongside more specific zebrafish studies, 
would likely aid identification of a detailed molecular mechanism of action for 
tanshinones.  
Overall, this work has provided further insight into the in vivo anti-inflammatory 
activities of tanshinones more widely, including various analogues and isomers, as well 
as structurally related molecules. The data and observations from these experiments, 
alongside the drug transporter expression data for both human and zebrafish 
neutrophils, have resulted in progress towards identification of effective, non-toxic 
compounds which might eventually be used in the clinic as anti-inflammatory 
compounds, and ideally for promoting the resolution of inflammation in vivo. 
 
 




All non-aqueous reactions were carried out in flame-dried glassware and in 
anhydrous solvents, unless stated otherwise. Anhydrous solvents were obtained from 
The University Of Sheffield Department of Chemistry Grubbs solvent system. All 
chemicals used were purchased from commercial suppliers. Propanal 57 was distilled 
immediately before use. para-Benzoquinone 32 was triturated with DCM before use. 
Dicyclopentadiene 143 was freshly cracked and distilled to provide pure 
cyclopentadiene 127 which was used immediately. All other reagents were used as 
received without further purification.  
Melting points were determined using a Gallenkamp melting point apparatus 
equipped with a thermometer. IR spectroscopy was performed on a PerkinElmer FT-IR 
Spectrum 65 or Spectrum 100 spectrometer, using either NaCl discs or a Universal 
diamond ATR. 1H, 13C and 19F NMR experiments were run on either a Bruker Avance 400 
or Bruker Avance III HD 500 spectrometer at 298 K. Chemical shifts (δ) are reported in 
parts per million (ppm) relative to the deuterated lock solvent as an internal standard, 
where s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br s = broad singlet, 
br d = broad doublet, br t = broad triplet, app d = apparent doublet, app t = apparent 
triplet, dd = doublet of doublets, ddd = double doublet of doublets, td = triplet of 
doublets, qd = quartet of doublets, dq = doublet of quartets. All coupling constants are 
reported in hertz, Hz. Mass spectrometry was carried out on either an Agilent 
Technologies 6530 or 7200 spectrometer, using either electron impact (EI) or 
electrospray ionisation (ESI). 
TLC was performed on Merck silica gel 60 F254 aluminium-backed plates and visualised 
using ultraviolet light followed by staining with potassium permanganate dip. Column 
chromatography was carried out using silica gel obtained from VWR Chemicals, particle 
size 40-63 μm. Reactions using microwave conditions were carried out on a CEM 
Corporation Discover S-class microwave synthesiser, at pressure ≤ 17 bar and power ≤ 
200 W. Reactions using ultrasonication conditions were performed in an Ultrawave U50 
ultrasonic cleaning bath, at a power of 50 W and an operating frequency of 50-60 Hz.   
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8.2 Synthesis of TI analogues and iso-TI analogues 
2-Bromo-6-methoxy-1,4-hydroquinone (28) 
 
Sodium percarbonate (18.71 g, 119.2 mmol) was added to a solution of 5-
bromovanillin 27 (25.03 g, 108.4 mmol) in THF (300 mL) and water (120 mL) and stirred 
at room temperature for 5 h. The reaction was quenched with sodium sulfite (15.00 g), 
filtered, and concentrated in vacuo. The organic product was extracted with ethyl 
acetate (3 x 300 mL), dried (MgSO4), filtered and concentrated in vacuo to give the 
hydroquinone 28 (20.34 g, 86%) as a grey solid which was used without further 
purification; mp 142-146 °C (lit.212 139-141 °C); δH[400 MHz; (CD3)2CO] 8.13 (1 H, s, OH), 
7.57 (1H, s, OH), 6.59 (1 H, d, J 2.6, ArCH), 6.50 (1 H, d, J 2.6, ArCH), 3.82 (3 H, s, OCH3); 
δC[100 MHz; (CD3)2CO] 150.7 (ArC), 148.7 (ArC), 137.3 (ArC), 110.0 (ArCH), 108.1 (ArC), 
99.6 (ArCH), 55.6 (OCH3). All data were in agreement with the literature.212 
2-Bromo-6-methoxy-[1,4]-benzoquinone (29) 
 
A solution of iron(III) chloride hexahydrate (125.4 g, 463.9 mmol) in water (600 mL) 
was added to a solution of 2-bromo-6-methoxy-1,4-hydroquinone 28 (20.32 g, 92.77 
mmol) in methanol (80 mL) with stirring. The resulting mixture was stirred at room 
temperature for 5 h. The organic layer was separated and extracted with DCM (3 x 250 
mL), combined, washed with water (500 mL) and brine (500 mL), dried (MgSO4), filtered 
and concentrated in vacuo to give the benzoquinone 29 (19.84 g, 99%) as an orange 
solid which was used without further purification; mp 152-156 °C (lit.212 160-162 °C); 
Page 171 of 246 
 
δH(400 MHz; CDCl3) 7.23 (1 H, d, J 2.2, CHCO), 5.98 (1 H, d, J 2.2, CHCO), 3.88 (3 H, s, 
OCH3); δC(100 MHz; CDCl3) 184.7 (C), 174.6 (C), 158.3 (C), 138.5 (=CH), 134.3 (C), 107.7 
(=CH), 56.9 (OCH3). All NMR data were in agreement with the literature.212 
General representative procedure A for radical decarboxylative alkylation reactions 
to form bromides 76, 81, 85-87 
A mixture of the quinone 29 (2.00 g, 9.26 mmol), carboxylic acid 75, 80, 82-84 (11.1 
mmol) and silver(I) phosphate (1.94 g, 4.63 mmol) in acetonitrile (70 mL) was stirred 
under a nitrogen atmosphere in the dark and heated at reflux. A solution of ammonium 
persulfate (4.23 g, 18.5 mmol) in water (70 mL) was added slowly over 20 minutes via 
dropping funnel, and the resulting mixture was stirred at reflux for 2.5 h. The solution 
was cooled to room temperature and poured onto ice (50 g). Aqueous NaOH (1 M, 10 
mL) and water (50 mL) were added and the organic layer was separated and extracted 
with DCM (3 × 150 mL). The organic extracts were combined, washed with brine (400 
mL), dried (MgSO4), filtered and concentrated in vacuo to give the crude product, which 




General procedure A was followed, using the carboxylic acid 75 (1.82 g), to give the 
bromide 76 (1.67 g, 54 %) as a yellow solid; mp 179-184 °C (lit.211 mp 149-152 °C); δH(400 
MHz; CDCl3) 7.24-7.14 (4 H, m, 4 × ArCH), 5.99 (1 H, s, CHCO), 3.88 (3 H, s, OCH3), 2.98-
2.92 (2 H, m, CH2), 2.82-2.76 (2 H, m, CH2), 2.45 (3 H, s, ArCH3); δC(100 MHz; CDCl3) 183.7 
(C=O), 174.8 (C=O), 158.3 (C), 149.0 (C), 138.6 (C), 136.2 (C), 133.2 (C), 130.4 (ArCH), 
129.1 (ArCH), 126.6 (ArCH), 126.2 (ArCH), 107.4 (CHCO), 56.7 (OCH3), 32.0 (CH2), 31.3 
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(CH2), 19.3 (CH3). All NMR data were in agreement with the literature.211 Two individual 
measurements performed for the melting point of this compound here indicated that it 
was around 30 °C higher than that reported in the literature, perhaps due to the 
production of a more pure compound in this case. 
3-Bromo-5-methoxy-2-(2-phenylethyl)-2,5-cyclohexadiene-1,4-dione (81) 
 
General procedure A was followed, but on a larger scale, using the quinone 29 (3.00 
g, 13.9 mmol), the carboxylic acid 80 (2.50 g, 16.7 mmol) and silver(I) phosphate (4.82 
g, 11.5 mmol) in acetonitrile (150 mL), and ammonium persulfate (6.34 g, 27.8 mmol) in 
water (100 mL), to give the bromide 81 (2.04 g, 46%) as a yellow solid; mp 138-141 °C 
(lit.211 138-140 °C); δH(400 MHz; CDCl3) 7.36-7.22 (5 H, m, 5 x ArCH), 5.98 (1 H, s, CHCO), 
3.87 (3 H, s, OCH3), 3.03-2.97 (2 H, m, CH2), 2.83-2.77 (2 H, m, CH2); δC(100 MHz; CDCl3) 
183.6 (C=O), 174.8 (C=O), 158.3 (C), 149.0 (C), 140.4 (C), 133.3 (C), 128.6 (2 x ArCH), 
128.53 (2 x ArCH), 126.5 (ArCH), 107.4 (=CH), 56.8 (OCH3), 33.8 (CH2), 33.2 (CH2). All data 




General procedure A was followed, using the carboxylic acid 82 (2.42 g), to give the 
bromide 85 (1.35 g, 38%) as a yellow solid; mp 144-147 °C (lit.211 143-145 °C); δH(400 
MHz; CDCl3) 7.66 (1 H, d, J 7.6, ArCH), 7.52 (1 H, t, J 7.6, ArCH), 7.46 (1 H, d, J 7.6, ArCH), 
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7.35 (1 H, t, J 7.6, ArCH), 6.00 (1 H, s, CHCO), 3.88 (3 H, s, OCH3), 3.08-2.95 (4 H, m, 2 x 
CH2); δC(100 MHz; CDCl3) 183.6 (C=O), 174.8 (C=O), 158.3 (C), 148.4 (C), 139.0 (C), 133.6 
(C), 131.9 (ArCH), 131.4 (ArCH), 128.6 (q, JC-F 30.0, ArC), 126.6 (ArCH), 126.0 (q, JC-F 5.7, 
ArCH), 124.5 (q, JC-F 273.6, CF3), 107.4 (=CH), 56.7 (OCH3), 32.9 (CH2), 30.3 (CH2). All data 
were in agreement with the literature.211 
3-Bromo-2-(2-fluorophenethyl)-5-methoxy-2,5-cyclohexadiene-1,4-dione (86) 
 
General procedure A was followed, using the carboxylic acid 83 (1.87 g), to give the 
bromide 86 (1.44 g, 46%) as a yellow solid; mp 144-148 °C (lit.211 134-137 °C); δH(400 
MHz; CDCl3) 7.25-7.19 (2 H, m, 2 x ArCH), 7.11-6.99 (2 H, m, 2 x ArCH), 5.97 (1 H, s, 
CHCO), 3.87 (3 H, s, OCH3), 3.06-2.99 (2 H, m, CH2), 2.92-2.85 (2 H, m, CH2); δC(100 MHz; 
CDCl3) 183.6 (C=O), 174.8 (C=O), 161.2 (d, JC-F 245.4, ArCF), 158.2 (C), 148.6 (C), 133.5 
(C), 130.8 (d, JC-F 4.6, ArCH), 128.3 (d, JC-F 8.1, ArCH), 127.1 (d, JC-F 16.2, ArC), 124.1 (d, JC-
F 3.4, ArCH), 115.3 (d, JC-F 22.0, ArCH), 107.4 (=CH), 56.7 (OCH3), 31.5 (CH2), 27.2 (CH2). 
All NMR data were in agreement with the literature.211 
3-Bromo-5-methoxy-2-(2-methoxyphenethyl)-2,5-cyclohexadiene-1,4-dione (87) 
 
General procedure A was followed, using the carboxylic acid 84 (2.00 g), to give an 
inseparable mixture of the bromide 87 and the benzoquinone 29 (1.07 g) as a yellow 
solid in a 60:40 ratio which was used without further purification. Analysis of the 1H NMR 
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spectrum of this mixture indicated a 33% yield of the bromide 87. A sample of this 
mixture was further purified for analytical purposes to give the bromide 87 as a yellow 
solid; mp 160-163 °C (lit.211 161-163 °C); δH(400 MHz; CDCl3) 7.22 (1 H, td, J 7.7, 1.6, 
ArCH), 7.15 (1 H, dd, J 7.7, 1.6, ArCH), 6.89 (1 H, td, J 7.7, 0.7, ArCH), 6.84 (1 H, d, J 7.7, 
ArCH), 5.96 (1 H, s, CHCO), 3.86 (3 H, s, OCH3), 3.84 (3 H, s, OCH3), 3.04-2.98 (2 H, m, 
CH2), 2.88-2.82 (2 H, m, CH2); δC(100 MHz; CDCl3) 183.7 (C=O), 174.9 (C=O), 158.1 (C), 
157.6 (C), 149.6 (C), 132.9 (C), 130.1 (ArCH), 128.7 (C), 127.8 (ArCH), 120.5 (ArCH), 110.2 
(ArCH), 107.3 (ArCH), 56.7 (OCH3), 55.3 (OCH3), 31.4 (CH2), 28.7 (CH2). All data were in 
general agreement with the literature.211 
General representative procedure B for Heck reactions to form diones 36, 77, 88-95 
A solution of the bromide 76, 81, 85-87 (2.24 mmol), palladium(II) acetate (25 mg, 
0.111 mmol), triphenylphosphine (59 mg, 0.225 mmol) and potassium carbonate (930 
mg, 6.73 mmol) in degassed toluene (80 mL mmol-1) was heated at reflux in the dark for 
17 h under a nitrogen atmosphere, with stirring. The mixture was cooled to room 
temperature, concentrated in vacuo, diluted with water (40 mL mmol-1), and extracted 
with DCM (3 x 40 mL mmol-1). The organic extracts were combined, washed with brine 
(80 mL mmol-1), dried (MgSO4), filtered and concentrated in vacuo to give the crude 
product which was separated from major impurities by flash column chromatography 
(silica gel, DCM) to give an inseparable mixture of the fully aromatised and non-
aromatised diones 36, 77, 88-95. 
3-Methoxy-8-methylphenanthrene-1,4-dione (36) and 9,10-dihydro-3-methoxy-8-
methylphenanthrene-1,4-dione (77) 
 
General procedure B was followed, using the bromide 76 (750 mg, 2.24 mmol), to 
give a bright orange solid (378 mg, 67%) as an inseparable mixture of diones 36 and 77 
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in a 75:25 ratio which was used without further purification. Selected 1H NMR data from 
product mixture corresponding to the dione 36: δH(400 MHz; CDCl3) 9.42 (1 H,  d, J 8.8, 
ArCH), 8.43 (1 H, br d, J 8.8, ArCH), 8.25 (1 H, br d, J 8.8, ArCH), 7.65 (1 H, dd, J 8.8, 6.9, 
ArCH), 7.50 (1 H, br d, J 6.9, ArCH), 6.17 (1 H, br s, CHCO), 3.97 (3 H, br s, OCH3), 2.77 (3 
H, s, CH3). All data were in general agreement with the literature.214 Selected 1H NMR 
data from product mixture corresponding to the dione 77: δH(400 MHz; CDCl3) 7.92-7.86 
(1 H,  app t, J 4.5, ArCH), 7.23 (2 H, d, J 4.5, ArCH), 5.99 (1 H, br s, CHCO), 3.88 (3 H, br s, 
OCH3), 2.79-2.74 (2 H, m, CH2), 2.74-2.70 (2 H, m, CH2), 2.36 (3 H, s, CH3). No data were 
reported in the literature for this compound. 
3-Methoxyphenanthrene-1,4-dione (88) and 9,10-dihydro-3-methoxyphenanthrene-
1,4-dione (89) 
 
General procedure B was followed, using the bromide 81 (200 mg, 0.622 mmol), to 
give a pale red solid (109 mg, 73%) as an inseparable mixture of diones 88 and 89 in a 
96:4 ratio which was used without further purification. Selected 1H NMR data from 
product mixture corresponding to the dione 88: δH(400 MHz; CDCl3) 9.55 (1 H, d, J 8.8, 
ArCH), 8.20 (2 H, app d, J 1.2, 2 x ArCH), 7.92 (1 H, d, J 8.1, ArCH), 7.77 (1 H, ddd, J 8.8, 
6.8, 1.2, ArCH), 7.66 (1 H, ddd, J 8.1, 6.8, 1.2, ArCH), 6.17 (1 H, s, CHCO), 3.96 (3 H, s, 
OCH3). All data were in general agreement with the literature.394,395 Selected 1H NMR 
data from product mixture corresponding to the dione 89: δH(400 MHz; CDCl3) 5.99 (1 
H, s, CHCO), 3.88 (3 H, s, OCH3), 2.83-2.78 (2 H, m, CH2), 2.76-2.72 (2 H, m, CH2). No data 
were reported in the literature for this compound. 
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3-Methoxy-8-(trifluoromethyl)phenanthrene-1,4-dione (90) and 9,10-dihydro-3-
methoxy-8-trifluoromethyl)phenanthrene-1,4-dione (91) 
 
General procedure B was followed, using the bromide 85 (1.35 g, 3.47 mmol), to give 
a dark orange solid (500 mg) as an inseparable mixture including diones 90 and 91 in a 
65:35 ratio alongside an additional unidentified compound, which was used without 
further purification. Selected 1H NMR peaks from product mixture corresponding to the 
dione 90: δH(400 MHz; CDCl3) 9.81 (1 H,  d, J 8.9, ArCH), 8.59 (1 H, dq, J 8.9, 0.9, ArCH), 
8.37 (1 H, d, J 8.9, ArCH), 8.06 (1 H, d, J 7.2, ArCH), 7.86-7.81 (1 H, m, ArCH), 6.23 (1 H, s, 
CHCO), 3.99 (3 H, s, OCH3). Selected 1H NMR peaks from product mixture corresponding 
to the dione 91: δH(400 MHz; CDCl3) 5.97 (1 H, s, CHCO), 3.85 (3 H, s, OCH3), 3.04-2.97 
(2 H, m, CH2), 2.80-2.74 (2 H, m, CH2). Selected 1H NMR peaks from product mixture 
corresponding to the unidentified compound: δH(400 MHz; CDCl3) 6.01(1 H, s, =CH), 3.89 
(3 H, s, OCH3). No data were reported in the literature for these compounds. 
8-Fluoro-3-methoxyphenanthrene-1,4-dione (92) and 9,10-dihydro-8-fluoro-3-
methoxyphenanthrene-1,4-dione (93) 
 
General procedure B was followed, using the bromide 86 (1.34 g, 3.95 mmol), to give 
a dark orange solid (197 mg) as an inseparable mixture including diones 92 and 93 in an 
80:20 ratio alongside an additional unidentified compound, which was used without 
further purification. Selected 1H NMR peaks from product mixture corresponding to the 
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dione 92: δH(400 MHz; CDCl3) 9.35 (1 H,  d, J 8.8, ArCH), 8.54 (1 H, d, J 8.8, ArCH), 8.29 (1 
H, d, J 8.8, ArCH), 7.74-7.67 (1 H, m, ArCH), 7.37-7.32 (1 H, m, ArCH), 6.21 (1 H, s, CHCO), 
3.98 (3 H, s, OCH3). Selected 1H NMR peaks from product mixture corresponding to the 
dione 93: δH(400 MHz; CDCl3) 5.95 (1 H, s, =CH), 3.84 (3 H, s, OCH3), 2.93-2.87 (2 H, m, 
CH2), 2.80-2.73 (2 H, m, CH2). Selected 1H NMR peaks from product mixture 
corresponding to the unidentified compound: δH(400 MHz; CDCl3) 6.90 (1 H, s, ArCH), 
5.99 (1 H, s, CHCO), 3.88 (3 H, s, OCH3). No data were reported in the literature for these 
compounds. 
3,8-Dimethoxyphenanthrene-1,4-dione (94) and 9,10-dihydro-3,8-
dimethoxyphenanthrene-1,4-dione (95) 
 
General procedure B was followed, using the bromide 87 (1.02 g, 2.91 mmol), to give 
a red solid (218 mg, 28%) as an inseparable mixture of diones 94 and 95 in an 82:18 ratio 
which was used without further purification. Selected 1H NMR data from product 
mixture corresponding to the dione 94: δH(400 MHz; CDCl3) 9.10 (1 H,  d, J 8.8, ArCH), 
8.71 (1 H, d, J 8.8, ArCH), 8.18 (1 H, d, J 8.8, ArCH), 7.66 (1 H, br t, J 8.4, ArCH), 6.98 (1 H, 
d, J 7.7, ArCH), 6.15 (1 H, s, CHCO), 4.04 (3 H, s, OCH3), 3.95 (3 H, s, OCH3). All data were 
in agreement with the literature.395 Selected 1H NMR data from product mixture 
corresponding to the dione 95: δH(400 MHz; CDCl3) 5.94 (1 H, s, CHCO), 3.83 (3 H, s, 
OCH3), 3.80 (3 H, s, OCH3), 2.88-2.82 (2 H, m, CH2), 2.77-2.72 (2 H, m, CH2). No data were 
reported in the literature for this compound. 
General representative procedure C for demethylation to form alcohols 9, 30, 96-98 
Aqueous NaOH (2 M, 50 mL g-1, 40.0 mmol) was added to a mixture of the fully 
aromatised and non-aromatised ethers 36, 77, 88-95 (378 mg, 1.50 mmol) in ethanol 
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(50 mL g-1), and the resulting mixture was stirred at reflux for 1 h. The solution was 
cooled to room temperature, acidified with aqueous HCl (1 M, 100 mL g-1), water was 
added (50 mL g-1), and the solution was extracted with ethyl acetate (3 × 63 mL g-1). The 
organic extracts were combined, washed with brine (250 mL g-1), dried (MgSO4), filtered 
and concentrated in vacuo to give the alcohols 9, 30, 96-98. 
3-Hydroxy-8-methylphenanthrene-1,4-dione (9) 
 
General procedure C was followed, using the mixture of diones 36 and 77 (378 mg, 
1.50 mmol) to give the alcohol 9 (347 mg, 97%) as a pale red solid that did not require 
further purification; mp 208-214 °C (lit.211 mp 209-212 °C); δH[400 MHz; (CD3)2SO] 11.67 
(1 H, br s, ArOH), 9.32 (1 H, d, J 8.8, ArCH), 8.51 (1 H, d, J 8.8, ArCH), 8.12 (1 H, d, J 8.8, 
ArCH), 7.69 (1 H, dd, J 8.8, 7.0, ArCH), 7.57 (1 H, d, J 7.0, ArCH), 6.15 (1 H, s, CHCO), 2.72 
(3 H, s, ArCH3); δC[100 MHz; (CD3)2SO] 185.5 (C=O), 184.3 (C=O), 160.6 (C), 135.6 (C), 
135.1 (C), 132.6 (C), 132.1 (ArCH), 130.4 (ArCH), 130.1 (C), 129.4 (ArCH), 125.8 (C), 125.2 




General procedure C was followed, using the mixture of diones 88 and 89 (222 mg, 
0.931 mmol) to give the alcohol 30 (200 mg, 97%) as a dark orange solid which was used 
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without further purification; mp 199-202 °C (lit.396 200 °C); δH[400 MHz; (CD3)2CO] 9.83 
(1 H, br s, OH), 9.58 (1 H, d, J 8.7, ArCH), 8.41 (1 H, d, J 8.7, ArCH), 8.19 (1 H, dd, J 8.7, 
1.7, ArCH), 8.10 (1 H, d, J 8.2, ArCH), 7.86-7.80 (1 H, m, ArCH), 7.77-7.71 (1 H, m, ArCH), 
6.25 (1 H, d, J 1.7, CHCO). All 1H NMR data were in broad agreement with the 
literature,211 although precise values were slightly shifted due to the different solvent 
used for analysis. 
3-Hydroxy-8-(trifluoromethyl)phenanthrene-1,4-dione (96) 
 
General procedure C was followed, using the mixture of diones 90 and 91 (500 mg) 
to give the crude alcohol 96 (447 mg) as an orange solid which could not be purified 
further by either flash column chromatography or recrystallisation. Selected peaks from 
1H NMR spectrum of crude material corresponding to the alcohol 96: δH[400 MHz; 
(CD3)2CO] 9.89 (1 H, d, J 9.0, ArCH), 8.64 (1 H, br d, J 9.0, ArCH), 8.40 (1 H, d, J 9.0, ArCH), 
8.21 (1 H, d, J 7.3, ArCH), 8.00-7.94 (1 H, m, ArCH), 6.31 (1 H, s, CHCO). All 1H NMR data 
were in broad agreement with the literature,211 although precise values were slightly 
shifted due to the different solvent used for analysis. 
8-Fluoro-3-hydroxyphenanthrene-1,4-dione (97) 
 
General procedure C was followed, using the mixture of diones 92 and 93 (194 mg) 
to give the crude alcohol 97 (170 mg) as a dark red solid which could not be purified 
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further by either flash column chromatography or recrystallisation. Selected peaks from 
1H NMR spectrum of crude material corresponding to the alcohol 97: δH[400 MHz; 
(CD3)2CO] 9.95 (1 H, br s, OH), 9.40 (1 H, d, J 8.8, ArCH), 8.60 (1 H, d, J 8.8, ArCH), 8.29 (1 
H, d, J 8.8, ArCH), 7.86-7.79 (1 H, m, ArCH), 7.51 (1 H, ddd, J 10.4, 7.8, 0.7, ArCH), 6.28 (1 
H, s, CHCO). All 1H NMR data were in broad agreement with the literature,211 although 
precise values were slightly shifted due to the different solvent used for analysis. 
3-Hydroxy-8-methoxyphenanthrene-1,4-dione (98) 
 
General procedure C was followed, using the mixture of diones 94 and 95 (218 mg, 
0.813 mmol) to give the alcohol 98 (192 mg, 93%) as a dark red solid which was used 
without further purification; mp 204-207 °C (lit.211 185-187 °C); νmax(NaCl discs)/cm-1 
3281 (O-H), 1657 (C=O), 1634 (C=O), 1582 (C=C); δH[400 MHz; (CD3)2SO] 11.65 (1 H, br s, 
OH), 8.97 (1 H, d, J 8.8, ArCH), 8.59 (1 H, d, J 8.8, ArCH), 8.02 (1 H, d, J 8.8, ArCH), 7.70 (1 
H, t, J 7.8, ArCH), 7.15 (1 H, d, J 7.8, ArCH), 6.13 (1 H, s, CHCO), 4.00 (3 H, s, OCH3). IR 
spectroscopy data were not reported in the literature. All other spectroscopic data were 
in agreement with the literature.211 
General representative procedure D for reactions with chloroacetone to form 
tanshinones 1, 31, 100, 102, 104 and isotanshinones 13, 99, 101, 103, 105 
A mixture of the alcohol 9, 30, 96-98 (100 mg, 0.42 mmol), ammonium acetate (32 
mg, 0.42 mmol, 4 mmol g-1) and chloroacetone (10 mL g-1, 12 mmol) was heated in a 
sealed tube at 110 °C for 15 minutes under microwave conditions. The solution was 
cooled to room temperature, diluted with water (400 mL g-1) and extracted with DCM 
(3 x 400 mL g-1). The organic extracts were combined, dried (MgSO4), filtered and 
concentrated in vacuo to give the crude mixture which was purified by flash column 
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chromatography (silica gel, DCM) to give the tanshinones 1, 31, 100, 102, 104 and 
isotanshinones 13, 99, 101, 103, 105. 
1,6-Dimethylphenanthro[1,2-b]furan-10,11-dione, TI (1) and 4,8-
dimethylphenanthro[3,2-b]furan-7,11-dione, iso-TI (13) 
 
General procedure D was followed, using the alcohol 9 (100 mg, 0.42 mmol) to give 
the dione 1 (21 mg, 18%) as a dark red solid; mp 232-234 °C (lit.204 229-230 °C); δH(400 
MHz; CDCl3) 9.23 (1 H, d, J 8.8, ArCH), 8.27 (1 H, d, J 8.8, ArCH), 7.77 (1 H, d, J 8.8, ArCH), 
7.54 (1 H, dd, J 8.8, 7.1, ArCH), 7.34 (1 H, d, J 7.1, ArCH), 7.30 (1 H, s, OCH), 2.68 (3 H, s, 
CH3), 2.30 (3 H, d, J 0.8, CH3); δC(100 MHz; CDCl3) 183.4 (C=O), 175.6 (C=O), 161.2 (ArC), 
142.0 (ArCH), 135.2 (ArC), 133.6 (ArC), 132.9 (ArCH), 132.7 (ArC), 130.7 (ArCH), 129.6 
(ArC), 128.3 (ArCH), 124.8 (ArCH), 123.1 (ArC), 121.8 (ArC), 120.5 (ArC), 118.7 (ArCH), 
19.9 (CH3), 8.8 (CH3); m/z (ESI+) 299 (10%, M+Na+), 277 (100, M+H+). All data were in 
general agreement with the literature.204,211,258 Also obtained was the dione 13 (22 mg, 
19%) as an orange solid; mp 218-220 °C (lit.203 219-220 °C); νmax(ATR)/cm-1 1655 (C=O), 
1588 (C=O), 1533 (C=C); δH(400 MHz; CDCl3) 9.66 (1 H, d, J 8.9, ArCH), 8.40 (1 H, dd, J 
8.9, 0.8, ArCH), 8.32 (1 H, d, J 8.9, ArCH), 7.63 (1 H, dd, J 8.9, 7.0, ArCH), 7.54-7.52 (1 H, 
m, OCH), 7.48 (1 H, dt, J 7.0, 0.8, ArCH), 2.76 (3 H, s, ArCH3), 2.41 (3 H, d, J 1.2, CH3); 
δC(101 MHz; CDCl3) 182.2 (C=O), 177.2 (C=O), 153.9 (ArC), 145.2 (ArCH), 136.0 (ArC), 
134.7 (ArC), 133.5 (ArC), 131.2 (ArC), 131.0 (ArCH), 129.8 (ArCH), 129.3 (ArCH), 127.2 
(ArC), 126.5 (ArC), 126.2 (ArCH), 122.1 (ArCH), 120.9 (ArC), 20.0 (CH3), 8.8 (CH3); m/z 
(ESI+) 299 (25%, M+Na+), 277 (100, M+H+). No 13C NMR spectroscopy data were reported 
in the literature; all other data were in general agreement with the literature.203,204,259 
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1-Methylphenanthro[1,2-b]furan-10,11-dione, 6-H-TI (31) and 8-methylphenanthro[3,
2-b]furan-7,11-dione, 4-H-iso-TI (99) 
 
General procedure D was followed, using the alcohol 30 (100 mg, 0.44 mmol) to give 
the dione 31 (24 mg, 21%) as a dark red solid; mp 229-233 °C (lit.211 226-229 °C); 
νmax(NaCl discs)/cm-1 2922 (C-H), 2852 (C-H), 1669 (C=O), 1593 (C=C); δH(400 MHz; CDCl3) 
9.42 (1 H, d, J 8.7, ArCH), 8.12 (1 H, d, J 8.7, ArCH), 7.83 (2 H, br d, J 8.7, 2 x ArCH), 7.71 
(1 H, br t, J 7.7, ArCH), 7.55 (1 H, t, J 7.7, ArCH), 7.33 (1 H, s, ArCH), 2.32 (3 H, s, CH3). No 
IR spectroscopy data were reported in the literature. 1H NMR data were in broad 
agreement with the literature,211 although precise chemical shift values were slightly 
shifted due to the different solvent used for analysis. Also obtained was the dione 99 
(28 mg, 24%) as an orange solid; mp 199-202 °C; νmax(NaCl discs)/cm-1 2921 (C-H), 1766 
(C=O), 1664 (C=O), 1536 (C=C); δH(400 MHz; CDCl3) 9.77 (1 H, d, J 8.5, ArCH), 8.28 (1 H, 
d, J 8.5, ArCH), 8.18 (1 H, d, J 8.5, ArCH), 7.90 (1 H, d, J 8.5, ArCH), 7.78-7.72 (1 H, m, 
ArCH), 7.68-7.61 (1 H, m, ArCH), 7.53 (1 H, s, ArCH), 2.40 (3 H, s, CH3); δC(101 MHz; CDCl3) 
182.2 (C=O), 177.2 (C=O), 153.7 (ArC), 145.3 (ArCH), 136.7 (ArC), 135.1 (ArCH), 134.0 
(ArC), 130.9 (ArC), 130.1 (ArCH), 128.7 (ArCH), 128.5 (ArCH), 128.0 (ArCH), 127.0 (ArC), 
126.5 (ArC), 122.3 (ArCH), 120.9 (ArC), 8.8 (CH3); m/z (EI+) 262.0622 (100%, M+ C17H10O3 
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1-Methyl-6-(trifluoromethyl)phenanthro[1,2-b]furan-10,11-dione, 6-CF3-TI (100) and 
8-methyl-4-(trifluoromethyl)phenanthro[3,2-b]furan-7,11-dione, 4-CF3-iso-TI (101) 
 
General procedure D was followed, using the unpurified alcohol 96 (435 mg) to give 
the dione 100 (6 mg, 1% over 3 steps) as a dark red solid; mp 204-208 °C; νmax(NaCl 
discs)/cm-1 1674 (C=O), 1550 (C=C); δH(400 MHz; CDCl3) 9.65 (1 H, d, J 8.9, ArCH), 8.50 
(1 H, d, J 8.9, ArCH), 7.98 (1 H, d, J 8.9, ArCH), 7.94 (1 H, d, J 7.2 ArCH), 7.75 (1 H, br t, J 
8.1, ArCH), 7.39 (1 H, br d, J 1.1, OCH), 2.33 (3 H, d, J 1.1, CH3); δC(100 MHz; CDCl3) 183.3 
(C=O), 175.2 (C=O), 160.2 (ArC), 142.8 (ArCH), 133.0 (ArC), 132.8 (q, JC-F 3.0, ArCH), 131.0 
(ArCH), 130.5 (ArC), 129.8 (ArC), 129.1 (ArCH), 127.0 (q, JC-F 30.3, ArC), 126.0 (q, JC-F 5.9, 
ArCH), 124.2 (q, JC-F 273.9, CF3), 123.1 (ArC), 122.1 (ArC), 121.2 (ArC), 120.8 (ArCH), 8.8 
(CH3); δF(377 MHz; CDCl3) -58.8; m/z (ESI+) 353 (18%, M+Na+), 331.0580 (100, M+H+ 
C18H10O3F3 requires 331.0577). Also obtained was the dione 101 (20 mg, 2% over 3 steps) 
as a dark brown solid; mp 183-186 °C; νmax(NaCl discs)/cm-1 1661 (C=O), 1601 (C=O), 
1536 (C=C); δH(400 MHz; CDCl3) 10.07 (1 H, d, J 9.0, ArCH), 8.58 (1 H, d, J 9.0, ArCH), 8.45 
(1 H, d, J 9.0, ArCH), 8.05 (1 H, d, J 7.1 ArCH), 7.79 (1 H, dd, J 9.0, 7.1, ArCH), 7.57 (1 H, 
q, J 1.1, OCH), 2.42 (3 H, d, J 1.1, CH3); δC(100 MHz; CDCl3) 181.4 (C=O), 176.7 (C=O), 
153.5 (ArC), 145.7 (ArCH), 134.0 (ArC), 132.4 (ArCH), 132.2 (ArC), 131.6 (ArC), 130.8 (q, 
JC-F 2.7, ArCH), 128.2 (ArCH), 127.2 (ArC), 127.0 (q, JC-F 5.9, ArCH), 126.7 (d, JC-F 3.0, ArC), 
126.5 (ArC), 124.3 (q, JC-F 274.0, CF3), 124.0 (ArCH), 121.0 (ArC), 8.7 (CH3); δF(377 MHz; 
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6-Fluoro-1-methylphenanthro[1,2-b]furan-10,11-dione, 6-F-TI (102) and 4-fluoro-8-
methylphenanthro[3,2-b]furan-7,11-dione, 4-F-iso-TI (103) 
 
General procedure D was followed, using the unpurified alcohol 97 (140 mg) to give 
the dione 102 (18 mg, 2% over 3 steps) as a dark red solid; mp 187-191 °C; νmax(NaCl 
discs)/cm-1 1675 (C=O), 1664 (C=O), 1594 (C=C); δH(400 MHz; CDCl3) 9.20 (1 H, d, J 8.8, 
ArCH), 8.45 (1 H, d, J 8.8, ArCH), 7.89 (1 H, d, J 8.8, ArCH), 7.67-7.60 (1 H, m, ArCH), 7.36 
(1 H, q, J 1.2, OCH), 7.22 (1 H, ddd, J 10.0, 7.8, 0.7, ArCH), 2.32 (3 H, d, J 1.2, CH3); δC(100 
MHz; CDCl3) 183.0 (C=O), 175.0 (C=O), 160.5 (ArC), 158.8 (d, JC-F 253.6, ArC), 142.5 
(ArCH), 133.3 (d, JC-F 2.5, ArC), 131.0 (d, JC-F 8.5, ArCH), 130.9 (ArC), 129.4 (d, JC-F 7.3, 
ArCH), 124.7 (d, JC-F 15.4, ArC), 122.5 (d, JC-F 4.7, ArCH), 122.4 (d, JC-F 2.3, ArC), 122.0 
(ArC), 121.0 (ArC), 119.3 (d, JC-F 1.6, ArCH), 111.1 (d, JC-F 19.3, ArCH), 8.8 (CH3); δF(377 
MHz; CDCl3) -120.7; m/z (ESI+) 326 (34%, M+2Na+), 303 (20, M+Na+), 281.0612 (100, 
M+H+ C17H10O3F requires 281.0608). Also obtained was the dione 103 (12 mg, 1% over 3 
steps) as a pale orange solid; mp 185-189 °C; νmax(NaCl discs)/cm-1 1662 (C=O), 1591 
(C=O), 1535 (C=C); δH(400 MHz; CDCl3) 9.56 (1 H, d, J 8.9, ArCH), 8.50 (1 H, d, J 8.9, ArCH), 
8.34 (1 H, d, J 8.9, ArCH), 7.71-7.64 (1 H, m, ArCH), 7.55 (1 H, d, J 1.0, OCH), 7.32 (1 H, 
dd, J 9.9, 7.8, ArCH), 2.41 (3 H, d, J 1.0, CH3); δC(100 MHz; CDCl3) 181.8 (C=O), 176.8 
(C=O), 158.4 (d, JC-F 253.0, ArC), 153.6 (ArC), 145.5 (ArCH), 134.5 (ArC), 131.9 (d, JC-F 2.8, 
ArC), 130.0 (d, JC-F 8.1, ArCH), 127.5 (d, JC-F 6.9, ArCH), 127.1 (d, JC-F 15.8, ArC), 126.8 (d, 
JC-F 2.6, ArC), 126.7 (ArC), 124.0 (d, JC-F 4.6, ArCH), 122.7 (d, JC-F 1.6, ArCH), 121.0 (ArC), 
112.1 (d, JC-F 19.3, ArCH), 8.7 (CH3); δF(377 MHz; CDCl3) -120.9; m/z (EI+) 280.0532 (100%, 
M+ C17H9O3F requires 280.0530).  
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6-Methoxy-1-methylphenanthro[1,2-b]furan-10,11-dione, 6-OMe-TI (104) and 4-
methoxy-8-methylphenanthro[3,2-b]furan-7,11-dione, 4-OMe-iso-TI (105) 
 
General procedure D was followed, using the alcohol 98 (100 mg, 0.39 mmol) to give 
the dione 104 (22 mg, 19%) as a dark brown solid; mp 249-253 °C; νmax(NaCl discs)/cm-1 
1670 (C=O), 1660 (C=O), 1587 (C=C), 1548 (C=C); δH(400 MHz; CDCl3) 9.00 (1 H, d, J 8.9, 
ArCH), 8.66 (1 H, d, J 8.7, ArCH), 7.82 (1 H, d, J 8.7, ArCH), 7.62 (1 H, app t, J 8.4, ArCH), 
7.34 (1 H, s, ArCH), 6.89 (1 H, d, J 7.8, ArCH), 4.04 (3 H, s, OCH3), 2.32 (3 H, s, CH3); δC(126 
MHz; CDCl3) 183.4 (C=O), 175.7 (C=O), 161.2 (ArC), 155.7 (ArC), 142.1 (ArCH), 133.5 
(ArC), 131.5 (ArCH), 131.2 (ArCH), 130.5 (ArC), 126.8 (ArC), 122.4 (ArC), 121.8 (ArC), 
120.7 (ArC), 118.5 (ArCH), 118.2 (ArCH), 105.5 (ArCH), 55.7 (OCH3), 8.8 (CH3); m/z (ESI+) 
315 (11%, M+Na+), 293.0813 (100, M+H+ C18H13O4 requires 293.0808). Also obtained was 
the dione 105 (21 mg, 18%) as a red solid; mp 231-234 °C; νmax(ATR)/cm-1 1662 (C=O), 
1582 (C=O), 1535 (C=C); δH(400 MHz; CDCl3) 9.32 (1 H, d, J 8.8, ArCH), 8.68 (1 H, d, J 8.8, 
ArCH), 8.24 (1 H, d, J 8.8, ArCH), 7.63 (1 H, dd, J 8.8, 7.9, ArCH), 7.51 (1 H, d, J 0.8, ArCH), 
6.95 (1 H, d, J 7.9, ArCH), 4.04 (3 H, s, OCH3), 2.40 (3 H, d, J 0.8, CH3); δC(101 MHz; CDCl3) 
182.3 (C=O), 177.2 (C=O), 155.3 (ArC), 153.9 (ArC), 145.1 (ArCH), 134.4 (ArC), 132.0 (ArC), 
130.5 (ArCH), 129.3 (ArC), 129.2 (ArCH), 126.5 (2 x ArC), 121.6 (ArCH), 120.8 (ArC), 119.8 
(ArCH), 106.2 (ArCH), 55.7 (OCH3), 8.8 (CH3); m/z (ESI+) 315 (43%, M+Na+), 293.0810 
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1,6-Dimethylphenanthro[1,2-b]furan-10,11-dimethyldioxole, TI-acetal (109) 
 
TI 1 (27 mg, 0.10 mmol) was dissolved in anhydrous THF (7 mL) and stirred under a 
nitrogen atmosphere at room temperature. Sodium borohydride (4.0 mg, 0.10 mmol) 
was added in a single portion, and the solution stirred for 30 minutes. The solution was 
poured onto ice/water (20 mL), acidified with aqueous HCl solution (1 M, 3 mL), and 
extracted with DCM (3 x 20 mL). The organic extracts were combined, dried (MgSO4), 
filtered and concentrated in vacuo to give the crude diol 108 as an olive-green solid (29 
mg), which was immediately dissolved in anhydrous toluene (10 mL). 2,2-
Dimethoxypropane (0.025 mL, 0.20 mmol) and para-toluenesulfonic acid monohydrate 
(25 mg, 0.13 mmol) were added, and the reaction was stirred under a nitrogen 
atmosphere at reflux for 2 h. The mixture was cooled to room temperature, aqueous 
saturated NaHCO3 solution (20 mL) added, and extracted with diethyl ether (3 x 20 mL). 
The organic extracts were combined, dried (MgSO4), filtered and concentrated in vacuo 
to give an off-white solid (38 mg), which was purified twice by flash column 
chromatography (silica gel, DCM, and then silica gel, 19:1 40/60 petroleum ether/ethyl 
acetate) to give the acetal 109 as a beige solid (11 mg, 34%); mp 176-180 °C; 
νmax(ATR)/cm-1 2917 (C-H); δH(400 MHz; CDCl3) 9.13 (1 H, d, J 8.4, ArCH), 8.22 (1 H, d, J 
9.2, ArCH), 7.89 (1 H, dd, J 9.2, 0.8, ArCH), 7.57-7.52 (2 H, m, 2 x ArCH), 7.45 (1 H, dt, J 
7.1, 0.9, ArCH), 2.79 (3 H, s, ArCH3), 2.46 (3 H, d, J 1.3, ArCH3), 1.91 (6 H, s, 2 x CH3); 
δC(126 MHz; CDCl3) 148.3 (ArC), 141.5 (ArCH), 138.2 (ArC), 137.8 (ArC), 134.1 (ArC), 130.7 
(ArC), 128.9 (ArC), 127.3 (ArCH), 125.6 (ArCH), 125.4 (ArCH), 120.4 (ArCH), 119.2 (ArCH), 
118.5 (ArC), 114.5 (ArC), 114.3 (ArC), 113.0 (ArC), 112.7 (ArC), 26.1 (2 x CH3), 20.2 
(ArCH3), 9.2 (ArCH3); m/z (ESI+) 319.1322 (100%, M+H+ C21H19O3 requires 319.1329), 383 
(8), 359 (28), 261 (22). 
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8.3 Towards the synthesis of other tanshinone analogues 
(E)-1-(1-Propenyl)piperidine (117) 
 
A mixture of piperidine 116 (9.10 mL, 91.8 mmol) and potassium carbonate (2.53 g, 
18.4 mmol) was cooled to 0 °C in an ice bath under a nitrogen atmosphere. Freshly 
distilled propanal 57 (4.40 mL, 61.2 mmol) was added dropwise over 45 minutes, and 
the mixture was stirred for a further 2 h at 0 °C. The mixture was filtered and washed 
with diethyl ether (20 mL), and the resulting filtrate was concentrated in vacuo to give 
the crude enamine 117 (8.83 g) as a colourless oil which was used without any further 
purification. Selected 1H NMR data from reaction mixture corresponding to the enamine 
117: δH(400 MHz; CDCl3) 5.82 (1 H, dq, J 13.9, 1.4, NCH=CHCH3), 4.37 (1 H, dq, J 13.9, 
6.5, NCH=CHCH3), 2.74-2.70 (4 H, m, 2 x CH2), 1.63 (3 H, dd, J 6.5, 1.4, NCH=CHCH3), 1.59-
1.44 (6 H, m, 3 x CH2). All NMR data were in general agreement with the literature.320,321 
(E)-4-(1-Propenyl)morpholine (120) 
 
A mixture of morpholine 119 (1.30 mL, 15.0 mmol) and potassium carbonate (780 
mg, 5.64 mmol) was cooled to 0 °C in an ice bath under a nitrogen atmosphere. Propanal 
57 (1.30 mL, 18.7 mmol) was added dropwise over 15 minutes, and the mixture was 
stirred for a further 2 h at 0 °C. The mixture was filtered and washed with diethyl ether 
(10 mL), and the resulting solution was concentrated in vacuo to give the crude enamine 
120 (1.45 g) as a colourless oil which was used without any further purification. Selected 
1H NMR data from reaction mixture corresponding to the enamine 120: δH(400 MHz; 
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CDCl3) 5.83 (1 H, dq, J 13.9, 1.4, NCH=CHCH3), 4.47 (1 H, dq, J 13.9, 6.5, NCH=CHCH3), 
3.75-3.71 (4 H, m, 2 x OCH2), 2.79-2.75 (4 H, m, 2 x NCH2), 1.65 (3 H, dd, J 6.5, 1.4, 
NCH=CHCH3). All NMR data were in general agreement with the literature.230,325,326 
(±)-trans-2,3-Dihydro-5-hydroxy-2-morpholino-3-methylbenzo[1,2-b]furan (121) and 
(±)-cis-2,3-dihydro-5-hydroxy-2-morpholino-3-methylbenzo[1,2-b]furan (122) 
 
para-Benzoquinone 32 (638 mg, 5.90 mmol) was dissolved in anhydrous DCM (15 mL) 
and cooled to 0 °C under a nitrogen atmosphere in an ice bath. A solution of the 
unpurified enamine 120 (750 mg) in anhydrous DCM (5 mL) was added dropwise over 
10 minutes, the reaction was warmed to room temperature, and stirred for 18 h. The 
reaction mixture was concentrated in vacuo to give the crude product as a dark brown 
gum (1.00 g), the 1H NMR spectrum of which contained product peaks which were in 
broad agreement with those in the literature.230,325 Selected 1H NMR peaks from crude 
reaction mixture corresponding to the trans-phenol 121: δH(400 MHz; CDCl3) 6.66-6.64 
(1 H, m, ArCH), 6.61-6.60 (2 H, m, 2 x ArCH), 4.97 (1 H, d, J 4.7, CH), 3.31-3.26 (1 H, m, 
CH), 2.86-2.79 (2 H, m, CH2), 2.63-2.56 (2 H, m, CH2), 1.33 (3 H, d, J 7.0, CH3). Removal of 
major impurities by flash column chromatography (silica gel, 1:1 40/60 petroleum 
ether/ethyl acetate) gave a different product, thought to be the other epimer 122, as a 
viscous brown oil (477 mg). Selected 1H NMR peaks: δH(400 MHz; CDCl3) 6.72-6.67 (2 H, 
m, 2 x ArCH), 6.65-6.61 (1 H, m, ArCH), 5.60 (1 H, d, J 2.3, CH), 5.28 (1 H, br s, OH), 3.89-
3.85 (1 H, m, CH), 3.19 (1 H, qd, J 7.3, 1.8, CH), 2.86-2.82 (1 H, m, CH), 1.36 (1 H, d, J 7.3, 








Aqueous HCl (1 M, 120 mL) was added to the crude benzofuranol 122 (2.43 g), and 
the resulting mixture was stirred at reflux for 18 h. The solution was cooled to room 
temperature and extracted with diethyl ether (3 × 150 mL). The organic extracts were 
combined, dried (MgSO4), filtered and concentrated in vacuo to give a viscous pale 
brown oil (1.42 g). The solid was purified by flash column chromatography (silica gel, 2:1, 
40-60 petroleum ether/ethyl acetate) to give the benzofuranol 58 (704 mg, 33% over 3 
steps) as a white solid; mp 94-96 °C (lit.230 mp 93-94 °C); δH(400 MHz; CDCl3) 7.40 (1 H, 
d, J 1.1, OCH), 7.32 (1 H, d, J 8.7, ArCH), 6.95 (1 H, d, J 2.5, ArCH), 6.82 (1 H, dd, J 8.7, 2.5, 
ArCH), 4.73 (1 H, br s, OH), 2.21 (3 H, d, J 1.1, CH3); δC(100 MHz; CDCl3) 151.1 (ArC), 150.3 
(ArC), 142.5 (ArCH), 129.9 (ArC), 115.5 (ArC), 112.7 (ArCH), 111.7 (ArCH), 104.6 (ArCH), 
7.9 (CH3). All data were in general agreement with the literature.230,325 
4,5-Dihydro-3-methylbenzo[1,2-b]furan-4,5-dione (59) 
 
A solution of 3-methyl-5-benzofuranol 58 (50 mg, 0.34 mmol) in methanol (1.5 mL) 
was cooled to 0 °C in an ice bath. Separately, Fremy’s salt (200 mg, 0.75 mmol) was 
dissolved in aqueous KH2PO4 (0.07 M, 17 mL, adjusted to pH 7) and cooled to 0 °C in an 
ice bath. The Fremy’s salt solution was added to the solution of the phenol 58 dropwise 
at 0 °C with stirring, and the reaction was stirred for a further 1 h at 0 °C. The red 
precipitate formed was collected by filtration, washed with cold water (5 mL) and cold 
40/60 petroleum ether (5 mL), and dried under low vacuum to give the crude dione 59 
(22 mg) as a red solid. The filtrate was extracted with ethyl acetate (3 x 20 mL) and the 
organic extracts were combined, washed with water (2 x 40 mL) and brine (40 mL), dried 
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(MgSO4), filtered and concentrated in vacuo to give further crude dione 59 (23 mg) as a 
red solid which was combined with the previously obtained red solid and used without 
further purification. Selected IR and 1H NMR data from reaction mixture corresponding 
to the dione 59: νmax(ATR)/cm-1 1632 (C=O), 1614 (C=O); δH(400 MHz; CDCl3) 7.30 (1 H, 
br s, OCH), 7.28 (1 H, d, J 10.3, COCH), 6.17 (1 H, d, J 10.3, =CH), 2.27 (3 H, d, J 1.0, CH3). 
All data were in general agreement with the literature.230 
1-Vinylcyclohexanol (125) 
 
A solution of cyclohexanone 126 (1.06 mL, 10.2 mmol) in anhydrous THF (25 mL) was 
cooled to 0 °C in an ice bath, under a nitrogen atmosphere. Vinylmagnesium bromide 
(1.0 M in THF, 31.0 mL, 31.0 mmol) was added dropwise, and the mixture was stirred at 
0 °C for 2 h. The reaction was quenched by the addition of saturated ammonium chloride 
solution (100 mL), and the organic layer was separated and extracted with diethyl ether 
(3 x 75 mL). The organic extracts were combined, dried (MgSO4), filtered and 
concentrated in vacuo to give a pale yellow oil (908 mg). The crude product was purified 
by flash column chromatography (silica gel, 4:1 40/60 petroleum ether/ethyl acetate) to 
give the alcohol 125 (692 mg, 54%) as a colourless oil which was used without further 
purification; δH(400 MHz; CDCl3) 6.00 (1 H, dd, J 17.4, 10.8, =CH), 5.27 (1 H, dd, J 17.4, 
1.3, =CHH), 5.06 (1 H, dd, J 10.4, 1.3, =CHH), 1.71-1.49 (10 H, m, 5 x CH2), 1.33 (1 H, s, 
OH). All data were in general agreement with the literature.330,331 
1-Vinylcyclohexene (123) 
 
para-Toluenesulfonic acid monohydrate (452 mg, 2.37 mmol) was added to a solution 
of 1-vinylcyclohexanol 125 (200 mg, 1.58 mmol) in pentane (10 mL), and the mixture 
was heated at reflux for 3 h. The mixture was cooled to room temperature, water (20 
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mL) was added, and the organic layer was separated and extracted with pentane (3 x 10 
mL). The organic extracts were combined, dried (MgSO4), filtered and concentrated in 
vacuo to give a pale yellow oil (200 mg). Purification of the crude mixture was attempted 
by flash column chromatography (silica gel, pentane) to give the impure diene 123 (11 
mg) as a colourless oil which was not purified any further. Selected 1H NMR data from 
product mixture corresponding to the diene 123: δH(400 MHz; CDCl3) 6.37 (1 H, dd, J 
17.5, 10.8, =CH), 5.78 (1 H, br s, =CH), 5.09 (1 H, d, J 17.5, =CHH), 4.91 (1 H, d, J 10.8, 
=CHH), 2.19-2.11 (4 H, m, 2 x CH2), 1.74-1.59 (4 H, m, 2 x CH2). All data were in general 
agreement with the literature.331,332 
6,9-Dihydro-6,9-methano-3-methylnaphtho[1,2-b]furan-4,5-dione (131) 
 
Freshly prepared unpurified dione 59 (20 mg) was dissolved in anhydrous DCM (4 mL) 
and cooled to -78 °C under a nitrogen atmosphere. Freshly cracked cyclopentadiene 127 
(0.35 mL, 4.2 mmol) was added and the reaction was stirred at -78 °C for 1 h. The 
reaction was warmed to room temperature and stirred for a further 2 h. The mixture 
was concentrated in vacuo to give a pale brown solid (23 mg) as a mixture of the dione 
131 and the phenol 58 in an 80:20 ratio which could not be purified further. Selected 1H 
NMR data from reaction mixture corresponding to the dione 131: δH(400 MHz; CDCl3) 
7.16 (1 H, q, J 1.2, OCH), 6.12 (1 H, dd, J 5.7, 2.9, =CH), 5.79 (1 H, dd, J 5.7, 2.9, =CH), 3.78 
(1 H, dd, J 7.8, 4.0, CH), 3.59 (1 H, br s, CH), 3.48 (1 H, br s, CH), 3.32 (1 H, dd, J 7.8, 4.0, 
CH), 2.22 (3 H, d, J 1.2, CH3), 1.72 (1 H, dt, J 9.0, 1.7, CHH), 1.62 (1 H, br d, J 9.0, CHH). All 
data were in general agreement with the literature.230 
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3,8-Dimethyl-4,5-dihydronaphtho[1,2-b]furan-4,5-dione (133) and 3,7-dimethyl-4,5-
dihydronaphtho[1,2-b]furan-4,5-dione (134) 
 
A mixture of the unpurified dione 59 (100 mg), isoprene 129 (2.0 mL, 20 mmol) and 
methanol (1.0 mL) in a sealed round-bottomed flask was warmed at 45 °C for 2 h in an 
ultrasonic cleaning bath (50-60 Hz, 50 W). The mixture was cooled to room temperature, 
concentrated in vacuo, and passed through a plug of silica (DCM). The eluted product 
mixture was concentrated in vacuo, toluene (30 mL) and chloranil (165 mg, 0.67 mmol) 
were added, and the mixture was heated at reflux for 18 h. The mixture was cooled to 
room temperature, concentrated in vacuo, passed through a plug of silica (DCM) and re-
concentrated in vacuo to give a red solid (32 mg) as a mixture of the phenol 58 and the 
diones 133 and 134 in a 70:20:10 ratio which was not purified any further. Selected 1H 
NMR data from reaction mixture corresponding to the dione 133: δH(400 MHz; CDCl3) 
7.98 (1 H, d, J 7.9, ArCH), 7.51 (1 H, s, ArCH), 7.27-7.24 (2 H, m, 2 x ArCH), 2.48 (3 H, s, 
CH3), 2.31 (3 H, s, CH3). All data were in agreement with the literature.11 Selected 1H 
NMR data from reaction mixture corresponding to the dione 134: δH(400 MHz; CDCl3) 
7.90 (1 H, br s, ArCH), 7.61-7.58 (1 H, m, ArCH), 7.45-7.43 (1 H, m, ArCH), 7.26-7.24 (1 H, 
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8.4 Synthesis of structurally related compounds 
β-Lapachone (112) 
 
Concentrated H2SO4 (1.0 mL) was added slowly to lapachol 114 (25 mg, 0.10 mmol), 
with stirring, until the solid completely dissolved. The solution was stirred for a further 
5 minutes and poured onto ice (20 g). The precipitate was filtered off by vacuum 
filtration and washed with cold water (5 mL) to give an orange solid. The crude product 
was purified by flash column chromatography (silica gel, DCM – 19:1 DCM/MeOH) to 
give the dione 112 (21 mg, 85%) as an orange solid; mp 151-153 °C (lit.333 152-154 °C); 
δH(400 MHz; CDCl3) 8.07 (1 H, dd, J 7.7, 1.0, ArCH), 7.83 (1 H, d, J 7.7, ArCH), 7.66 (1 H, 
td, J 7.7, 1.0, ArCH), 7.52 (1 H, td, J 7.7, 1.0, ArCH), 2.58 (2 H, t, J 6.7, CH2), 1.87 (2 H, t, J 
6.7, CH2), 1.48 (6 H, s, 2 x CH3); δC(101 MHz; CDCl3) 179.9 (C=O), 178.6 (C=O), 162.1 (ArC), 
134.8 (ArCH), 132.6 (ArC), 130.7 (ArCH), 130.1 (ArC), 128.6 (ArCH), 124.1 (ArCH), 112.7 
(ArC), 79.3 [C(CH3)2], 31.6 (CH2), 26.8 (2 x CH3), 16.2 (CH2). All data were in general 
agreement with the literature.307,333 
Norlapachol (115) 
 
Lapachol 114 (150 mg, 0.62 mmol) was dissolved in THF (5 mL), sodium carbonate (72 
mg, 0.68 mmol) in water (5 mL) was added, and the solution was heated to 60 °C. 
Aqueous hydrogen peroxide (30%, 1.0 mL, 13 mmol) was added and the solution was 
heated at 60 °C for 4 h. The reaction was cooled to rt, acidified with concentrated HCl 
(0.2 mL), and quenched with sodium sulfite (3.0 g). Aqueous NaOH (25%, 5 mL) and 
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copper(II) sulfate (625 mg, 3.9 mmol) in water (5 mL) were added and the mixture was 
stirred at room temperature for 1.5 h. The solution was filtered through a pad of Celite, 
acidified with concentrated HCl (7 mL) and extracted with diethyl ether (3 x 75 mL). The 
organic extracts were combined, washed with brine (200 mL), dried (MgSO4), filtered 
and concentrated in vacuo to give an orange solid. The crude product was purified by 
recrystallisation from n-hexane to give the dione 115 (73 mg, 52%) as an orange solid; 
mp 123-125 °C (from n-hexane), (lit.307 121-122 °C); νmax(NaCl discs)/cm-1 3364 (O-H), 
2928 (C-H), 2910 (C-H), 1662 (C=O), 1645 (C=O), 1627 (C=C), 1593 (C=C); δH(400 MHz; 
CDCl3) 8.15 (1 H, d, J 7.6, ArCH), 8.11 (1 H, d, J 7.6, ArCH), 7.78 (1 H, td, J 7.6, 1.1, ArCH), 
7.71 (1 H, td, J 7.6, 1.1, ArCH), 7.55 (1 H, br s, OH), 6.02 (1 H, br s, CH), 2.01 (3 H, s, CH3), 
1.70 (3 H, s, CH3); δC(101 MHz; CDCl3) 184.8 (C=O), 181.6 (C=O), 151.2 (C), 143.6 (C), 
134.9 (ArCH), 133.0 (ArCH), 132.9 (C), 129.5 (C), 126.9 (ArCH), 126.1 (ArCH), 120.9 (C), 
113.7 (CH), 26.6 (CH3), 21.8 (CH3); m/z (ESI+) 251 (5%, M+Na+), 229.0862 (100, M+H+ 




Concentrated H2SO4 (1.5 mL) was added slowly to norlapachol 115 (30 mg, 0.13 
mmol), with stirring, until the solid completely dissolved. The solution was stirred at 
room temperature for a further 5 minutes, poured onto ice (20 g) and rinsed with water 
(20 mL). The solution was extracted with DCM (3 x 40 mL), and the organic extracts were 
combined, washed with brine (100 mL), dried (MgSO4), filtered, and concentrated in 
vacuo to give an orange/pink solid. The crude product was purified by trituration with 
cold hexane (2 x 2 mL) and dried under high vacuum to give the dione 113 (29 mg, 95%) 
as an orange solid; mp 190-193 °C (lit.399 188-189 °C); δH(400 MHz; CDCl3) 8.10 (1 H, d, J 
7.6, ArCH), 7.68-7.64 (2 H, m, 2 x ArCH), 7.63-7.57 (1 H, m, ArCH), 2.97 (2 H, s, CH2), 1.63 
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(6 H, s, 2 x CH3); δC(101 MHz; CDCl3) 181.4 (C=O), 175.7 (C=O), 168.8 (ArC), 134.5 (ArCH), 
131.9 (ArCH), 130.9 (ArC), 129.3 (ArCH), 127.9 (ArC), 124.6 (ArCH), 115.0 (ArC), 93.8 
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10. Appendix 
10.1 Previous studies in the Renshaw group found that various tanshinones 
accelerated resolution of neutrophilic inflammation in zebrafish 
 
Data obtained by Dr. Anne Robertson. DMSO used at 0.5% concentration, all other 
compounds used at concentrations of 1, 10 and 25 µM as indicated. Data shown as mean 
± SD; n = approximately 40 larvae from 4 independent experiments. * P < 0.05, ** P < 
0.01, *** P < 0.001, all other results not significant, in comparison to the DMSO control 
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10.2 E3 medium 









All 10x E3 stock solution was autoclaved prior to dilution and use in experiments. 
 
10.3 Tricaine solution 







2.867 g NaCl (5.00 mM) 
0.127 g KCl (0.17 mM) 
0.483 g CaCl2.2H2O (0.33 mM) 
0.817 g MgSO4.7H2O  (0.33 mM) 
Deionised water up to 1 L 
 
100 mL 10x E3 stock solution 
Deionised water up to 1 L 
Optional: add 3 drops 1% methylene blue solution (in 
deionised water) as fungicide 
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10.4 Phylogenetic trees with proportional branch lengths 
10.4.1 Subsets of SLC transporter proteins were expressed and regulated in primary human 
neutrophils 
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Annotated phylogenetic trees in (a) circular and (b) unrooted display modes indicate 
evolutionary relationships between SLC transporter proteins in human neutrophils. 
Branch lengths are proportional to genetic distance. In (a), for resting primary human 
neutrophil expression data (inner circle), expressed proteins were marked with a black 
dot, whereas proteins not expressed were denoted with a white dot. For GM-CSF 
(second circle from centre) and TNFα (third circle from centre) regulation data, 
significant up-regulation of a gene was denoted with a green box, significant down-
regulation was denoted by a red box, and a lack of significant change in regulation 
unmarked. For human neutrophil proteomics data (outer circle), any proteins identified 
in one or more of the analyses were denoted with a blue box, and any not identified 
were denoted with a white box. 
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10.4.2 Subsets of ABC transporter proteins were expressed and regulated in primary 
human neutrophils 
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Annotated phylogenetic trees in (a) circular and (b) unrooted display modes indicate 
evolutionary relationships between ABC transporter proteins in human neutrophils. 
Branch lengths are proportional to genetic distance. In (a), for resting primary human 
neutrophil expression data (inner circle), expressed proteins were marked with a black 
dot, whereas proteins not expressed were denoted with a white dot. For human 
neutrophil proteomics data (outer circle), any proteins identified in one or more of the 
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10.5 Comparison of human drug transporter expression between distinct 
RNAseq datasets 





Wright et al., 2013 Chatterjee et al., 2016 
SLC16A3 416.071 206.7938 
SLC2A3 384.863 146.301 
SLC25A37 365.439 No data 
SLC44A2 296.96 305.502 
SLC11A1 241.006 375.1498 
SLC6A6 174.964 308.898 
SLC43A2 142.397 195.5783 
SLC15A3 114.121 203.8168 
SLC12A6 107.268 86.26105 
SLC15A4 101.968 132.1664 
SLC38A2 73.4412 51.29513 
SLC45A4 62.3642 34.80962 
SLC25A3 60.4501 74.8113 
SLC31A2 59.4817 107.9547 
MTCH1 58.9362 96.06843 
SLC19A1 56.8214 50.80168 
SLCO3A1 53.1765 134.5328 
SLC12A9 52.23 147.5515 
SLC40A1 37.6849 166.2416 
UCP2 35.2824 77.73278 
SLC25A44 33.7158 58.39863 
SLC20A1 33.0773 16.14776 
SLC9A1 25.9958 31.72053 
SLC22A4 24.431 30.64313 
SLC25A28 23.1132 26.53685 
DIRC2 22.9076 4.079744 
SLC39A1 21.6872 24.02363 
SLC22A18 21.182 36.2852 
SLC38A10 21.1819 30.27238 
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SLC7A5 20.6468 1.637648 
SLC9A8 19.8604 18.75233 
SLC25A5 19.6541 35.83148 
SLC29A1 17.9369 36.96945 
SLC3A2 17.5905 22.47888 
SLC25A11 17.5471 25.77163 
SLC8B1 16.841 11.64638 
SLC7A7 16.7696 31.3496 
SLC16A5 14.6446 30.8605 
SLC35A2 12.2554 9.707798 
SLC8A1 12.0016 10.08038 
SLC16A6 11.2322 5.730955 
SLC35A4 11.1066 13.25903 
SLC39A7 10.6539 34.74275 
SLC25A51 10.198 10.5348 
SLC35C2 10.005 28.4959 
SLC35E1 9.68586 No data 
SLC36A1 9.58739 8.930435 
SLC10A3 9.23775 11.80692 
SLC36A4 9.22429 5.119257 
SLC35A5 7.91078 17.37549 
SLC39A6 7.26005 7.351105 
SLC25A1 7.10385 10.06107 
SLC37A3 7.06368 29.04458 
SLC48A1 6.77426 8.336738 
SLC25A29 6.73623 11.61707 
SLC23A2 6.58677 6.764668 
SLC22A15 6.44345 17.17855 
SLC39A9 6.18562 7.195905 
SLC31A1 5.99872 7.739965 
SLC2A1 5.77547 3.62349 
SLC35B1 5.4807 No data 
SLC35E2B 5.37585 14.90033 
SLCO4C1 5.25519 6.557368 
SLC46A3 5.17528 5.261813 
SLC35E3 4.72873 No data 
SLC35F5 4.69507 12.34666 
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SLC26A8 4.56664 3.324936 
SLC30A5 4.42129 8.462588 
SLC38A1 4.33379 1.82469 
SLC19A2 4.02632 0.802967 
SLC22A1 3.91727 15.31258 
SLC50A1 3.9015 6.878278 
SLC35A1 3.80725 No data 
SLC18A2 3.7171 1.370494 
SLC27A3 3.67019 No data 
SLC25A46 3.57248 4.63701 
SLC30A9 3.53037 4.27509 
SLC17A5 3.49068 3.028465 
SLC25A40 3.45767 8.186168 
SLC43A3 3.4212 No data 
SLC2A14 3.36893 0.906642 
FLVCR1 3.3331 11.74628 
SLC25A32 3.31725 1.141212 
SLC35B3 3.31298 6.968573 
SLC12A4 3.29637 No data 
SLC35E2 3.24559 14.90033 
SLC35B2 3.1499 No data 
SLC25A20 3.0388 13.83024 
SLC39A3 3.00139 4.865003 
SLC25A16 2.88922 2.370293 
SLC37A1 2.87833 No data 
SLC44A1 2.79355 2.664965 
SLC7A6 2.78867 2.361488 
SLC39A13 2.78257 4.708685 
SLC4A2 2.70562 14.91975 
SLC25A45 2.66672 4.06514 
SLC30A6 2.55172 3.284525 
SLC25A39 2.43246 2.116713 
SLC5A9 2.41311 2.3544 
SLC25A14 2.27557 4.54853 
SLC25A36 2.24725 1.794893 
MFSD7 2.17705 4.75029 
SLC9A6 2.12071 2.086033 
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SLC12A1 1.97848 11.74522 
SLC6A8 1.96133 2.048953 
SLC37A2 1.94582 2.08544 
SLC30A7 1.90897 7.608707 
SLC25A24 1.90318 2.7849 
SLC52A2 1.83537 6.545528 
SLC30A1 1.65508 2.871723 
SLC35C1 1.6161 2.864028 
SLC25A33 1.60194 0.085965 
SLC35D1 1.57019 0.861985 
SLC26A6 1.53617 3.069608 
SLC39A8 1.51151 0.808593 
SLC24A3 1.49052 0.976179 
SLC6A12 1.48353 3.38105 
SLC39A11 1.44917 1.204404 
SLC35D2 1.43724 3.107213 
SLC25A25 1.39899 1.099743 
SLC1A4 1.39617 0.302471 
SLC25A13 1.38929 1.150665 
SLC16A14 1.34748 0.57943 
SLC51A 1.32701 No data 
SLC25A38 1.32695 1.032691 
SLC25A30 1.26993 1.05837 
SLC25A22 1.19878 3.907003 
SLC5A6 1.17366 1.142233 
SLC35A3 1.16899 1.344898 
SLC1A5 1.10623 0.933738 
MTCH2 1.07897 3.649688 
SLC24A4 1.07192 2.226199 
SLC25A34 1.04847 1.105145 
SLC5A5 1.0317 0.001373 
SLC33A1 0.98935 1.418693 
SLC5A3 0.967574 No data 
SLC7A8 0.962858 1.744048 
UCP3 0.927209 0.659301 
SLC23A1 0.905577 0.376388 
SLC4A5 0.891422 0.893974 
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SLC2A5 0.880448 0.6242 
SLC7A11 0.839899 0.126315 
SLC12A7 0.816008 0.604336 
SLC38A9 0.768943 2.547703 
SLC36A2 0.710032 0.017288 
SLC25A19 0.679593 0.659763 
SLC11A2 0.660908 0.767677 
SLC25A15 0.649624 0.352065 
SLC27A4 0.64666 1.151295 
SLC16A4 0.646018 0.26843 
SLC9A7 0.621709 0.838211 
SLC26A11 0.601788 0.602508 
SLC4A7 0.592421 0.398962 
SLC22A5 0.586358 1.134696 
SLC10A1 0.582003 0.089458 
SLC25A17 0.58162 1.582018 
SLC26A2 0.557363 0.367065 
SLC37A4 0.545263 1.466712 
SLC20A2 0.523111 1.663723 
SLC39A4 0.511753 2.772043 
SLC15A2 0.494293 No data 
SLC25A12 0.491284 0.947139 
SLC16A13 0.49106 0.266753 
SLC9A4 0.472869 0.029917 
RHBG 0.454494 0 
SLC46A2 0.393315 0.506613 
SLC7A1 0.392402 0.113242 
SLC41A1 0.39035 0.153188 
SLCO4A1 0.386293 0.030919 
SLC39A10 0.375107 0.280526 
SLC12A2 0.358682 0.251158 
SLC10A7 0.354472 0.47415 
SLC4A8 0.346928 1.085581 
SLC24A1 0.343325 0.556316 
SLC16A1 0.341766 0.100955 
SLC41A3 0.33136 1.309153 
SLC29A3 0.3301 0.613083 
Page 232 of 246 
 
SLC28A2 0.319969 0 
SLC6A16 0.313818 0.702131 
SLC25A53 0.301434 3.752335 
SLC25A26 0.300095 0.448138 
SLC41A2 0.293223 1.133091 
SLC2A6 0.275303 0.812577 
SLC2A8 0.273322 0.814157 
SLC45A3 0.269156 0.69311 
SLC6A20 0.25677 0.06559 
SLC18B1 0.256123 0.353239 
SLC2A4 0.252583 0.003538 
SLC3A1 0.249917 0.161592 
SLC6A13 0.235715 0.26222 
SLC44A4 0.222833 0.025491 
SLC43A1 0.220751 0.140674 
SLC25A42 0.217023 0.229577 
SLC39A14 0.215165 0.066361 
SLC12A8 0.215099 24.8685 
SLC2A9 0.213474 1.134367 
SLC9A9 0.206143 0.471828 
SLC15A1 0.205513 0 
SLC27A1 0.190422 0.350563 
SLC35F1 0.183551 0 
SLC30A4 0.17871 0.043864 
SLC25A18 0.173669 0.178288 
SLC23A3 0.171536 No data 
SLC27A2 0.165621 0.147139 
SLC17A9 0.163025 0.220222 
FLVCR2 0.161085 2.995074 
SLC25A35 0.155719 0.474642 
SLC25A23 0.152735 0.092535 
SLC25A27 0.15039 0.499895 
SLC25A10 0.148419 1.767058 
SLC2A13 0.142042 0.254337 
SLC38A5 0.140477 0.244678 
SLC14A2 0.138358 0.023388 
SLC35B4 0.135503 0.133596 
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SLC16A7 0.133516 0.174023 
SLC22A13 0.132108 0.031119 
SLC22A14 0.128302 0.112629 
SLC45A2 0.124561 0.079131 
SLC47A1 0.123309 0.295644 
SLC14A1 0.120003 0.049875 
SLC2A11 0.119388 No data 
SLC9B2 0.117721 No data 
SLC25A43 0.110956 0.305292 
SLC38A6 0.106089 No data 
SLC25A2 0.105079 0.012352 
SLC28A1 0.105037 0.018301 
SLC35E4 0.099345 0.114885 
SLC22A17 0.096723 0.019834 
SLC7A10 0.096162 0.056653 
SLC4A1 0.094702 No data 
SLC52A1 0.093662 0.002782 
SLC7A9 0.091258 0.059758 
SLC38A7 0.090202 0.139128 
SLC5A10 0.084047 0.008357 
SLC16A8 0.076297 0.09536 
SLC22A9 0.075539 0 
SLC7A14 0.071874 0 
SLC35F2 0.07121 0.088443 
SLC18A1 0.06938 0.193916 
SLC26A4 0.06696 0.013925 
SLC35G2 0.066789 0.004921 
SLC30A8 0.064359 0.004751 
SLC13A4 0.062869 0.292333 
SLC9B1 0.06115 0.013052 
SLC28A3 0.057827 0.036177 
SLC22A16 0.056745 0.14271 
SLC32A1 0.055365 0 
SLC16A10 0.055337 0.013955 
SLC45A1 0.055306 0.026179 
SLC24A5 0.055127 0.314604 
SLC2A12 0.053854 0.341995 
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SLC29A2 0.053376 0.038654 
SLC25A47 0.049291 0.007801 
SLC16A11 0.048024 0 
SLC22A23 0.047533 0.146284 
SLC25A4 0.047498 0.070657 
SLC25A52 0.046697 0.01043 
SLC26A1 0.045243 0.203451 
SLCO1A2 0.044854 0 
SLC4A4 0.044376 0.018906 
SLC4A9 0.043369 0.053466 
SLC5A11 0.042816 0.009208 
SLC6A14 0.040641 0 
SLC9A3 0.038749 0.010525 
SLC35G1 0.038543 0.138574 
SLC1A2 0.038243 0.001444 
SLC35G6 0.036646 0 
SLC19A3 0.035449 0 
SLC27A5 0.03506 0.057876 
SLC46A1 0.034287 0.0454 
SLC4A10 0.031961 0.010504 
SLC29A4 0.031852 0.002375 
SLC4A11 0.030189 0.006052 
SLC13A1 0.030136 0 
SLC13A5 0.028342 0.014783 
SLC10A4 0.027983 0.008142 
SLC1A3 0.027724 0.080618 
SLC16A12 0.027205 0 
SLC26A5 0.026607 0 
SLC1A7 0.026587 0.053328 
SLC35G5 0.026139 0 
SLC8A2 0.024413 0.011955 
SLC10A5 0.021475 0 
SLCO5A1 0.021423 0.01598 
SLC9A5 0.017925 0.008151 
SLC4A3 0.017676 0.044514 
SLC44A3 0.017549 0.089591 
SLC38A11 0.017394 0.057391 
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SLC17A3 0.0168 0 
SLC5A2 0.016518 0.188793 
SLC34A1 0.014604 0.007438 
RHCG 0.014434 0 
SLC6A4 0.014124 0.042066 
SLC34A3 0.013134 0 
SLC6A2 0.012301 0 
SLC7A4 0.01204 0 
SLC44A5 0.010659 0.004211 
SLC24A2 0.009822 0 
SLC8A3 0.009751 0.074688 
SLC38A3 0.009671 0 
SLC36A3 0.009293 0 
SLC12A3 0.008825 0.008359 
SLC1A1 0.007744 0.014113 
SLC12A5 0.006559 0.027903 
SLC2A10 0.006494 0.096226 
SLC39A5 0.006383 0.008053 
SLC16A2 0.006309 0 
SLC26A7 0.006272 No data 
SLC6A3 0.005945 0.001777 
SLC22A7 0.005874 0 
SLC9A2 0.004401 0.007815 
SLC6A9 0.003785 0 
SLC13A3 0.002597 0 
SLCO1B7 0 0 
SLC22A31 0 No data 
SLC26A10 0 No data 
SLCO1B1 0 0 
SLC25A6 0 17.00073 
SLC39A2 0 0.039487 
SLC35F3 0 0.032623 
SLC35D3 0 0.026302 
SLC34A2 0 0.010175 
SLC30A2 0 0.009504 
SLC27A6 0 0.008934 
SLC10A6 0 0.006882 
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RHAG 0 0.004514 
SLC17A7 0 0.004465 
SLC22A3 0 0.003755 
SLC26A3 0 0.002922 
SLC16A9 0 0.002449 
SLC52A3 0 0.002154 
SLC17A8 0 0.002021 
SLCO2B1 0 0.001259 
SLC10A2 0 0 
SLC13A2 0 0 
SLC15A5 0 0 
SLC17A1 0 0 
SLC17A2 0 0 
SLC17A4 0 0 
SLC17A6 0 0 
SLC18A3 0 0 
SLC1A6 0 0 
SLC22A10 0 0 
SLC22A11 0 0 
SLC22A12 0 0 
SLC22A2 0 0 
SLC22A24 0 0 
SLC22A25 0 0 
SLC22A6 0 0 
SLC22A8 0 0 
SLC25A21 0 0 
SLC25A31 0 0 
SLC25A41 0 0 
SLC25A48 0 0 
SLC26A9 0 0 
SLC2A2 0 0 
SLC2A7 0 0 
SLC30A10 0 0 
SLC30A3 0 0 
SLC35F4 0 0 
SLC35G3 0 0 
SLC38A4 0 0 
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SLC38A8 0 0 
SLC39A12 0 0 
SLC47A2 0 0 
SLC51B 0 0 
SLC5A1 0 0 
SLC5A12 0 0 
SLC5A4 0 0 
SLC5A7 0 0 
SLC5A8 0 0 
SLC6A1 0 0 
SLC6A11 0 0 
SLC6A15 0 0 
SLC6A17 0 0 
SLC6A18 0 0 
SLC6A19 0 0 
SLC6A5 0 0 
SLC6A7 0 0 
SLC7A13 0 0 
SLC7A2 0 0 
SLC7A3 0 0 
SLC9C1 0 0 
SLC9C2 0 0 
SLCO1B3 0 0 
SLCO1C1 0 0 
SLCO2A1 0 0 
SLCO6A1 0 0 
UCP1 0 0 
 
The table shows all human SLC transporter genes and their expression values (given as 
FPKM values) as found in datasets from Wright et al. and Chatterjee et al.375,384 Entries 
are given as the mean of replicate values, in descending order of expression according 
to the dataset by Wright et al. Any genes which could not be identified in the dataset by 
Chatterjee et al. are labelled as ‘No data’. 
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Wright et al., 2013 Chatterjee et al., 2016 
TAP1 143.682 456.3108 
TAP2 51.0473 132.7189 
ABCA7 37.334 178.8746 
ABCG1 25.6516 No data 
ABCA1 17.5845 11.97111 
ABCC5 12.5493 16.24293 
ABCD1 7.27776 9.552486 
ABCF1 7.27122 5.90886 
ABCA2 7.15235 18.60513 
ABCC1 6.83516 8.063192 
ABCF3 4.72307 14.26925 
ABCC9 2.21629 0 
ABCD3 1.59239 1.14281 
ABCF2 1.21202 1.350599 
ABCA5 1.18218 1.080757 
ABCD4 1.11062 7.700425 
ABCB10 1.00666 1.87598 
ABCC6 0.970651 2.83314 
ABCC10 0.940023 4.91765 
ABCB7 0.927628 1.25014 
ABCC2 0.839153 17.38025 
ABCE1 0.599287 0.6684927 
ABCB5 0.53339 0.00458515 
ABCB6 0.367747 20.8678 
ABCB1 0.319107 0.2100675 
ABCB8 0.313178 1.246972 
ABCA13 0.291386 0.4219312 
ABCC4 0.218874 0.505737 
ABCA9 0.139689 0.03220053 
ABCB9 0.0938531 0.05274925 
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ABCB11 0.0664028 0.02136092 
ABCC3 0.0612735 2.804117 
ABCA3 0.0505832 0.05429485 
ABCD2 0.0494921 0.02637948 
ABCA10 0.0291777 1.080757 
ABCG2 0.026239 0.000778308 
ABCB4 0.014383 0.2529438 
ABCC11 0.0118731 0.00540443 
ABCA6 0.0101404 0.01867935 
ABCA4 0.00612525 0.009292483 
ABCA12 0 0 
ABCA8 0 0 
ABCC12 0 0.001889568 
ABCC8 0 0 
ABCG4 0 0.001287225 
ABCG5 0 0 
ABCG8 0 0 
CFTR 0 0 
 
The table shows all human ABC transporter genes and their expression values (given as 
FPKM values) as found in datasets from Wright et al. and Chatterjee et al.375,384 Entries 
are given as the mean of replicate values, in descending order of expression according 
to the dataset by Wright et al. Any genes which could not be identified in the dataset by 
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10.6 Phylogenetic trees with proportional branch lengths 
10.6.1 Zebrafish larval neutrophils and non-neutrophil cells expressed distinct subsets of 
SLC transporter proteins 
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Annotated phylogenetic trees in both (a) circular and (b) unrooted display modes 
indicate evolutionary relationships between SLC transporter proteins in zebrafish. 
Branch lengths are proportional to genetic distance. In (a), for both neutrophil (inner 
circle) and background cell (outer circle) expression data, expressed proteins were 
marked with a black box, whereas proteins not expressed were unmarked. 
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10.6.2 Zebrafish larval neutrophils and non-neutrophil cells expressed distinct subsets of 
ABC transporter proteins 
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Annotated phylogenetic trees in both (a) circular and (b) unrooted display modes 
indicate evolutionary relationships between ABC transporter proteins in zebrafish. 
Branch lengths are proportional to genetic distance. In (a), for both neutrophil (inner 
circle) and background cell (outer circle) expression data, expressed proteins were 
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10.7 Drug transporters expressed in both human and zebrafish neutrophils 
10.7.1 A subset of SLC drug transporters was expressed in both human and zebrafish 
neutrophils 

























SLC25A36 slc25a36a; slc25a36b 
SLC25A39 slc25a39 
SLC25A40 slc25a40 


























slc3a2a; slc3a2b;   
slc3a2_3of3; slc3a2_4of4 
SLC40A1 slc40a1 
SLC43A2 slc43a2a; slc43a2b 
SLC43A3 slc43a3b 
SLC44A2 slc44a2 
SLC48A1 slc48a1a; slc48a1b 
SLC4A2 slc4a2b 











The list shows all SLC drug transporter genes which were expressed in primary human 
neutrophils, and which also had at least one corresponding zebrafish orthologue (shown 
here alongside the relevant human gene) expressed in zebrafish neutrophils. 
 
10.7.2 A subset of ABC drug transporters was expressed in both human and zebrafish 
neutrophils 
Human gene Zebrafish orthologue gene(s) 









The list shows all ABC drug transporter genes which were expressed in primary human 
neutrophils, and which also had at least one corresponding zebrafish orthologue (shown 
here alongside the relevant human gene) expressed in zebrafish neutrophils. 
